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Introduction 
Thymidine kinase (TK) is a key enzyme in the salvage pathway of nucleotide 
metabolism catalysing the transfer of the terminal phosphate group of ATP to the 
5’-hydroxyl group of thymidine. The product dTMP is subsequently phosphorylatad 
by nucleoside kinases to dTTP, which is used for the synthesis of DNA. 
In mammalian cells the total TK activity is expressed by two genetically 
distinguishable isoenzymes: TKI and TK2. TKI is only present in dividing cells and 
TK2 is present both in non-dividing and dividing cells but at a much lower level. Of 
the two isoenzymes TKI is the most studied and the one generally referred to when 
talking about TK activity. 
For several reasons, TKI has become increasingly important in molecular 
biology and medicine. TKI is cell cycle regulated, with the amount of TKI protein 
and activity increasing markedly with the onset of DNA synthesis (S phase) and 
then declining to a very low level in G, phase. As TKl is expressed concomitantly 
with other proteins and enzymes involved in DNA synthesis, it is assumed that TKI 
plays a role in the replication of DNA. The combination of being cell cycle regulated 
and involved in DNA synthesis make TKl useful as a model system for gene 
expression and particular for the cell-cycle specific events taking place at the G,/S 
transition. An investigation of TKl gene expression will not only provide insight into 
regulation mechanisms in normal cells but also into cancer cells. 
In a variety of cancer and virus-infected cells the expression of TKI differs 
from the expression in normal cells. Generally, the level of TK activity is increased. 
Cancer cells with a changed ratio of TKI and TK2, e.g. expression of TKl in 
quiescent malignant cells and/or expression of TK enzymes with biochemical 
properties different from the normal counterparts, TKI and TK2 have been 
observed. Biochemical differences of TK’s in cancer cells together with many DNA 
viruses encoding for their own TK, which have a broader substrate specificity than 
the human host TK, are extremely useful in the treatment of cancer and virus- 
infected cells with nucleoside analogs. Nucleoside analogs are modified nucleosides 
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that, when phosphorylated by nucleoside kinases inhibit further DNA synthesis 
either by incorporation into DNA or by inhibition of DNA polymerases. A very 
efficient treatment with nucleoside analogs is seen in the treatment of Herpes 
Simplex Virus type 1 infections. Herpes Simplex virus encodes for its own TK, 
which can phosphorylate the nucleoside analog acyclic guanidine, while the human 
host TK cannot. Only cells infected with Herpes simplex virus will be affected - and 
killed - from the treatment with acyclic guanidine. However, not all nucleosida 
analogs are so selective in their effect. In the treatment of Human immunedeficency 
virus (HIV) the nucleoside analog azidothymidine (AZT) is used. The triphosphate 
of AZT inhibits the virus transcriptase and thus blocks for further DNA synthesis. 
As AZT also is phosphorylated by the host TKI , HIV infected and non-infected cells 
are influenced by the AZT treatment. 
To ensure the development of nucleoside analogs that will only interact with 
the altered or the virus-encoded TK’s, it is important that the phosphorylating 
enzyme is characterized with respectto structure, activity and specificity. However, 
even through TKI has been investigated throughout at the genetic level, TKI is not 
very well characterized at the protein level. This is due to a low amount of TKI in 
the cells and a high instability of TKI during the purification. Achieving enough 
materials from mammalian tissue for structural analysis, which demands protein in 
the mg-scale, is therefore an overwhelming task. However, expression of a cloned 
TKI gene in E.co/i, it will be possible to achieve adequate amounts of protein for 
structure analyses by Nuclear Magnetic Resonance or X-ray diffraction. The 
structure-function relationship can be investigated by performing site-directed 
mutagenesis. This will give a knowledge about the structure of the active site in 
TKI and facilitate the development of new nucleoside analogs. 
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Aims 
The complex regulation of TKI gene expression differs from one cell type to 
another. To create selective nucleoside analogs, it is of high value with a detailed 
knowledge about the phosphorylating enzyme regarding expression, substrate 
specificity and molecular structure. 
This Ph.D thesis describes two different approaches for studying the regulation of 
TKI. 
In the first part I investigated the relation between TKI mRNA and TK 
activity in normal quiescent human lymphocytes stimulated to enter the cell cycle. 
As different regulation mechanisms may cause development of malignant cells, I 
also investigated the relationship between TKI mRNA level and TK enzyme activity 
in a quiescent malignant cell type, chronic lymphatic leukemia (CLL). To measure 
the level of TKI mRNA a very sensitive method, Competitive PCR, was established. 
In the second part I studied the structure-function relationship of TKI TKI 
purified from lymphocytes was expressed as a glutathione-S-transferase fusion 
protein in Ecoli. Two TKI mutants with deletions from the C-terminal were 
constructed by the Recombination PCR method. In one mutant, TKI-193, a stop 
codon was introduced at amino acid position 194, deleting 40 amino acids from the 
C-terminal. According to a hypothetical structure for TKI no function-essential site 
is deleted in this mutant. In the other mutant TKI -176, 57 C-terminal residues were 
deleted. According to the hypothetical structure, two residues (CYS”~ and Arg”‘) 
which may contribute to ATP and/or substrate binding were absent in this 
construction. To evaluate any structure-function relationship, the recombinant TKI 
wildtype and TKI mutants were characterized and compared with native 
lymphocyte TKI . 
Background 
Thymidine kinase 
Th ymidine kinase (TK) - a salvage pathway enzyme 
The DNA precursors (dATP, dCTP, dGTP and dTTP) can be synthesised by two 
different pathways, the de nova pathway and/or the salvage pathway. In the de 
nova pathway the deoxyribonucleotides are synthesised from ribonucleoside diphos- 
phate through reduction of the 2’-hydroxyl group. The key enzyme for this reaction 
is ribonucleotide reductase (Thelander and Reichard 1979). In the salvage pathway 
the DNA precursors are synthesised by phosphorylation of deoxyribonucleosides, 
originating from the breakdown of DNA in dying cells or from damaged DNA. Figure 
1 shows a survey of the salvage pathway and the last steps in the de novo path- 
way leading to dTTP. 
dCTP 
dCK 4 
dCyd + dCMP + dCDP + CDP 
TK & inorganic t compounds 
dUrd + dUMP + dUDP + UDP 
TK J 
dThd + dTMP 
J 
dTDP 
4 
dTTP 
Figure 1: Synthesis of dTTP by salvage and de nova pathway. The right side rapraesant the de nova 
synthesis, while the left side is salvage synthesis. 
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In the synthesis of dTTP, production of dTMP is the critical step. dTMP can 
be produced either by methylation of dUMP or by TK phosphorylation of dThd. 
dUMP can be produced by TK phosphorylation of dUrd or by deamination of dCMP. 
Both deoxyuridine and thymidine are phosphorylated by TK, so this gives TK a 
central position in the synthesis of the dNTP’s. 
As denovo synthesis can provide a dividing cell with all the necessary DNA 
precursors, it would be easy to regard the salvage pathway solely as a “cheaper” 
way to provide DNA precursors. However, there are important roles for the salvage 
pathway enzymes. Cohen et al (I 983) have shown that in S-phase thymocytes’, 
the de novo synthesis is responsible for the production of the purine DNA 
precursors whereas the pyrimidine DNA precursors are synthesised primarily by the 
salvage pathway. Likewise, in resting or G, thymocytes, where there is no 
ribonucleotide reductase activity the salvage pathway provides the cell with 
deoxyribonucleotides necessary for DNA repair (Cohen et al 1983). 
dTTP as a regulator of the dNTP pool 
An important role for the enzymes in the salvage pathway is also to maintain a 
balanced dNTP pool. It is well known that an imbalanced dNTP pool can result in 
cell killing, mutation induction, induction of chromosomal aberrations and 
carcinogenesis (Kunz 1988, Meuth 1989). As shown in Figure 1 TK plays an 
important role in the dTTP synthesis. dTTP, on the other hand has a major role in 
regulation of the dNTP pool. Ribonucleotide reductase catalyses the reduction of all 
the NDP to dNDP and the regulation of this reduction is controlled by the balance 
between the end products, the dNTP’s. In the balance between the dNTP’s, dTTP 
’ thymocytes are immature T lymphocytes 
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is essential. An increase in the dTTP pool down-regulate reduction of CDP and up- 
regulate the reduction of GDP, which then up-regulate the reduction of ADP. So, 
an increase in the dTTP pool shifts the specificity of ribonucleotide reductase away 
from pyrimidine ribonucleotides and towards reduction of purine ribonucleotides 
(Thelander and Reichard 1979, Reichard 1987). As TK play an important role in 
dTTP synthesis, a deregulated TK will cause an imbalanced dTTP pool and that 
affect incorporation of the correct nucleotide into DNA. 
TK as a tumour marker 
As mention previously human cells have two TK’s, TKI and TK2. TKI is activated 
at the G 1 /S phase of dividing cells whereafter the level of TKl fluctuates with the 
progression through the cell cycle, being highest at DNA-synthesis (Bell0 1974, 
Munch-Petersen and Tyrsted 1977). TKI is therefore a good indicator of cell 
proliferation and is used as a tumour marker for a number of malignant diseases 
such as breast cancer (O’Neill et al 1992, Robertson et al 1990, Romain et al 1995) 
and non-Hodgkins lymphoma (Schwartz 1992, Hallek 1992). In a study of Romain 
et al (1995) 290 breast cancer patients were included in a 1 O-year follow-up study. 
Measurement of serum TKI activity showed a good correlation between TKI level 
and malignancy, and a high TKI level was strongly associated with shorter overall 
survival. 
Ellims et al (1981) have investigated the occurrence of TKI and TK2 in 
patients with chronic lymphatic leukemia (CLL). The distinction between TKI and 
TK2 activity were done, using the pronounced differences in substrate specificity. 
Both isoenzymes use ATP efficiently as phosphate donor, but TK2 can also use CTP 
efficiently, whereas it is a poor phosphate donor for TKI (Ellims et al 1981, Ellims 
et al 1983, Sakamoto et al 1984, Sakamoto et al 1992). Ellims et al (1981) showed 
that in the indolent forms of CLL the dominating enzyme was TK2, but in the more 
aggressive forms of CLL the dominating enzyme was TKI They suggested that the 
appearance and level of TKI in CLL is coupled to aggressiveness of the disease. 
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lsoforms of TK7 and TK2 in leukemic cells 
Enzymatic characterization of TK in several cancer types, has revealed TKs with 
enzymatic properties different from TKI and TK2 (Munch-Petersen and Tyrsted 
1985, Munch-Petersen and Tyrsted 1986, Munch-Petersen 1990). In these 
experiments the characterization was based on substrate kinetics with thymidine 
and ATP plus inhibition kinetics with dTTP. In three patients with AML (acute 
myelocytic leukemia) (Munch-Petersen and Tyrsted 1988) and in one patient with 
CLL (chronic lymphatic leukemia) (Munch-Petersen and Tyrsted 1986) a TK enzyme- 
form with thymidine substrate kinetics and TTP inhibition kinetics similarly to TKI 
from dividing lymphocytes was observed. However, the enzyme, nominated TKI- 
one (oncogenic form of TKI), had a lower molecular weight and an altered ATP 
kinetic than TKI (Munch-Petersen and Tyrsted 1986). In a patient with AMOL 
(acute monocytic leukemia) yet two other forms of TK appeared. These two 
enzymes, called TK3-one and TK4-one, differed from TKI and TK2 in kinetic 
properties and in molecular weight (Munch-Petersen and Tyrsted 1985). The three 
oncogenic forms of TK have also been observed in CML (chronic myelocytic 
leukemia), where three patients posses the TK3-one form, two patients have the 
TK2-one form and one patient has the TKl-one form (Munch-Petersen 1990). 
Apparently, leukemic cells express different forms of the normal 
counterpart, TKI and TK2. Whether the altered TK enzymes are part of the 
development of a cancer cell or a consequence of it, is not known. 
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The cell cycle 
TKI is a cell cycle regulated enzyme tightly associated with DNA replication. Before 
explaining the several regulation mechanisms responsible for TKI expression and 
regulation during the cell cycle, an overview of the mechanisms controlling the cell 
cycle will be presented. 
The phases of the cell cycle 
The proliferative cell cycle can be divided into four distinct phases; G,, S, G, and 
M. 
The genome is replicated in S-phase and in the following G, phase the cell 
prepares for entry into M-phase, where the chromosomes condense and structural 
proteins important for mitosis are synthesized. After separation of the duplicated 
chromosomes and subsequently cell division the cells transverses into the G, phase. 
Here, the cell synthesizes many factors and enzymes needed for replication, and it 
is by far the phase where the cycling cell spend most of its time. In late G, a major 
control mechanism for cell proliferation is exerted. The mechanism, called the 
restriction-point (R-point) (Pardee 1974) controls the onset of a new cell cycle. Only 
cells that have a certain amount of growth factors can pass the R-point and start 
a new cell cycle. If conditions do not support a new cell cycle, a normal cell will not 
pass the R-point, but will instead enter a G, phase. Cells in G, phase are non- 
dividing but have still the potential to reenter the cell cycle. While the G, cells await 
a stimulation to reenter the cell cycle, proteins and RNA molecules are degraded 
and the rate of protein synthesis is markedly decreased (Furukawa et al 1990, 
Hofbauer and Denhardt 1991). 
To be able to leave G, phase and enter G, phase the cell must respond to 
some “competence factors”, which for lymphocytes may be an antigenic stimulus. 
The competence factors enhance expression of a set of genes, called early-response 
genes, including the proto-oncogenes’ c-myc, c-fos and c-j& (Hofbauer and 
Denhardt 1991). It has been shown that especially c-myc protein is important for 
the commitment to leave G, phase, as cells in which c-myc expression is prevented 
do not leave G, phase (Evan and Littlewood 1993). When the competent cells 
respond to a second group of growth factors, “the progression factors”, e.g. 
lymphocytes respond to interleukin 2, they will progress into early G,-phase. Further 
progression into late G, phase depends on the availability and abundance of a third 
set of growth factors, such as the insulin-like growth factors-l (IGF-1) (Pardee 
1989, Hofbauer and Denhardt 1991). In late G, phase another class of genes, the 
delayed-response genes, are transcribed. These include the genes for among others 
the cyclin-dependent kinases, thecyclins, thymidine kinase, dihydrofolate reductase 
and DNA polymerase u (Hofbauer and Denhardt 1991). 
Transcription of some of these genes, e.g. the cyclins and the cyclin-dependent 
kinase are depending upon the product of the early-response c-myc gene (Furukawa 
et al 1990). At this point in G, the cell prepares for a new cell division, and after 
passage of the R-point the cell is independent of exogenous growth factors. 
2proto-oncogenes are the normal counterparts in the eucaryotic genome 
to the oncogenes carried by some retroviruses. A single mutational event in a 
proto-oncogene is sufficient to activate it so the oncogene product can 
contribute to the abnormal growth of cells. 
3c-myc, c-fos and c-jun encodes proteins that are implicated in 
transcription. The c-myc protein intertact directly with DNA and influence gene 
expression and DNA repair. c-fos and c-jun proteins contributes to the formation 
of the API comlex (gene regulatory protein) that bind to specific sites in 
promoter/enhancer elements and augment transcription (Hofbauer and Denhardt 
1991) 
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Control mechanisms in the cell cycle 
More than 100 genes responsible for cell cycle regulation have been identified 
(Hofbauer and Denhardt 1991). It is out of the scope of this thesis to present a 
detailed elucidation of the mechanism controlling the cell cycle, but I will give an 
overview of the mechanisms taking place in the cycle. 
C yclins and c yclin-dependen t protein kinases 
Progression through the cell cycle is tightly linked to the activation of cyclin- 
dependent protein kinases (Cdk). Activation of a Cdk requires binding to a 
regulatory protein, ~a cyclin. 
A general feature of the cyclin-Cdk complex is, that the concentrations of 
the Cdk stay constant through the cell cycle, whereas the concentrations of most 
of the cyclins fluctuate. This promotes a sequential activation and inactivation of 
the cyclin-Cdk complexes that control the progression through the cell cycle. 
To transverse the cell cycle different cyclins are required at different stages 
(figure 2). 
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Figure 2: Cp9ifl.S through the cell c yclus 
Cyclin D’s 
+ Cdk.2 
Cdk4 
Cdk6 
[ Cdk2 Cyclin E + Cdk2 
In progression through G, phase two cyclins are the key regulators. The D-type 
cyclins (Dl, D2, D3) which associate with either Cdk4 or Cdk6, drive the cell 
through the R-point (Lew et al 1991, Sherr 1994) by phosphorylation of the Rb 
(retinoblastoma) protein. From here, cyclin E in combination with Cdk2 takes over 
and controls the passage through the G,/S transition (Lew et al 1991, Dulic et al 
1992). After entrance into S-phase the cyclin E-Cdk2 complex dissociates and 
cyclin E is degraded (Sherr 1994). Cdk2 can now combine with cyclin A, into a 
complex which is believed to activate replication of DNA (Sherr 1993). During S 
and G, phase an inactive complex of cyclin B and Cdc2 (also called Cdkl) is 
accumulating. A dephosphorylation of Cdc2 in the cyclin B-Cdc2 complex at the 
end of G, activates Cdc2 and signals an entrance into M-phase (Hunter and Pines 
1994). In M-phase there is an important checkpoint to ensure that the mitotic 
apparatus is correctly formed and the chromosomes are properly aligned. The cell 
can only pass this point if cyclin B is degraded, resulting in the release of inactive 
Cdc2. 
There are more cyclins to control progression through the cell cycle than the 
above mentioned. These include cyclin C, F, G and H but their role is not fully 
elucidated (Hunter and Pines 1994). 
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Regulation by tumour suppressors 
The Rb protein is a turnout’ suppressor4 which is an important regulator of cell 
proliferation. Through the cell cycle the Rb protein alternates between an inactive 
phosphorylated form and an active hypophosphorylated form. Rb is 
hypophosphorylated in G, phase, phosphorylated just before S phase and remains 
so until late M phase. Active, hypophosphorylated Rb binds a set of regulatory 
genes that favour cell proliferation. The binding inactivates the regulatory genes by 
preventing these from binding to the appropriate gene sequence. 
Hyperphosphorylated Rb protein is unable to bind regulatory genes, which then bind 
to the target genes and start transcription (Levine 1993). 
One of the regulatory genes is probably the cellular transcription factor E2F. 
The promoters of several genes activated in late G, contain binding sites for E2F. 
These genes includedihydrofolate reductase, thymidine kinase and DNA polymerase 
CI. But also genes which are critical for controlling the entrance into S-phase, such 
as Rb and cyclin A contains a site for E2F. It is therefore assumed that E2F is a 
critical regulator of activation of genes at the GJS-phase boundary (Nevins 1992a, 
Farnham et al 1993). For example, during G,, hypohosphorylated Rb protein 
interacts with E2F and by that inhibits binding of E2F to the DNA (Chellappan et al 
1991, Weintraub et al 1992). However, when the cyclin E-Cdk2 complex (which 
signals entrance into S-phase) has been assembled in late G,, the Rb in the Rb-E2F 
complex is hyperphosphorylated (Cobrinik et al 1992, Hollingsworth et al 1993), 
thereby releasing “free” E2F, which can bind to the promoter and start transcription 
(Nevins 1992a, Nevins 1992b). 
Another control mechanism is exerted by the tumour suppressor ~53. p53 
is a transcription factor but the gene or genes it regulates is not fully elucidated. 
Levine (1993) has shown that when normal cells are exposed to UV irradiation, the 
?umour suppressor genes encode proteins that suppress tumour 
formation. If both allels of a tumour suppresor is lost by mutation, the lack of a 
functional suppressor can initiate a cancer 
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level of p53 protein increases due to a stabilization of the protein. The increased 
level of p53 protein blocks for progression through the cell cycle, allowing the cell 
to pause in G, while DNA repair proceeds. Cells with mutant p53 protein do not 
stop in G,and move into S-phase with damaged DNA (Levine 1993). 
CdK inhibitory proteins 
The assembly of the cyclin-Cdk complex and their phosphorylation of other cell 
cycle regulatory proteins, e.g. Rb allows the cell to progress through the cell cycle. 
Besides this positive regulation, negative regulation occurs at check points. These 
regulation mechanisms are under control of CKI proteins (Cdk inhibitory proteins) 
that binds to the cyclin-Cdk complexes and inhibits their activity. It seems that 
inhibition of a cyclin-Cdk complex is a question of how many “CKls” there are 
bound to the complex. During G, phase cyclin D-Cdk4 and cyclin E-Cdk2 complexes 
normally bind a single molecule of ~21 (Hunter 1993, Sherr 1994) and the complex 
signals progression into S-phase. ~21 is induced as part of the delayed early 
response to mitogen in cells entering the cycle from G, phase. However, the ~21 
gene expression is also under control of the tumour suppressor ~53. Increased level 
of p53 increase the level of ~21, which effect binding of more than one p21 
molecule to the cyclin E-cdk2 or/and cyclin D-cdk4 complexes. This inactivates the 
cyclin-Cd k complex, thereby preventing progression into S-phase (Sherr 1994, Peter 
and Herskowitz 1994). 
Two other negative regulators of G, progression are the tumour 
suppressor’s p27 and ~16. It has been shown that arrest of cells in late G, by 
addition of TGFB (transforming growth factor p) is associated with over expression 
of p27 (Peter and Herskowitz 1994). It is supposed that p27 inhibits cyclin E-Cdk2 
activity in the same way as p21 (Sherr 1994). Recently it has been shown that 
Cdk4 and Cdk6 activity is under control of pl6 (Lukas et al 1995). pl6 is important 
as a negative regulator in late G, as it inhibits phosphorylation of Rb by binding to 
the Cdks, thereby preventing progression into S-phase. 
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Cell cycle and cancer 
The R-point in late G, is an important control mechanism, to ensure that cells are 
properly “equipped” before they start a new cell division. The passage of the R- 
point and probably other minor checkpoints, are deregulated in malignant cells, due 
to deregulation of the cyclin-Cdk complexes (Hunter 1994). Lack of control can be 
due to aberrant expression of positive regulators, such as the cyclins and Rb, or 
lack of negative regulators, such as the CKI (~16, p21 and ~53). Both types of 
changes have been documented in tumour cells (Hunter and Pines 1994). 
Tumour cells do also display defects in a GJM checkpoint, allowing cells 
with damaged or incompletely replicated DNA to initiate mitosis. As mentioned 
previously, entrance into the M-phase is controlled by the cyclin B-Cdc2 complex. 
To enter M-phase the cyclin B-Cdc2 has to be activated, through a 
dephosphorylation of Cdc2. In normal cells DNA damaged by, e.g. radiation 
prevents dephosphorylation and arrests the cells in G,, by a yet unknown 
mechanism. In several tumour cell lines, the cyclin B-Cdc2 complex is 
dephosphorylated regardless of the state of the DNA and therefore enters M-phase 
with damaged DNA (Hunter and Pines 1994). 
TKI as a model system for S-phase specific events 
The combination of being cell cycle regulated and being involved in DNA synthesis 
have provided that TKI is used as a model system for the regulatory events taking 
place at the G,/S boundary of the cell cycle. An investigation of TKl gene 
expression will not only provide insight into regulation mechanisms in normal cells 
but also into cancer cells. 
A very good system for investigation of S-phase specific events is to use 
lymphocytes stimulated to cell division by mitogen. Peripheral blood lymphocytes 
are regarded as differentiated cells representing the end stage of lymphoid 
maturation. The cells are in a non-dividing stage and may have spent several years 
there without replicating DNA or undergoing mitosis. However, the cells have not 
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lost the ability to reenter the cell-cycle upon certain stimuli, e.g. by the mitogen 
PHA (phytohemagglutinin). PHA is an extract from the red kidney bean, Phase&s 
vulgaris, (Nowell 1960). PHA has an agglutinating effect on the red and white blood 
cells, but is also able to trigger biochemical and cellular events that transform the 
non-dividing lymphocytes into a metabolically active cell. Initially after PHA addition, 
an increase in RNA, protein and DNA synthesis is observed (Hausen et al 1969). 
The increase in the rate of DNA synthesis is observed at =20 hours after PHA 
addition and is followed by a concomitant increase in the size of the dNTP pool 
(Munch-Petersen et al 1973, Tyrsted and Munch-Petersen 1977). At the onset of 
DNA synthesis several late-response genes, including DNA polymerase, thymidylate 
kinase, dihydrofolate reductase and thymidine kinase (Hofbauer and Denhardt 1991) 
show dramatically increased activities. Therefore PHA stimulation of lymphocytes 
is a good model system for studying changes and regulation of S-phase specific 
enzymes, e.g. thymidine kinase. 
16 
Regulation of TKI expression 
The human cytosolic thymidine kinase locus (TKl) is located on chromosome 17 
q23-25 (Solomon et al 1993). The TKI gene is 12.9 kb and consists of seven 
exons and intervening introns. The size of the exons is: 130, 32, 111, 94, 90, 120, 
851 base pair (bp) for exons 1 through 7, respectively (Flemington et al 1987). 
Together they code for a 1430 bp mRNA with an open reading frame of 702 bp, 
specifying a protein of 25.5 kDa (Bradshaw 1983, Bradshaw and Deininger 1984). 
Transcriptional regulation 
Quiescent cells express very low levels of TKI (Bell0 1974, Johnson et al 1982) 
while at the onset of DNA synthesis, there is a severalfold increase in the rate of 
transcription, resulting in an increase in TK activity (Stuart et al 1985, Coppock and 
Pardee 1987, Stewart et al 1987). The very precise onset of transcription at the G,- 
S border suggests that sequences in the TKI promoter have an influence on the 
increase of transcription. That the TKI promoter can confer cell cycle regulation is 
seen from experiments with chimeric constructs of the TKI gene. When the non- 
cell cycle regulated genes, chloroamphenicol transferase (C/IT) (Travali et al 1988) 
and neomycin resistance gene (neo) (Kim et al 1988); respectively, are under 
control of the TKI promoter, both genes are maximally expressed in the S-phase, 
concomitant with the DNA synthesis. 
The expression of eucaryotic genes is governed by a gene control region 
that consist of promoter and regulatory elements. Generally, most promoters for 
genes transcribed by RNA polymerase II contain three motifs for sequence-specific 
DNA binding proteins; a TATA-box, a CCAAT-box(es) and GC-rich elements. The 
TATA-box binds the general transcription factor, TFIID, and through a series of 
reactions RNA polymerase II is bounded. It is assumed that the CCAAT box play a 
strong role in determining the efficiency of the promoter, but the CCAAT box can 
also be a target for regulation. The GC-rich sequences (GGGCGG) bind the 
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transcription factor SPI. The promoter region responsible for transcription of the 
TKI gene is located at region -456 to + 32 bp. It contains a TATA-like sequence, 
two inverted CCAAT sequences and several GC-rich sequences. The two inverted 
CCAAT-boxes in the TKI promoter is found at -40 (the proximal CCAAT) and at -70 
(the distal CCAAT), see figure 3 (Kreidberg and Kelly 1986, Flemington et al 1987, 
Arcot et al 1989). 
- 413 -231 -115 -71 -52 -41 -21 fl +61 
CCGCCC-GGGCGG-GGGCGG-ATTGG- GGGCGG -ATTGG-TTTAAA’ - 
Figure 3: The human TKI promoter. The numbers refer to the first nucleotide in the written sequence 
starting from + 1 which is the transcription start. +61 is the translation start. CCRU is the ceil cycle 
regulating unit, see text. The figure is based on Kreidberg and Kelly 1986. 
Site-directed mutagenesis of the distal CCAAT-box shows that the box is 
important for TKI expression. A TKI minigene, which was under the control of a 
TKI promoter with mutation in the distal CCAAT box, was transfected into TK- 
ts135 cells. The mutation (deletion of the first C in CCAAT) resulted in a loss of 
promoter activity (Lipson et al 1989). Recently, it has been shown that both the 
distal and the proximal CCAAT box contribute to the promoter strength but the 
contribution is not equivalent. Excision of the proximal CCAAT-box did not alter 
expression from the TKl promoter, whereas excision of the distal CCAAT-box 
reduced expression to 55% of that of the parental promoter (Mao et al 1995). 
Mutation of either the proximal or the distal CCAAT-box reduced the promoter 
strength to about 40% of that of the native TKI promoter. Apparently, a mutation 
‘TKts13 is a temperature-sensitive TK deficient mutant, derived from 
hamster fibroblast. As HAT (hypoxantine, aminopterin, thymidine) medium does 
not support the growth of TKts13, the transformants can be selected by their 
phenotype in HAT medium. 
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in a CCAAT-box is more fatal than a deletion, which can be explained by the fact 
that when a CCAAT box is removed, other protein binding sites can partially or 
completely substitute for the missing segment. It is suggested that the distal 
CCAAT box can substitute for the proximal CCAAT-box, but the reverse is not 
possible (Mao et al 1995). 
To delimit the minimal promoter sequence that confers cell cycle regulation, 
Kim and Lee (1991) created a series of TKI promoter subfragments with deletions 
from the 5’end. The TKI -promoter was fused to the neo gene and transfected into 
K12s cells. They identified a 70 bp region spanning - 133 to -64, designed CCRU 
(cell cycle regulatory unit, figure 3 page 17) to be essential for cell cycle regulation. 
This region contains the distal inverted CCAAT-box, a GC-island and an area (-84 
to -109) with E2F-like protein binding sites (the consensus sequence is 
5’TTTSSCGC, where S is C or G, Farnham et al 1993). Mutations of the E2F-like 
sequences eliminated the S-phase specific transcription of TKI (Kim and Lee 1992). 
In investigations of the promoter elements responsible for TKI regulation 
Arcot et al (1989) have shown that the distal and the proximal CCAAT-box bind the 
same cellular protein factor, NF-Y. It was shown that the proximal CCAAT-box has 
a higher affinity for NF-Y than the distal CCAAT-box. As the NF-Y protein normally 
binds to non cell cycle regulated promoters, the higher affinity to the proximal 
CCAAT-box may indicate an involvement in constitutive expression of TKI. Results 
from Pang and Chen (1993) support the idea of differential binding to the two 
CCAAT-boxes. They showed that the binding of a CCAAT-binding protein was 
growth specific. In quiescent young fibroblast (IMR-90, human embryonic lung 
fibroblast) no binding of nuclear protein could be detected, but in serum-stimulated 
fibroblast an increased level of binding was detectable. However, in old serum- 
stimulated fibroblast the binding activity was barely detectable. Competition 
experiments with other CCAAT binding proteins showed that the binding of the 
6K1 2 is a hamster lung fibroblast cell line. It is temperature-sensitive. 
When shifted to the non-permissive temperature, 39”C, the cells cynchronize in 
G,. 
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nuclear protein was highly specific for the distal CCAAT-box of the human TKI 
promoter. Pang and Chen (1993) suggested a unique identity for this binding 
protein, based on its physical properties. They named the protein, CBP/tk (CCAAT 
Binding Protein for TK gene). Recently, it has been shown by western blot that 
CBP/tk is identical to the NF-Y protein (Chang and Liu 1994). NF-Y consists of two 
subunits, NF-YA and NF-YB (Hooft van Huijsduijnen et al 1987). Both factors are 
required for DNA binding and both are present in the binding complex. Using the 
same cells as Pang and Chen (1993), Chang and Liu (1994) demonstrated that the 
A-subunit of NF-Y was expressed differently in serum-stimulated and quiescent 
cells. The level was high in serum-stimulated IMR-90 cells but absent in quiescent 
cells, whereas the level of NF-YB was unaltered. It was concluded that the altered 
expression of the A-subunit in quiescent and serum-stimulated IMR-90 cells 
accounts for the induction of TKI-mRNA in these cells (Chang and Liu 1994). 
Post-transcriptional regulation 
The TKI promoter is activated at the G,-S border, resulting in a S-phase specific 
increase in TKI -mRNA. However, the transcriptional regulation cannot fully account 
for the induction or increase in TKI mRNA and enzyme activity. Nuclear run on 
experiment’s reveal a 4-fold increase in transcription rate for serum stimulated cells 
followed by a 20-fold increase in TKl mRNA (Stewart et al 1987, Coppock and 
Pardee 1987). These results show the presence of other regulation mechanism. 
There are indications for post-transcriptional regulation through RNA 
processing. Investigations of BALB/c 3T3’ cells progressing from G, into S-phase 
have shown a dramatic change in the processing of TKI hnRNA (heterogeneous 
nuclear RNA) when cells reach the G,-S boundary. Cells were synchronised in G, 
by serum-starvation. In G, very little mature nuclear TKI mRNA was detectable, 
‘BALB/c 3T3 are mouse cells. 
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while in G, a very high. molecular weight TKI hnRNA appeared. At the G,.S 
boundary the very high molecular TK hnRNA was processed to smaller molecular 
TK hnRNA and an accumulation of the mature 1.4 kb TKI mRNA within the nucleus 
was observed. These results suggest that factor(s) required for processing of TKI 
hnRNA is either synthesized or activated at the G,-S boundary, allowing for the 
accumulation of mature TKI mRNA (Gudas et al 1988). 
Gudas et al (1993) investigated the TKI-mRNA level in Chinese hamster 
embryo fibroblasts CHEF/18 cells synchronized in G,, early G, and mid G,. After 
serum stimulation, the steady state level of TKl mRNA and transcription rate was 
investigated. They showed that the TKI specific transcriptional and post- 
transcriptional mechanism could be uncoupled. It was concluded that a 
transcriptional mechanism was involved in the regulation of TKI mRNA during 
progression from G, into the G,. For the progression from G, to the S-phase, 
primarily post-transcriptional mechanisms were involved. 
Translational regulation 
Studies of serum-stimulated rat cells transfected with different constructs of human 
TKI-cDNA, under control of a variety of heterogeneous promoters (Ito and Conrad 
1990) indicate that TKI protein and enzyme activity is regulated independent of 
TKI mRNA. When TKI cDNA was under the control of, e.g. the SV40 early 
promoter, TKI mRNA level was high through G, phase, whereas the protein and 
enzyme level were low until ten hours after serum-stimulation. The induction of TKl 
mRNA is therefore uncoupled from the induction of TKI activity and TKI protein. 
In experiments with HeLa cells, Sherley and Kelly (1988) have revealed a 
different post-transcriptional regulation mechanism. Cycling HeLacells synchronized 
by centrifugal elutriation and mitotic selection were used to investigate the relation 
between TKI mRNA, TKI activity and TKl protein. They observed that during a cell 
cycle the increase in TKI mRNA was less than 3-fold. Measurement of the TKI 
protein with a specific antiserum raised against the purified HeLa enzyme, revealed 
that the increase in TKI protein between G, and G, was 15-fold with a good 
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correlation to TKI activity level. Pulse labelling experiments showed that cells in S 
and G, incorporate [%methionine into thymidine kinase about 12-fold more 
efficient than cells in G,. It was concluded that the increase in enzyme activity and 
protein were due to increased utilization of TKI mRNA. 
Post-translational regulation 
Evidence for a post-translational regulation mechanism in cycling cells was found 
by Kauffman and Kelly (1991). Human minigenes were expressed in murine cells 
deficient in TK expression. The minigenes were under expression of the TK 
promoter, the heterologous SV40early promoter orthe HSV promoter, respectively, 
and all exhibit cell cycle regulation. By addition of nocodazole (NOCs) to the 
transfected cells, Kauffman and Kelly (1991) have delimited the timing of 
degradation of TKI protein to occur between metaphase and cytokinesis. Here, the 
half-life of TKI was less that 20 minutes, in comparison to 40 hours for the rest of 
the cell cycle. The specific degradation of TKI protein before M/G, phase may be 
controlled by sequences in the C-terminal of the polypeptide. A construct where the 
last 40 amino acids were removed (TKI ~40), was not cell cycle regulated and TKl 
protein and TK activity was stabilized throughout the cell cycle. Results from 
Kauffman et al (1991) support the importance of C-terminal residues in serum- 
dependent regulation of thymidine kinase. Transfection of serum starved mouse 
cells with TKI ~40 under control of an independent promoter resulted in expression 
of TKI protein and activity in quiescent (G,) cells (Kauffman et al 1991). 
In serum-stimulated HL-609 cells it was shown (Chang and Huang 1993) 
*NOC is a microtubule inhibitor, that arrest cells between metaphase and 
anaphase. 
‘HL-60 is a human promyelocytic cell line. HL-60 cells are 
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that the TKI protein was phosphorylated in a growth dependant manner, and the 
fluctuation of TK activity was correlated to the extent of phosphorylation of seryl 
residues (Chang and Huang 1993). Likewise, a growth dependent phosphorylation 
of TKI protein has also been documented in proliferative and M-phase arrested 
HeLa cells (Chang et al 1994). The TKI phosphorylation was 6 to &fold higher in 
cells arrested in M-phase than in proliferative cells and the phosphorylated TKI had 
a 1 O-fold lower affinity for thymidine (K, = 15 ,um) than TKI in proliferative cells 
(K, = 1.5 FM). Chang et al (1994) suggested that the hyperphosphorylation 
observed in M-phase results from a M-phase specific phosphorylation. 
Yet another regulation mechanism operating atthe enzymatic level has been 
found by Munch-Petersen et al (1993). In normal human lymphocytes TKI is 
functionally active as a dimer which in presence of ATP can form a tetramer (the 
so-called ATP effect). The ATP effect is reversible and the two forms of TKI have 
different enzymatic properties. The dimer (-ATP) has a low affinity for thymidine (K, 
= 15 PM), while the tetramer (+ATP) has a high affinity for thymidine (K, = 0.7 
PM). 
The results of Munch-Petersen et al (1993) and Chang and Huang (1994) 
shows there are two forms of TKI. The investigations of Chang and Huang (1994) 
was performed with crude enzyme extracts and it is suggested that a mitotic kinase 
be responsible for the change between the two forms. The experiments of Munch- 
Petersen et al (1993) showed that the two forms of TKI were enzymatically 
different and also had a different native molecular weight. As Munch-Petersen et 
al (1993) used pure enzyme and showed that the transition between the two TKI 
forms occurred at 4OC, it is very unlikely that a protein kinase associated with the 
enzyme is responsible for the transition. Whether the work of Munch-Petersen et 
al (1993) and Chang and Huang (1994) complement each other or the results which 
look similar, are due to different factors is not known. 
undifferentiated but can be induced to differentiation by TPA (12-0- 
tetradecanoyl-phorbol-13-acetate) 
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Structure of human TKI 
In the treatment of virally-induced human disorders and malignant conditions 
nucleoside analogues are widely used. These analogues must be phosphorylated to 
exhibit their toxic effect on the DNA synthetic level. To ensure the development of 
selective analogs it is important that the phosphorylating enzyme is characterized 
with regard to it’s structure, activity and specificity. 
X-ray crystallography or NMR (Nuclear Magnetic Resonance) can elucidate 
the 3D (three-dimensional) structure of a protein. Unfortunately, crystallization of 
proteins is time-consuming and may be difficult to succeed. Even through NMR- 
analyses of larger biomolecules are in rapid development, the size of the 
biomolecules is the biggest limitation. Molecules larger than 25-30 kDa cause 
problems due to the overlap of resonances and their increased line width. Such 
limitations make it difficult to resolve protein structure. 
However, as the sequence of a protein contains some information to define 
the 3D structure, data about protein folding, conserved regions and active sites can 
be obtained from EDB technology. These include the use of database technology 
to store, retrieve and compare known sequences; computer graphics to display 
models and manipulate known 3D structures. Together these techniques in 
combination with site-directed mutagenesis studies can give information of the 
possible 3D structure of proteins. Nevertheless, it is important to specify that the 
3D structure of a protein cannot solely be predicted from its amino acid sequence 
and therefore the computer models can only give a proposed structure. For an exact 
structure it is necessary to await a structure obtained by X-ray crystallography or 
NMR analyses. 
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Alignment of the primary structure of human TKI with other TKs 
The functional essential domains in a protein are most likely found in the highly 
conserved gene regions. By alignment of the primary structure of a protein from 
different species, the highly conserved regions can be identified. 
From size, quaternary structure, substrate specificity and feedback inhibition 
by dTTP all TKs can be grouped into two separate classes (Black and Hruby 
1990a). Class 1 comprises the Herpesviridae family, characterized by a subunit size 
of 49 kDa and functional active as a dimer. Class 1 TK is not feedback inhibited by 
dTTP and can use both dCyd and dThd as substrates. Some class 1 TKs are also 
able to phosphorylate dTMP to dTDP. The dTDP is produced by thymidine 
monophosphate kinase (dTMPK) (Gentry 1992). The best known member of class 
1 is probably Herpes Simplex Virus type 1 (HSV 1). 
Class 2 covers all the non-herpetic TKs, including human, chicken, hamster, 
mouse, E. co/i and the members of the foxviridae family. In this class the TK 
polypeptides have a subunit size of approximately 20-25 kDa, which assemble into 
an active tetramer. Class 2 members have a strict substrate specificity for thymidine 
and are feedback-inhibited by dTTP (Black and Hruby 1990b, 1992b). 
Figure 4 shows the alignment of the primary structure of several class 2 
TKs. The alignment is based on information from Gentry (1992) and Bockamp et al 
(1991). The figure shows seven regions of complete identity, nominated as domain 
1 through 7, identified by Black and Hruby (1990b). 
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domain 1 domain 2 
II 
HUM:MSCINLPTVLPGSPSKTROQIPVIL~GPMFSGKSTEL~M~RRVRR~FQIAQYKCLS' 
HAM:-NY----------------------,-----------,-,-----,-----N--- 
MO":--Y--------S-------------,-----------,-,-----,--------- 
~~~:-~-~~~-~-~----~~p-----~-~,-----------,-,-~~~~,~-~~~~~~- 
VAC : MNG-H-.L-I,----.---.--,I,-----,Y.------V 
/- 
I--- 
H"M:VIKYAKDTRYSSSFCTHDR PACLLRDVAQEALGVAIVI" 
-:--------------S-------D----------.-----A-,-. 
MO~:-----------N--S------.~----M-----.~..L----,-. 
CHI:LV--------T~GVS---.--..-R---A-Q-.Y..---S-,-- 
VAC:T---SN-N--GTGLW---K-NF---E-TK-C--LESITDFSj-- 
domain 3 domain 4 
I 1 I 
HUM:GIDEGQFFPDI~MEFCEAMANAGKT~VIVAALDGTFQRK~PFGAILNLVPLAES1'5 
-:-----------,V----V-------,-.-----------,A--S---------- 
~~~:-~---~~~~~~,"~~--~-~~~~~~,~~------~~~~~,~~~S~~~~~~.~~~ 
CHI:-----------,V----K---T---,-------------,A--S----Y-.--. 
VAC:-----------,V----R---E.-I,-------------/..NN.---I--S-M 
i I I 
domain 5 domain 6 domain 7 
/ I - 1 
H"M:~VVKLTAVCM~ECFREAAYT~KRLG~TEKEVEVIGGADKYl~SVCR~LCY189 
HAM:,...--..--,---------,----,L-------------.,----,v-- 
MO":,---..-.--/---------,----,L--------------,--..,--- 
CHI:/----N----I-.Y..-S----IA-R---lA.R------------~----~A-- 
VAC:I---------IK--K--SFS~---JE-T-I-I----N-M-Q~..--~K-- 
I I - - 
HOM:FKKASGQPAGPDNKENCPVPGKPGEAVAARKLFAPQQILQCSPAN."' 
-:---S-V-------------L-Q---.S-V--------V--HNST.- 
MO”:---S-A-T--S-..,--L-L-Q----LW-----S--V--YNS-- 
CHI:-Q-.RP-QL-SE----V-MGV-QLDMP-S--I--S 
VAC: IDS 
Figure 4: Multiple aligment of primary sequence of vertebrate TKs from: HUM; human, HAM; hamster, 
MOU; mouse, CHI; chicken. Poxviral thymidine kinase from VAC; vaccinia virus. Domain l-7 represent 
sequences having complete identity with human TKI. Identical residues are indicated by ‘-‘. Additional 
gaps are indicated by ‘. : 
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As seen from figure 4 the vertebrate TKs are very closely related to each other. 
Further, a significant sequence homology between human TKI and the vaccinia 
virus (a poxvirus) TK is observed, with 82% amino acid identity (Kauffman and 
Kelly 1991). The vertebrate TKs have additional 15 N-terminal and 42 C-terminal 
(human) residues, respectively (Boyle et al 1987). Whether, the vertebrate TK was 
the ancestor and lost its N and C terminals when it became incorporated into the 
virus genome, or a poxvirus-like enzyme was the ancestor, is an open question 
(Boyle et al 1987); Kauffman and Kelly (1991) have shown that the’last 40 C- 
terminal residues in human TKI are responsible for cell cycle regulation of human 
TKI, but not for TK activity. During evolution the viral TK may have lost the C- 
terminal region of the protein, because cell cycle regulation is not necessary for 
virus multiplication. Another possibility is that the C-terminal of vertebrate TKs has 
evolved to serve as a regulatory function, rather than having an enzymatic role. 
The homology of the vertebrate TKs with E,co/i TK (not shown in the figure) is 
around 50% (Bockamp et al 1990). According to a genealogic tree relating 
prokaryotic, viral and vertebrate TK amino acid sequences (Bockamp et a) 1990, 
Gentry et al 1992), E.co/i does belong to a group separate from the groups of 
vertebrates and pox viruses, respectively. Herpes viral TKs are not included in 
Figure 4 because apart from three highly conserved areas (see next chapter) there 
is no apparent similarity between the sequence of herpesvirus TKs and 
vertebratelpoxviral TKs. As mentioned earlier most (if not all) herpes viral TKs have 
deoxycytidine kinase activity and it is suggested that herpes viral TKs are evolved 
from cellular deoxycytidine kinase (Harrison et al 1991). 
Alignment of the primary structure of several TKs with isofunctional 
en2 ymes 
In an attempt to address a function of the highly conserved regions, alignment with 
an isofunctional enzyme with resolved structure can reveal the function of the 
conserved regions. Proteins with the same function do often have a similar 
conformation. HumanTKl belongs to the family of nucleotide-binding enzymes, and 
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two isofunctional members of this family are adenylate kinase (ADK) and the protein 
elongation factor EF-Tu. ADK is a phosphate-transferring enzyme, catalysing the 
reversible monophosphorylation from adenosine monophosphate to thediphosphate 
(MgATP + AMP + MgADP + ADP). EF-TU binds GTP and this complex binds to an 
amino-acyl tRNA molecule. The crystal structure for both ADK and EF-TU has been 
resolved by X-ray crystallography (for ADK: Pai et al 1977 and for EF-Tu: Berchtold 
et al 1993). For ADK an NMR structure (Fry et al 1985, Yan and Tsai 1991) has 
also been solved. 
Folkers et al (1991) have aligned some class 1 and class 2 thymidine 
kinases with ADK and EF-Tu. They have predicted three conserved regions to be 
essential for substrate binding and transfer of phosphate groups. The regions are 
the nucleotide binding site (A), the thymidine binding site (B) and a site which may 
be important for phosphate binding and transfer (C) (figure 5). 
A: 
The nucleotide binding site: 
HSVl 
EBV 
HUM 
H?4M 
MOU 
VAC 
ADK 
EFT” 
48 TLLRvYIDgPHGMmTT 
40 PACSLFLECAPGVSML 
18 RGQIQVILCPMFSUEL 
18 RGQIQVILgPMFSGKsTEL 
18 RGQIQVILGPMSF-EL 
3 GGHIQLII~PMSF~EL 
7 KSKIIFW~GPGS~QC 
10 PHVGVNIT~WDH~LT 
Mg2+ binding aspartic acid: 
B: 
The thymidine binding site: 
HSVl 156 ALTLI FDRHPIAAL 
EBV 142 DCWIL -LLSAS 
HUM 102 FPDIMEFCEAMANAGKTVIVAALD.GT~PFGAI 
H?.M 102 FPDIVEFCEVM?+NAGKTVIVAALD.GT~FGSI 
MOU 102 FPDIVDFCEMMANEGKTVIVAALD.GT~FGSI 
VAC 87 FPDIVEFCERMANEGKIVIVAALD.GT~PFNNI 
ADK 98 EVKQGEEFERKI..GQPTLLLYVDAGP--------- 
EF-TU 84 AD...WKNMITGAILILWAATD-G---------- 
HSVl 
EBV 
HUM 93 VIGIDEGQF 
HAM 93 VIGIDEGQF 
MOU 93 VIGIBEGQF 
VAC 78 VIGIDEGQF 
ADK 89 GFLIBGYPR 
EFTU 75 YAHVD_CPGH 
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c: 
phosphate binding and transfer: 
HSVl 317 mRPMHVF.I.LDYDQSPA.eAL 
EBV 314 -~SE........FQDDL...~EI 
HUM 164 mGTEKEVEVIGGADKYHS.VCRLCY 
HAM 164 uGLEKEVEVIGGADKYHS.VCRVCY 
MOU 164 wGLEKEVEVIGGADKYHS.VCRVCY 
VAC 149 uGEETEIEIIGGNDMYQS.VCRKCY 
ADK 14.9 ~ETYYKATEPVIAFYEKRG~VN 
EF-TU 
Figure 5: Aligment of various TK sequences with the isofunctional ADK and EF-TU. HSVl: herpes 
simplex virus type 1 TK, ESV; epstein barr virus TK, HUM; human TK, HAM; hamster TK, MOU; mouse 
TK, VAC; vaccinia virus TK, ADK; adenylat kinase from rabbit muscle, EF-TV; elongation factor. 
Homologous sequences are denoted in dark and underlined. ‘: “denotes gaps and “-” denotes that the 
homologous sequence could not be found. The figure is constructed after that of Folkers et al I199 II. 
The proposed secondary structure of TKI 
Computer programs with the probability for an amino acid to promote o-helix, p- 
strand or ,&turn, respectively, are used to predict the secondary structure of a 
protein. Further, comparisons with isofunctional enzymes are performed, as 
isofunctional enzymes may share some characteristic supersecondary structure. An 
example is the Rossman fold, a unit consisting of a ,f3up-unit. The Rossman fold is 
a very common feature in nucleotide-binding proteins (Bradley et al 1987). 
The conserved domains for human TKl and an alignment of the predicted 
secondary structure (Folkers and Trumpp 1987, Folkers et al 1991) led to a very 
high degree of similarity with ADK. This resulted in a hypothetical model for the 
human TKI 3D structure, see figure 6 and table 1. 
29 
Figure 6: The proposed structure of A: human TKT compared with the X-ray structure of B: ADK from 
rabbit muscle (Fry et al 19851. a-helixes are illustrated by bars and &strands are illustrated by arrows. 
A is reprinted with permission from Folkers, G., Trumpp-Kallmeyer, S., Gutbrod, O., Krickl, 3.. Fetzer, 
J. and Keil, G.M. J. Cornput.-Aided Mol. Design, 5 (199 I] 385404. Copyright 199 1 ESCDM Science 
Publishers B. V.. 
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Table 1: The hypothetical location of B-strands and a-helixes in human TKI. The numbers refer to the 
$-strand and a-helix, starting from the N-terminal in figure 6. The table is based on information from 
Folkers et al 119871, Folkers and Trumpp 119871, Folkers et al 119891 and Folk.% et al (19911. 
b-strands in human TKl 
P2 F’=QlAQ” 
P3 Vs41G196 
P4 V’201VALL’25 
P5 V’85CRLC’89 
o-helixes in human TKI 
al K3*STELMRRVRR4’ 
l.72 see text 
a3 see text 
a4 see text 
a5 
I 
P’03DIMEFCEAMANA”5 
a6 
a7 
Comparison of figure 6 and table 1 reveals 3 u-helixes (2, 3 and 4) depicted 
in the figure not accounted for in table 1. These a-helixes are lying between amino 
acid 49-92 and secondary structure prediction state that it is an area with large 
helical character (Folkers et al 1991). Unfortunately, this area has a low primary 
structural homology to ADK, so alignment with ADK could not specify the precise 
location of the u-helixes. As seen from figure 4 (page 25) it is also an area with 
very high variety through the various vertebrate TKs, so it is assumed that this 
region is located at the surface of the protein and does not play an essential role in 
substrate binding and conversion (Folkers et al 1991). 
Folkers et al (1991) predict that human TKI contains five parallel P-strands 
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and a very common structural feature for nucleotide binding enzymes. It is, as 
already  mentioned,  the  mononucleotide  binding  domain also called the Rossmann 
fold. In figure 6 and table 1 it corresponds to &a1&. 
In  this  theoretical model, the phosphate-binding loop, represented by  the 
sequence GZ6PMFSGK, appears after  the first B-strand.  This loop is followed  by a 
very  high  conserved  hydrophilic sequence, presumably an  a-helix.  The  putative  Mg- 
binding Asps7 is located at the C-terminus of the third P-strand. The thymidine 
recognition site with the sequence FlZ8QRK is found  in  a  loop  region  after  the  fourth 
P-strand, just above the nucleotide-binding site. Approximately 40 amino acids 
downstream of the supposed thymidine recognition site are the homologous 
sequence K'64RL, the  phosphate  binding site. Geometrical, it is assumed that the 
phosphate  binding site is above the  nucleotide  binding  site. 
The hypothetical  structure  of  human TKI has  been  validated by a 
Ramachandran  plot, a two-dimensional  plot  of  the  phi (p) and psi (U/) angles in  the 
peptide  bonding. Due to  the partly double-bonding  character of  the  peptide  bond 
and sterical  hindrance  between  the amino acid R-groups, the  free  rotation  around 
the phi (-N-C"-) bond and the  psi (-Ca-C') bond  is  restricted.  The Ramachandran plot 
gives the permitted values of phi and psi for different residues. A proposed 
structure  is  validated if less than  5-10%  of  the  phi and psi coordinates are located 
in  theoretical  unfavored areas. The theoretical TKI structure  was also investigated 
for  intramolecular  hydrogen  bonds and the appearance of charged amino acids  in 
the  core region. To achieve the  most stable  structure, the polar  groups in the  core 
region will form  hydrogen bonds. In the model, this  was  the case for 90% of  the 
internal polar groups. Normally, charged side chains will only appear in the core 
region, if  they  participate  in  the  catalytical process. In  the model, there  were t w o  
charged  amino  acid in the  core region, Lys3' and Asp". It is  suggested that Lys3' 
participate in phosphate  binding  and  Asp97  in  Mg"-binding. It must be stated  that 
this structure for human T K I  is purely hypothetical. To examine if and how  the 
conserved  regions are important  for enzyme structure and function,  site-directed 
mutagenesis must be performed. Up-to-date, there are no reports about site- 
directed mutagenesis of human TKI. As previous mentioned the homology of 
human  TK1 with ADK  and several other class 2 TKs is  high  (figure 4, page 25 and 
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5, page  27). Therefore, results  from  site-directed  mutagenesis  in ADK and  class 2 
TKs may provide an insight  into  the  function essential  sites in  human TKI. 
In  the  following Iwill describe the  three  conserved  regions  (figure  5) and the 
site-directed  mutagenesis  experiments  performed  in  related TKs  and ADK. 
The  nucleotide  binding  site 
Many ATP-binding enzymes bind ATP as a complex with Mg2+. The consensus 
sequence for  the  Mg-ATP  binding site, consist  of two motifs,  nominated  segments 
A and B. Segment  A (figure  5.A),  the ATP-binding motif  consists  of  the  consensus 
sequence GXYYXGKZ, where X is any  amino acid, Y is often a glycine  or a proline 
and for ATP/ADP binding  protein Z is  usually a  threonine (Rose et al 1985).  This 
sequence is also called the glycine loop because of its relative high contain of 
glycine.  Structurally  this  segment is a  flexible loop, bounded by a  P-sheet  and  an 
a-helix  and is a part  of  the Rossmann fold.  The  importance of  the  glycine  loop  has 
been shown  by Liu and Summers (1 988) by site-directed  mutagenesis. In HSV-1 the 
consensus  sequence  is  GXXGXGKT and changes of any of  the Gly to Val  resulted 
in an inactive enzyme. 
Segment B (figure  5.A)  is  the  Mg2+-binding  motifs,  which in t e  most  simple 
form  is represented by  the consensus  sequence Xh  Xh  Xh  Xh D, where  Xh  is  any 
hydrophobic amino  acid (Myles  et al 1991 ). The  aspartic  acid is  the  key  residue in 
this segment and is normally found at the end of a P-strand (Black and Hruby 
1992a). In ADK (from  pig  muscle)  the ATP  binding  consensus  sequence  is  located 
between amino acid Gly15 and GlyZ2 (figure 5.A and 6.B) and the Mg2+ binding 
amino acid is  predicted to  be Asps3 (Yan and Tsai 1991). NMR-analyses of ADK 
from rabbit muscle (Fry et al 1986) show, that binding of Mg-ATP involves 
structural  changes  in several  regions of  the enzyme, with  the largest  displacement 
(6  A) occurring  at  the  glycine-rich  loop.  During  binding  of  Mg-ATP  the  conformation 
of the protein change from an "open" to  a more "close" conformation. This 
conformational change may  affect:  1) The  accessibility to  the substrate  binding  site. 
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(2) Modification  of  binding-site  affinity.  (3) The  conformational  change  may  bring 
the  catalytic  groups  towards  the  reaction  centre and facilitate  the  transfer  of a 
phosphoryl  group (Fry et al 1986). The crystal  structure  of ADK was  first  resolved 
by Pai et  al  (1 977). They  suggested the ATP  binding-site to  be  located  between a- 
helix  69-84 and 100-107, and then  according  to  figure 6.B, to  be located  on  the 
right side of  the  glycine loop.  The  AMP  binding-site was  suggested to  be located 
between  the  glycine  loop  16-22, u-helix 23-30 and the  C-terminal a-helix (figure 
6.B). This prediction has caused  debate and several reports  suggest  a 
rearrangement  for  the  localisation  of  the two substrates. Kim et al (1 990) have 
performed  site-directed  mutagenesis of several  highly  conserved arginine’s, which 
were predicted to interact with phosphoryl groups of AMP and MgATP. They 
mutated Arg44, Arg13’, Arg13’ and Arg14’ to  Ala and found  that Arg13’ interacted 
with  MgATP  and  with  AMP  but  with a decreased affinity. Arg13’ interacts  only  with 
AMP and  Arg’49  interacts with  AMP and to a lesser extent  with  MgATP.  Arg44 does 
not  interact with either AMP or MgATP  but  may be located  in  the  AMP  binding-site. 
Based on  these  results  they suggested  placing ATP on  the  left side of  the loop, with 
the a and  P-phosphate  groups  of ATP around the  glycine  loop. The  AMP binding  site 
is placed  on  the  right side.  Binding of ATP to  the glycine  loop agrees with results 
from Yan  and  Tsai (1  991 ). ’!jMg’+-NMR analyses on ADK (from chicken)  reveal that 
Asp93, which  correspond  to  Asp97  in  human  TKI,  participates  in  binding  of  the co- 
substrate  Mg-ATP.  Substitution  of  Asp93 + Ala  resulted in a 650-fold decrease in 
V,,,(ATP). Asp93  binds  the Mg2’  which,  in  turn orients the  polyphosphate  chain so 
the  phosphate  groups are accessible for  transfer  (Yan and  Tsai 1991 1. Interaction 
of  the  highly  conserved  glycine  rich  loop  with ATP instead of  AMP is  more  probable 
as ATP  is generally  required for  most kinases, whereas AMP  is  not  (Gentry  1992). 
Black  and Hruby  (1 992a) showed  that  site-directed mutagenesis of  the  Mg- 
binding Asp8’ in vaccinia  virus TK (which correspond to Aspg7 in human TKI)   to  
hydrophobic residues; AspS2 -+ Leu,  Asp8’ * He, Asp8‘ + Val, respectively,  resulted 
in an inactive enzyme. But, mutation of AspSZ --z Asn resulted in a mutant with 
minor TK activity (9.4%). All  the above  mentioned  mutants  retained  their  tetramer- 
form.  When GlyE4, which is part  of  the  highly conserved region around the Mg’+- 
binding site, was  mutated  to a Val, the enzyme activity as well as the  tetramer- 
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conformation  was  lost. This shows  that Asp" in vaccinia  virus  is  involved in Mgz+ 
binding whereas Glys4 has  a structural  role  in  the  oligomerization  of  the enzyme. 
Recently, a crystal  structure  of  a  truncated,  but  fully  active  HSV-1 TK was 
resolved (Wild et al 1995). HSV-1 TK was expressed in €.coli as a glutathione 
(GST)-fusion protein. Due to unspecific cleavage by thrombin, the 33 N-terminal 
amino  acid  was  deleted  (Michael  et  al  1995).  From  the  crystal  structure it appears 
that  the phosphate-chain  of ATP transverse the glycine  loop but  the  Mg2+  binding 
amino  acid  is not revealed (Wild  et al 1995). 
For human TKI segment  A  is  predicted to span amino acid  26-34,  while Dg7 
in the  motif VIGIDg7 may  be the  putative  Mg2+-binding residue (these t w o  
sequences  correspond to domains  1 and 3 from figure 4). 
The thymidine  binding  site 
As seen in figure 5, region B includes a sequence, for  human TKI  represented by 
the consensus  sequence F"'QRK and for  HSV-1 TK represented by F"'DRH. This 
sequence is highly conserved between class 1 and 2 TKs, but HSV-1 TK has an 
Asp'62 corresponding to  Gln114 in vaccinia virus TK. In the  view  of  the  different 
substrate  specificity  for  the  two enzymes, it was suggested that  this  domain  may 
be involved  in  nucleoside  binding (Folkers and Trumpp 1987). Experiments in  favour 
of this  proposal are seen with HSV-1 TK where  mutation  of  Asp'62 + Asn  resulted 
in a  completely  inactive enzyme and mutation  of Ala'@ + Thr  resulted  in  decreased 
affinity  ofHSV-1 TK for  the  nucleoside analog  BvdU (E-5-bromovinyl- 
2'deoxyuridine)  (Darby  et al 1986).  Another example is seen in the  acyclovir  (ACV)- 
resistant  mutant  of a varicella  zoster  virus,  VZV, (a herpesvirus, not  shown in the 
figure).  In  this TK  mutant, in comparison with the  wildtype VZV, is a change of the 
highly conserved Arg13' in  the F128DRH motif  to Gln. It was  suggested  that  this 
amino  acid  change  was  responsible  for  the  lack  of  ability to phosphorylate  acyclovir 
(Sawyer  et al 1988). The F12'DRH motif  in  wildtype  VZV  corresponds to F"j'DHR 
in HSV-1 TK so this indicated that  the F16'DRH motif  is  important  for  recognition  of 
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acyclovir.  However, HSV-1 TK accepts acyclovir as substrate  whereas  BHVI-TK 
(a  bovine herpes virus) does not, and both TKs posses similar  amino  acids in the 
FDRH motif. Thus,  additional amino acids may be part  of  the  thymidine  recognition 
site. For HSVI-TK  two other highly conserved regions, D215RL and K317RL, have 
been  suggested to  be part  of  the  active site. Michael  et al (1  994) have  constructed 
the  mutants Asp215 + Arg and Lys317 + Gly. Both  mutants  were  enzymatical active, 
with  the same K, value as the  wildtype,  but a 4-fold  lower V,,,. These mutations 
are rather dramatical, with a change in  polarity and an increased size. Therefore, 
Michael  et al (1 994) suggested a location  for Asp215 and Lys317 on  the  surface of 
the  protein  instead of the  core region.  ,This contradicts  the  hypothetical  model  for 
HSVI-TK (Folkers et al 1991)  but agrees with the preliminary X-ray  structure of 
HSVI-TK  (Wild  et al 1995). 
A phosphate  binding  site 
Region C contains a sequence which is very high conserved in many TKs. For 
human TKI the sequence is represented by the amino acids: K’64RL and it is 
assumed that  this  region  might play a role  in  phosphate  binding  and  transfer of a 
phosphate  group to thymidine (Folkers et al 1991 ). 
Also, in  region C and near the  C-terminal are two highly  conserved  residues 
in nearly all TKs, C Y S ’ * ~  and Argle7,  believed to have an influence  on ATP  and/or 
phosphate  binding (Folkers et al 1991 ). 
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Experimental 
Introduction 
The  regulation  of TKI  gene expression  is  complex  and  differs  from  one  cell type  to 
another. To create  selective  nucleoside analogs, it is  of  high value with a  detailed 
knowledge about the phosphorylation enzyme regarding substrate specificity, 
molecular  structure  and  expression. 
In the first part of my Ph.D thesis I wanted to investigate the relation 
between  expression  of TKI mRNA and TKI  activity in quiescent  human 
lymphocytes  stimulated  to enter the cell cycle  by PHA stimulation. As different 
regulation  mechanisms  may  cause  development of malignant cells, I also wanted 
to  investigate the TKI mRNA and TKI  activity relationship in a  quiescent  malignant 
cell type,  chronic  lymphatic leukemia (CLL). 
As  mentioned earlier (page  14),  lymphocytes  stimulated to  growth  by PHA 
are  a very  used  system  for  investigations  of S-phase specific  events  and the  system 
is  well  characterized  with  respect  to TK activity,  DNA  synthesis and cell  division 
(Barlow and Ord 1975, Munch-Petersen and Tyrsted 1977, Tyrsted and Munch- 
Petersen 1977). However,  the  level  of TK1 mRNA in  quiescent and PHA stimulated 
lymphocytes  has  not been  determined. 
The  standard  assays  for  detection and quantification  of RNA include 
Northern  blot  hybridization a d RNase protection assays. Nevertheless, beside being 
very time-consuming, the quantity of RNA required and the efficiency of RNA 
binding to  the hybridization membranes limits the method. Especially, when  low 
copy mRNA as TKI mRNA is used. As the material from patients with CLL was 
restricted,  a  more  sensitive  method  was  necessary.  The  competitive PCR method 
(Gilliand  et al 1990)  can  provide  a  much  more  sensitive  method  of  detection and 
quantification. The method  includes  purification  of  total RNA and  reverse 
transcription  of RNA to cDNA.  The  quantification is  achieved by  co-amplification  of 
37 
a  competitive  template that uses the same primers as those  of  the  target  cDNA,  but 
the  competitive  tempates  can be  distinguished  from  the  target  cDNA after 
amplification. The relative amounts of target cDNA versus a competitor can be 
revealed by ethidium-stained gel. Because the  starting  concentration  of  the 
competitive  template is known,  the  initial  concentration  of  the  target cDNA, which 
is  taken as representative  for  the mRNA can be determined. 
Comparing  the  ratio  of TKI mRNA and TKI  activity  in healthy  lymphocytes 
and in CLL cells,  respectively,  may  reveal  differences in  the  regulation  of TK I .  
I also wanted  to  study  the  structure-function  relationship  of  TKI.  As described, the 
3D  structure of human TKI  (figure 6.A, page 29) is  only  a  hypothetical  structure 
based  on computer  models and alignment  studies. 
Structural  elucidation  of  proteins by NMR-analyses or X-ray  crystallography, 
demand  amounts  in  the range of  mg.  The  purification  of TKI  from human  sources 
is  a  very  time-consuming  task, as the cellular amount  of TKI  is  very  low.  From 1.5 
x 10” PHA stimulated lymphocytes (isolated from 12  I of donor blood) -30 p g  
pure TKI  can  be isolated  (Munch-Petersen  et  al  1991). Therefore, having an  easily 
available source of pure TKI is important. This can be achieved by expressing 
eukaryotic genes in  procaryotes  such as €.coli. 
In 1994, Jensen constructed an  expression system  for  direct  expression  of 
human TKI  in €.coli. The amino acid coding sequence of TKI was cloned from 
pTK1 1 (Bradshaw and Deininger 1984)  into a pET3a vector and transformed €.coli 
BL21  (DE3)lysS. With  this  system  the  unmodified  TKI  protein  was expressed but 
the  yield  was  only  1  mg  TKI  proteid bacterial  culture,  before  purification. For this 
reason, I have  chosen to  work  with a different  expression  system  (pGEX2T-TKI) 
where  the  human TKI gene is expressed as a fusion  protein  with  glutathione S- 
transferase (GST). Fusion proteins  have  the advantage that  the  bacterial  part of  the 
fusion  protein  “masks”  the  eucaryotic gene. This  normally  allows  for  expression  of 
larger amounts  (Marston  1986). 
To achieve information about the structure-function relationship I have 
constructed two  TKI  mutants.  As  the  long  term  perspective is to  perform NMR- 
analyses on  TKI polypeptide,  this had an influence  on  the  type  of  mutants. The 
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subunit  molecular size of TK1 is 24 kDa (234 amino acids) and in absence of ATP 
it will appear as a  dimer (48 kDa), which  is above the  limit  of  what  can  be analysed 
by NMR. Therefore,  deletion‘s mutants  were  constructed.  In one mutant,  TK?-1 93, 
a stop codon is introduced a t  amino acid position 194, deleting 40 amino acids 
from  the C-terminal. According to  the  hypothetical  structure,  no  function-essential 
site  is  deleted in this  mutant. The  other  mutant, TKI-176, contains  a  stop  codon 
at amino acid position 177. According t o  the hypothetical structure, the two 
residues C ~ S ” ~  and Arg”’, which may contribute to ATP and/or  substrate  binding 
are removed.  CyslE6 and Arg’” are in a supposed  P-strand  region, covering  amino 
acid  1 85-1 89 (table 1, page 30). Beside deleting  the  last P-strand,  a part  of  the  last 
putative a-helix (number 7) are also deleted. 
The stop codon was introduced by site-directed mutagenesis. The PCR 
method  is  best  known as a method for detection and amplification  of a specific 
DNA sequence, but PCR is also an excellent  method  for  site-directed  mutagenesis 
of a DNA sequence. Modifications can be  introduced,  because  the  primer  sequence 
is  incorporated  into  the  amplification  products.  Substituting one or a few 
nucleotides  in  the  primer sequence will cause  alterations  of  the DNA sequence. The 
PCR-product  can then be used in  cloning  procedures. One strategy  for  subcloning 
of PCR fragments is to take advances of €,coli’s ability to  recircularize linear 
plasmid molecules by a recombinational process. The recombination PCR (Jones 
and Howard 1991, Jones and Winistorfer 1992, Jones 1994) is a method for 
making  DNA  joints in vivo by  the  recombination  of PCR-generated homologous  DNA 
ends in €.coli. The  basis  for  this event is that  DNA ends containing  short  regions 
of  homology  can  undergo intramolecular recombination in  vivo in €.coli (Conley et 
al 1986a, Conley et al 1986b). Even recombination-deficiency (recA-) cells can 
produce  transformants  from linear DNA, although with an  approximately  40-fold 
lower  frequency  (Conley and Saunders 1984). 
The mutants and the recombinant wildtype proteins are expressed and 
purified. Pure enzyme is used for enzymatic characterizations. To evaluate the 
effect of deleting 40 and 57 amino acids, respectively, comparisons with the 
recombinant  wildtype and the  native  lymphocyte  TKI are performed. 
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Methods for  quantification of TKI mRNA  in  healthy  lymphocytes  and 
in lymphocytes from patients with CLL. 
Cells 
Peripheral  blood from  six  control persons was  collected in Heparin vacuum  tubes. 
Peripheral  blood, fromfive patients with untreated  chronic  lymphatic  leukemia (CLL) 
was similarly  collected at Roskilde Hospital. 
Isolation of mononuclear  white blood cells 
The lymphocytes were isolated by the Isopaque-Ficoll  gradient centrifugation 
(Bayum  1976). Peripheral blood (20 ml) was  transferred to  50 ml centrifuge  tubes 
and centrifuged 10  min  at  900 RPM. The plasma  layer was  discarded  and an equal 
amount  of PBS (phosphate  buffered saline) was added. The plasma/PBS solution 
was placed  on  top  of 2/3 volume  of Isopaque-Ficoll. After  centrifugation  for 30 min 
a t  2500 RPM, the lymphocyte layer was washed three times with repeated 
suspension with PBS/5% FCS (fetal  calf  serum) and centrifuged  for  5  min a t  1600 
RPM. Finally, the cells were resuspended in 8 ml PBS/5% FCS and the  cell  numbers 
were  determined  by  coulter  counting.  After  counting,  the cells were  pelleted  and 
either  stimulated  with PHA or stored a t  -8OOC (in  portions  of  5x106  cells). 
PHA stimulation of lymphocytes  from  healthy  persons 
Lymphocytes  from  control  persons  were suspended in  RPMI-1640  medium 
supplemented with  10% FCS and 20 pg/ml penicillinlstreptomycin. at a 
concentration  of I O 6  cells per ml  in  5% CO, a t  37OC. The cells  were stimulated to 
growth  by 20 pg/ml PHA for 48, 72, 96 and 168 h, respectively.  The  cells  were 
harvested,  counted  and  stored  similarly to unstimulated  lymphocytes. 
Enzyme extract 
The  isolated  cells  from CLL patients and control  persons  were  suspended  in  Loebs 
buffer (20 mM K-phosphate  buffer  (pH 7.4), 15% glycerol,  1 mM K-EDTA, 10 mM 
DTT (dithiotreitol)), lysed by sonication (40W, 3 x 1-2 sec) and centrifugated at 
20,0009 for 30 min. The  supernatant  (the enzyme extract)  was used for TK activity 
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measurement  and  determination  of  total  motein. 
TK activity assays 
The radioactive assay for measuring TK activity  is based on  the  conversion  of  the 
substrate  [3H]dThd  to  [3H]dTMP and  removal  of  the  unphosphorylated  substrate  on 
anion  exchange  filters (DEAE-cellulose 81 paper) by  three  times  washing  in 5 mM 
ammoniumformiate and one  times  in H,O for 5 min. The  nucleotides  were  eluted 
from the filters with 0.2 M KCIlO.1 M HCI and the radioactivity determined by 
scintillation  counting.  Activity  is measured as initial  velocities  (Munch-Petersen and 
Tyrsted  1977,  Munch-Petersen  et al 1991)  by applying  samples  of 13 pi on DEAE 
filters 5, 10 and 15 min  after  starting  the  reaction  by  addition  of enzyme extract  to 
the assay mixture. The reaction  temperature  is 37OC. One unit  of enzyme activity 
is  the  amount  of  enzyme  catalysing  the  formation  of  one  nmol  dTMP per min. The 
standard assay mixture  contained:  50  mM Tris-HCI (pH  7.5). 10 mM DTT, 2.5 mM 
ATP, 2.5  mM MgCI,, 3 mM NaF, 0.5 mM CHAPS (3-[(3-Cholamidopropyl)- 
dimethylammonio]-1-propanesulfonate), 3 mglml BSA (bovine  serum albumin) and 
10 pM 3H-thymidine (2 Cilmmol),  in a total  volume  of 50 pl. In assays with CTP  as 
phosphate  donor ATP was  substituted with equimolar CTP. 
Protein  determination 
The protein content was measured by Coomassie brilliant blue as described by 
Bradford (1 976). 
RNA purification 
Total RNA was  purified by  the  method  of  Chromczynski and  Sacchi (1 987). Use of 
guanidinium  thiocyanate,  which  is a strong  inhibitor  of ribonucleases provides a 
preparation  of  non-degraded RNA. The purity  of  the RNA preparation  was  improved 
by applying an extra  phenol  extraction and alcohol  precipitation.  5x106  cells  were 
centrifuged 14,OOOg for 10 min and the  supernatant  discarded. 500 p1 of  solution 
D (4 M guanidinium  thiocyanate, 25  mM  sodium  citrate  (pH 7), 0.5% sarcosyl, 0.1 
M 2-mercaptoethanol) was added. Sequential 50 pI sodium acetate (2 M, pH 4), 
500p1  phenol  and loop1 chloroform:isoamylalkohol(49:1) was added. The  samples 
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were  mixed  thoroughly  by  inversion  after  the  addition  of each  reagent.  The final 
suspension  was  cooled  on  ice  for 15  min and centrifuged 20,OOOg for 1 0  min a t  
4OC. The aqueous phase (RNA) was transferred to  a fresh tube and 500 p1 
isopropanol  was added. The samples were  mixed and placed at -2OOC for  at least 
1 h to precipitate RNA. To sediment RNA the samples were  centrifuged 10,OOOg 
for 20 min a t  4OC. The supernatant was discarded and the RNA pellet was 
dissolved  in 150 pI solution  D and afterwards  precipitated  by 200 p1 isopropanol 
and incubation a t  -2OOC for a t  least 1 h. After  centrifugation a t  10,OOOg for 10  min 
at 4OC, the  pellet  was dissolved in  100 p1 DEPC (diethyl  pyrocarbonate)-treated 
EDTA-buffer  (0.5  mM,  pH 8.0). The purity  was  improved  by  adding 50 pl 
phenol:chloroform:isoamylalkohol (25:24:1)  and  the samples centrifuged 5,OOOg 
for  1  min  at  room  temperature. The liquid phase was transferred to a fresh  tube and 
0.1  volume  of 3 M NaAc and 3 volume  of 96% EtOH was added.  Before 
precipitation the samples were placed at -2OOC for at least 1 hour and then 
centrifuged  at 10,OOOg for 10 min at 4 O C .  The RNA pellet was  dissolved  in 50 p1 
DEPC-treated EDTA-buffer. The RNA quality  was examined by agarose gel 
electrophoresis  and  the  concentration  estimated  from  optical  density a t  260 nm. 
The purity  was measured by the 260  nm/280  nm ratio. 
Estimation of RNA recovery 
In  two experiments 3H-uridine (5 pCi/ml, 5 Ci/mmol) was added to the growth 
medium  during  PHA-stimulation  of  the  lymphocytes.  A  total  of  5x1 O6 labelled  cells 
was  harvested  on 3 MM filters and non-incorporated  3H-uridine  was  washed  away. 
From  an equal number of cells, RNA was  isolated and applied to 3 MM filters.  The 
radioactivity  on  the  filters  was determined by scintillation  counting.  The  amount  of 
the  isotope  in RNA was compared with the  amount  of  the  isotope  in  the cells. The 
RNA recovery  estimated  from these  comparisons was between  70-90%. 
Northern  Blot 
The RNA preparations  were  fractionated  under  denaturing  conditions  on a 1 .S% 
agarose gel containing 2.2 M formaldehyde and transferred to  a Hybond N+ 
membrane.  The  probes were human TKI  cDNA  from  plasmid pTKl1 (Bradshaw  and 
42 
Deininger 1984) and humanp-actin  cDNA labelled with 3zP-dCTP. Hybridisation  was 
done with a high  stringency  wash. 
Reverse  transcription 
Total RNA was  converted  to  cDNA  using  the enzyme  reverse  transcriptase  (RT), 
random  oligonucleotides  (hexamer) and dNTPs. RNA (0.67  pg) was transcribed to 
cDNA  in a 50 p1 volume  of I x  PCR-buffer ( IO mM Tris-HCI (pH  8.3), 50 mM KCI, 
0.015% gelatine, 0.1 % Tween 20), 7.5 mM MgCI,, I m M  of each of  the dNTP’s, 
40 units RNasin, 7 pM random  hexamers  and 250 units of M-MLV reverse 
transcriptase RNase H minus. The reaction was ended after 2 h a t  37OC. The 
extent of reverse  transcription  was  controlled  by a parallel reaction  where 3H-TTP, 
instead  of TTP was added. Aliquot  of  the  reaction  mixture was applied on 3 MM 
filters.  The  non-incorporated 3H-TTP was  removed  from  the  filter  by  washing  3x1 0 
min in 1 M HCI containing 0.6 mM Na,P,O,, 10  min in 0.26 M NaAc/EtOH and 
finally in EtOH. The  radioactivity  was measured by  scintillation  counting. 
Competitive  PCR 
Quantification of TKI mRNA is performed by the competitive PCR method as 
described by Gilliand e t  al (1990). 
For quantification  of  TKI mRNA exon 1 and exon 2 with  intron 1 from  the 
TK gene is used as internal standard and exon 1 and 2 as the target cDNA 
fragment.  The  primer pair used for  amplification  of  both  the  genomic  DNA and the 
cDNA are identical. The sizes of  the  resulting  fragments  were  138  bp with cDNA 
as template and 248  bp with genomic  DNA  as  template.  The  internal standard  of 
248 bp genomic  DNA was prepared by PCR with DNA as template and using  the 
primers  mentioned above. The product  was  quantified  by agarose gel 
electrophoresis with different  amounts  of DNA.  The unknown amount of cDNA was 
estimated  from a set  of PCR reactions  performed in a dilution series with known 
amounts  of  the  genomic DNA. The PCR products  were separated by agarose  gel 
electrophoresis. The amount of cDNA (g) in the sample was estimated as that 
amount  (g)  of  genomic  DNA  giving equal intensity  of  the  two  amplification  products 
(figure 7). The number of TKI  cDNA copies was calculated from the amount of 
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cDNA, by division with  the average molecular weight  of  the  138 bp  cDNA  fragment 
(average molecular weight/base = 308). The number of copies TKI  cDNA was 
taken as  representative  for  the  number of TK1 mRNA. 
A: 
exon1 i n h n  exon2 
C: 
* 
equal mtensii 
Figure 7: A schematic  example of the  Competitive PCR. A: The  same  primer  pair  is used to amplify 
genomic  DNA  and  cDNA  resulting  in a 248 bp fragment  for genomic DNA and a 138 bp fragment  for 
cDNA. B: titration with dilutions of TK1 genomic DNA competing with l p1 of cDNA (138 bp]. C: 
Analysis of the amount of cDNA. From the sample with equal intensity the amount of cDNA is 
calculated. The  number of  TKI cDNA  was  taken as reprzsentative  for  the  amount of TK1  mRNA. 
The competitive PCR analyses were performed in a volume  of 25 /.!I 
containing l x  PCR buffer  (1 0 mM Tris-HCI (pH 8.3). 50  mM KCI, 0.01 5% gelatine, 
0.1 % Tween 20), 0,28 nM  of each  primer (Sense primer: TKI  : 5’CTT GGA GAG 
TAC TCG GGT TCG TG 3‘, Anti-sense primer: TK2: 5’CCT TTT CCT GAG AAC 
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ATC GGC 3') ,  200 MM of  the dNTP's, 1.5 mM MgCI, and 0.5 units of Thermus 
aquaticus DNA polymerase. Heat-denatured cDNA ( lOO°C, 2 min) and internal 
standard  were  added to  the reaction  mixture, with a layer of mineral oil to avoid 
evaporation. The amplification was performed in a Perkin-Elmer/Cetus Thermal 
Cycler according to the following program: denaturation for 1 min a t  95OC, 
annealing for  1  min  at  6OoC and  polymerisation  for  1  min  at 72OC, for 35 cycles. 
Methods for  investigations  of TKI structure-function  relationship. 
Plasmid 
The  plasmid, pGEX2T-TKI,  was  constructed  by  the  groups  of Dr. Hofbauer  and Dr. 
Folkers. As it is not published, I will present a short description of the cloning 
procedure  (figure 8). 
The  amino  acid coding region of TKI  from human  lymphocytes  was PCR- 
amplified.  The t w o  primers  used to amplify TKI are designed with  restriction  sites 
in the 5'ends (BamHI and Sphl, respectively). The resulting PCR product was 
subcloned  into  the  expression  vector pGEM. In pGEM, the  BamHI-TKI-Sphl 
fragment is surrounded by a Kphl and Hind 111 restriction site. This fragment is 
subcloned  into  the  pBluescript II KS +/- vector. pBluescript II KS +/- is digested 
with  BamHl and EcoRl and the  BamH1-TKI-EcoR1  fragment  is  then  subcloned  into 
the  expression  vector pGEX2T, resulting  in  the pGEX2T-TK1  plasmid (figure 8). In 
pGEX2T, the fusion protein is cleaved with the restriction protease thrombin. 
Thrombin  recognises  the  sequence LVPRGS (single  letter  code)  and  cleaves  after 
the  arginine (R). To construct  the  thrombin cleavage  site in pGEX2T-TK1 
modifications  of  the  N-terminal inTKI  was necessary. MCS  of  the  N-terminal  of the 
native TKI  was changed t o   B M C S .  Likewise, to  reconstruct  the EcoRl site the C- 
terminal  was  modified. ILQCSPAN of  the  native  TKI  was  changed  to ILQCMQA. 
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BamHI-TKl-Sphl 
IPCR-product)  pBluescript 'L > Hindlll 
pBlue TK1 pG€X2T Sphl 
script Sphl 
Hindlll pGEX2T EcoRl 
EcoRl 
BamHl 
Figure 8: Cloning of pGEX2T-TK1 by thegroups of Dr.  Hofbauer and Dr. Folkers. 
The pGEX2T vector contains the ladq gene region coding for the lac 
repressor, so expression  of  the GST fusion  protein  is  independent  of  the  €.co/ihost 
lac1 status. The expression of GST fusion proteins is under control of the tac 
promoter and is  efficiently repressed until  induction  with  the  lactose analog 
isopropyl  B-D-thiogalactoside (IPTG). 
E.coli  strains 
KY895: a TK-deficient  strain (F-, tdk-l,  ilv-276) (Hiraga et ai 1967). 
Max  efficiency DH5a competent cells: (F, @80d/acZ~MI 5 A(/acZYA-argF) recAl 
endAI thi-l) (Life Technologies). 
Recombination  PCR 
In the recombination PCR technique two separate PCR-reactions are performed. 
Each reaction  contains  the pGEX2T-TK1 plasmid, carrying  the  TKI  insert  that is to 
be mutated. Prior to each PCR-reaction, pGEX2T-TK1 is linearized by  digestion  with 
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a restriction enzyme. The linearization serves two purposes. First, any circular 
plasmid  products,  which  otherwise will be favoured in the  transformation  procedure 
are eliminated.  Secondly, amplification  of large fragments  from linear templates is 
easier than from circular, supercoiled structures. In reaction 1 pGEX2T-TK1 is 
linearized by Aat II and in reaction 2 pGEX2T-TK1 is linearized by Hpa I. The 
restriction  sites are located  outside  the  fragment to be  amplified. 
The PCR-reaction is  performed with a primer containing  the  mismatch bases, 
designated  the  mutagenic primer. The second  primer  is non-mutagenic and is  used 
to delimit  the  amplified  fragment.  A sense and an anti-sense version of both  the 
mutating and non-mutating primers are constructed. Each PCR-reaction is then 
performed with a mutagenic and a non-mutagenic primer, resulting in t w o  PCR- 
fragments  with  omologous ends.  Combining  the two PCR fragments and 
transforming them into high competent DH5a €.coli cells results in an in vivo 
recombination.  The  product  is a mutant with the desired mutation  (figure 9). 
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pGEQT-TK1 pGECT-TK1 
1- 1- 
I I . . 
3 4 
Figure 9: Recombination PCR. X shows  the  location of the desired mutation. Primer 1 and 3 are the 
mutagenic primers with the mismatch baselsl indicated by: -v-. The non-mutagenic Primers are 
nominated 2 and 4. The two PCR reactions result in two fragments with homologous  ends: where end 
1 and 3 are  homologous to each other  and  end 2 and 4 are  homologous to each  other. pGEX2T-TKI-mut 
contains  the site-specific mutation. 
As the  only change in  the  mutants  is  the  introduction  of  a  stop  codon,  this  cannot 
be  used  for  differentiation  between  the  parent and the  mutant  clone. Therefore, in 
these  experiments the mutagenic  primers  were  designed so they  contained  a  unique 
restriction  site  overlapping  the  stop  codon. This allowed  for  identification  of  the 
transformants and served as a  control  for  the  occurrence  of  the  desired  mutation. 
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Primers used for recombination  PCR 
Mutagenic  primers: 
TKI-193.1, sense: 
189  194 200 
5’T’’’AC TTC  AAG  AAG GCC TGA G= CAG CCT  GCC GGG CCGsD03’ 
TGA 
Stop codon 
GA GCT C 
Sacl site 
TK1-193-2, anti-sense: 
200 194 189 
5 ‘ C G G C C C G G C A G G C T G s C T s A G G C C T T C l ’ T G A A G T A 3  
TK1-176.1. %erne: 
172  177  183 
5’G’’IC GAG GTG AAT GGG I G A   G C I G A C  AAG  TAC CAC TCCS83’ 
TGA 
Stop codon 
GA GCT C 
Sacl site 
TK1-176-2. anti-sense: 
t a3 177  172 
B’GGAGTGGTACiTGTG&GCTCACCCAATCACCTCGAC3’ 
The non-mutagenic  primers: 
Lacl-l: 5’CS”CA CGC  GGG AAA CGG TCT  GAT  AAG 3’ 
Lacl-2: 5’C”’TT ATC AGA CCG TTT CCC  GCG  TGG 3 
Figure 10: Primer sequence for  the mutagenic and non-mutagenic primers. Altered bases are shown in 
dark and underlined.  The numbers above the primer refer to amino  acid position whereas the number 
in the primer refer  to  the position of binding  in TKI. 193 and 176 refer to  the last coding amino acid  in 
thepGEX2T-TKI-193 and pGEX2T-TKl-176  construct, respectively. Lac refers to the location of the 
primers  in the Lac1 gene region. 
Location  of  the  non-mutagenic primers to  the  lad gene region ensures that  the  two 
PCR fragments  have similar size. 
The PCR-reactions contained in a total volume of 50 pl: 0.24 pg/ml linearized 
plasmid, 0.36 pM of each  primer, 200 PM of each dNTP, 1.5 mM MgCI,, IxPCR 
buffer ( I O  mM Tris-HCI (pH 8.3), 50 mM KCI, 0.015% gelatine, 0.1 % Tween 20), 
and 1.5 units  of Thermus aquaticus DNA polymerase. A drop of mineral oil was 
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placed on top of each reaction mix before amplification. The amplification was 
performed according to  the  following program: denaturation for 1  min  at 95OC, 
annealing for  1  min a t  58OC and polymerization  for 3.5 min a t  72OC, for 30 cycles. 
Purification  of  PCR-products  from  low-melting  agarose-gel 
The PCR product  was analysed  and  purified from a 1 % low  melting agarose gel. 
The PCR-fragment was excised  under  UV-light a t  360 nm. 5  volume  of  TE-buffer 
( I O  mM Tris-HCI pH 8,3, 1 mM EDTA pH 8.0) was added and the agarose was 
melted a t  65OC in a water  bath.  After  cooling to room-temperature,  1  volume  of 
phenol  was  added and the  mixed  solution  was  centrifuged 14,OOOg for  5  min. The 
liquid phase was transferred to a fresh  tube  and  the  phenol  extraction  was  repeated 
3 times. To precipitate  the  nucleic acids, 1 /I 0 volume  of 3 M NaAc and 3 volume 
96% EtOH was added and the  tubes were kept a t  -2OOC for  at least 1 h before 
centrifugation  of  the  nucleic acids was  performed a t  20,OOOg for  15  min  at 4OC. 
The pellet  was  dissolved  in E-buffer.  The product  was visualized by electrophoresis 
on  a 1 % agarose gel. If 5 p1 of  the  ethidium  bromide stained  PCR-product could be 
clearly seen, the amount of  products  was  sufficient  for  transformation  of €.coli. 
Transformation  procedure 
Approximately 30 ng (2.5 pl) of each PCR-product was mixed and transformed 
directly  into MAX Efficiency  DH5a  competent E.coli ( >  1x1 O9 transformants/,ug of 
pBR322; Gibco BRL/Life technologies). In prechilled 10  ml Ole Dich tubes, the 
following  reactions are preformed: 
1: 50 p1 competent cells + 5 p1 of premixed PCR-products from reaction 1 and 2 (ratio 1 : l ) ,  
2: 25 HI competent cells + 2.5 pI of control DNA (stock pUC 19 solution (0.01 ~ g l m l ) .  
3: 25 pI competent cells + 5.0 p1 of PCR-products from reaction 1 and 5.0 p1 TE-buffer. 
4: 25 p1 competent cells + 5 . 0 ~ 1  ofPCR-products from reaction 2 and 5.0 p1 TE-buffer. 
5 :  25 pI competent cells + 10 p1 TE-buffer. 
After addition of the DNA, the solutions were mixed carefully. The cells were 
incubated on ice for 30 min, whereafter they were heat-chocked for 45 sec a t  
42OC. The cells  were  cooled on  ice  for 2 min  whereafter 0.9 ml of room-tempered 
S.0.C (see  appendix  1)  medium  were added. After  incubation  with  shaking  for 1 
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h at 37OC the  cells  were dispensed onto LB plates. 
Reaction 5, containing  only  competent cells was  plated  onto LB plates - ampicillin. 
Reaction 2, containing  the  control  DNA  was  diluted  1 :l00 with S.0.C medium and 
100 p1 was plated onto LB plates containing 100 pg/ml ampicillin. The other 
reactions  were  used  undiluted and 100-4OOpl was spread onto LB plates  containing 
100 pg/ml ampicillin. 
Calculation of the transformation  efficienc y 
To calculate the transformation efficiency, the number of colony forming units 
(CFU) with  the  positive  control  (pUCl9)  was calculated. 
CFU/pg = CFU on the control plate 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  x the dilution factor 
pg pUCl9  used for the  transformation 
According to  the manufactures  (Gibco BRL Life  Technologies) the  transformation 
efficiency  should be  higher  than  1x106 CFU/pg pUCl9. 
Individual  colonies  were  grown  overnight  at 37OC in TB medium  (see  appendix 1) 
containing 100  pg/ml ampicillin.  Plasmid DNA was  isolated  (Alkaline 
minipreparation,  Sambrook  et al 1989)  and  the clone of  interest  was  selected  by 
Sac1 digestion. 
Sequence  analysis 
Thewild-type  (pGEX2T-TK1) and mutant(pGEX2T-TKI-193and pGEX2T-TK1-176) 
plasmids  were  used to  transform  the  TK-deficient E.co/istrain, KY895.  KY895  was 
made competent  according to  the CaCI, method  (Sambrook  et al 1989).  Ampicillin 
resistant bacteria were grown overnight a t  37OC in LB medium containing 100 
pg/ml ampicillin. Plasmid DNA was isolated with the PEG (polyethylene glycol)- 
precipitation  method  (Sambrook  et  al  1989). Alkaline  denaturation  and  preparation 
of samples for  sequencing  were  done  according to "Step-by-step  protocols  for  DNA 
sequencing with sequenase version 2.0 T7 DNA  polymerase" (8th edition, United 
states  biochemical). The  clones  were  sequenced  on  both  strands by  the  dideoxy 
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method with the Sequenase version 2.0 DNA sequencing kit (United  states 
Biochemical),  using  the  following primers. 
Sense  primers: 
pGEX-Seq-l : 5'CTATCCCACAAATTGATAAGT 3' 
pBAF3 : 5'CCAAAGACACTCGCTACAGC 3' 
pTK6 : 5'CCATTTGGGGCCATCCTGAACCTG 3' 
TKI-176-1 :5'GTCGAGGTGATTGGGTGAGCTCACAAGTACCACTCC 3' 
Antisense primers: 
pGEX-Seq-2 : 5'ACGTGACTGGGTCATGGCTGC 3' 
TKI-205-2 : 5'CCTTCCTGGCACTAGTCAGTTCTCTTTGTT 3' 
pBAF2 : 5'GTCAGCTTCACCACGCTCTC 3' 
pBAFl : 5'CGGTCATGTGTGCAGAAGCT 3' 
The  sequence strategy is shown  in  figure 11 
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5 '  l I , I I I I l 3' 
pGEX2T-Seq-2 
205-2 . 
Baf  -2 
B a f  -1 
pGEX2T-Seq-l 
Baf -3 
TK-176-1 
pTK6 
Figure l l :  Sequence strategy  for  the human  lymphocyte's  TK1  cDNA insert in pGEX2T.  The  numbers 
refer to bases  in TK l cDNA.  The first base in the  start codon  is  numbered 1. The surrounding  part  is 
pGEX2T  cDNA.  The  arrowhead signifies the location of primer  binding. - shows the area 
sequenced with  that primer. 
Protein  expression 
Ampicillin  resistant  KY895/pGEX2T-TKII  KY895/pGEX2T-TK1-193 and 
KY895/pGEX2T-TK1-176  were  grown  overnight  at 37OC in LB medium (see 
appendix  1)  containing 100pg/ml ampicillin.  The overnight  culture was diluted 1 : 10 
in LB medium  containing 100 pglml ampicillin or  in ABTG medium  supplemented 
with amino  acid  mix (see  appendix 1). The culture  was  grown  to ODsoo = 0.5 at 
25OC. The'production of the glutathione S-transferase-thymidine kinase 1 (GST- 
T K I )  fusion  protein  was  induced by addition  of  the  lactose  analog IPTG at a final 
concentration  of 0.1 mM.  After  15-17  hours  of  growth,  the cells were  harvested 
at 4000 RPM for  15  min a t  4OC. 
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Preparation of bacterial  extracts 
The cells were resuspended in 1/20 culture volume of lysis buffer 1 (50 mM 
Tris/HCI, pH 7.5,  5 mM EDTA, 1 mM DIT,  10% glycerol,  1 % Triton X - l  00, 0.1 mM 
PMSF (phenylmethylsulfonyl  flouride), and 150pg/ml lysozyme).  Portions of 3-4 ml 
were  lysed  on ice by sonication (50 W, 3x10 sec).  The  sonicate was  centrifugated 
a t  20000g for 20 min a t  4OC and filtered  through  a  0.45 p m  sterile  filter. 
Induction  of  the  fusion  protein  was  monitored  by measurements of  the TK activity 
and the GST activity  was  monitored with the  substrate  1 -chloro-2,4-dinitrobenzene 
(CDNB). 
Detection of GST-fusion  protein 
The induction  of  the  fusion  protein  was  monitored  by  the GST substrate CDNB. The 
GST-catalyzed reaction  of CDNB with glutathione  produces  a  conjugate that  can  be 
measured by absorbance at 340 nm (GST gene fusion system, Pharmacia Biotech 
1 994). 
50 pol of crude extract was added to 1 ml of CDNB solution ( I m M  CDNB, 1 mM 
reduced Glutathione, 100 mM K-phosphate buffer  pH 6.5) in a quartz  cuvette and 
the absorbance a t  340 nrn was  recorded a t  one-minute  intervals  for 5 min. 
Glutathione  affinity  chromatography 
Glutathione agarose is an affinity  matrix,  where  the  glutathione  is  coupled to  epoxy 
activated agarose through  the  oxirane  group. The glutathione agarose binds  the 
GST-part of  the  fusion  protein.  Glutathione agarose (750mg/1 Om1 bed  volume)  was 
swelled  overnight  at 4 O C  in  buffer 2 (50  mM Tris/HCI, pH 7.5,  5 mM EDTA, I m M  
DTT, 10% glycerol, 1 YO Triton X-100) and packed into a 25 mm x 200 mm 
disposable  column. The following  steps  were  performed  at 4OC. The column  was 
washed and  equilibrated with  10-1 5  bed  volume of  buffer 2. Crude extract ( =  500 
mg)  was applied and recirculated  over  the  column.  Unbound  proteins  were  removed 
by  washing with 5-8 bed  volume  of  buffer 2. The column  was  equilibrated with 5 
bed  volume  of  buffer  3 (20 mM Tris/HCI, pH 8.4, 150  mM NaCI, 2.5  mM CaCI,, 
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0.1 % Triton X-100, 1 mM DTT). Cleavage of TK1 protein from the GST-partner 
was  performed  with  thrombin a t  room  temperature.  Three  vials of  thrombin  (Sigma) 
were  resuspended  in  1 bed  volume  of  buffer 3, loaded onto  the  column and slowly 
recycled  over  the  column  for  1-1.5  h. The  eluate was  continuously  kept  at 4OC. 
The column was further washed three times with 1 bed volume of buffer 3. To 
elute  remains of  fusion  proteins  the  column  was  washed  with - 4 bed  volume of 
buffer 4 (5 mM glutathione  in  lysis  buffer 2). To stabilize the TK1  enzyme  during 
freezing  and  thawing 10% glycerol  was added to  the samples. 
Sephadex G-25 chromatography 
The  eluate from  the  glutathione agarose column  was desalted by G-25  sephadex 
chromatography. 
The  Sephadex G-25  column (500 ml)  was  equilibrated with 3 bed  volume of  buffer 
5 (20 mM K-phosphate  pH 6.0, 5 mM MgCI,, 10% glycerol, 2 mM DTT). Fractions 
containing TK1 protein from glutathione agarose column were applied to G-25 
column and eluted with the buffer 5. Protein content and conductivity were 
continuously measured. 
CM-sepharose  column 
The  column  (1 0 mm X  20mm)  was  equilibrated  with  buffer 6 (1 0 mM K-phosphate 
buffer  pH 7.0, 5 mM MgCI,, 10% glycerol, 5 mM DTT).  The  desalted fractions  were 
applied and unbound material washed away. The TK1 protein was eluted with 
buffer 7 (1 00 mM K-phosphate  buffer, pH 8.0, 5 mM MgCI,, 10% glycerol,  5 mM 
DTT, 0.5 mM CHAPS, 0.1 M KCI). 
SDS-polyacrylamide gel ISDS-PAGE) 
The subunit  molecular  weight was determined  by SDS-PAGE with a  4.5%  stacking 
gel  and a 1.2 or 15% separation gel prepared by standard  methods  (Sambrook et 
al 1989). The  samples  were  denatured a t  95OC for 2 min in protein  loading  buffer 
(1 25 mM Tris-HCI, 10 mM DTT, 1 YO SDS, 0.1 YO Bromphenol Blue and 25% 
glycerol)  before  loading  onto  the gel. Proteins  were  visualized by silver  staining  and 
the gel was dried on a slab gel drier for 2 h at 6OOC. 
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Determination of native  molecular  weight by gel filtration  chromatography 
The native  molecular  weight  was  estimated  on Sephadex G-200 (5 mm x 20 mm) 
or Superose 12 ( I O  mm x 300 mm  column  connected to a  Gradifrac,  Pharmacia). 
In both cases, the  columns  were  equilibrated  with  buffer 8 (50 mM Tris, pH 7.4, 
5 mM MgCI,, 0.1 M KCI, 5 mM DTT). When  determining  the  molecular  weight  in 
presence of ATP the enzymes  were  preincubated with 2.5 mM ATP and the  column 
was  pre-equilibrated with  buffer 8 containing 2.5 mM ATP. The  molecular weight 
was  estimated  by  comparing  the  retention  times  for  the sample with the  retention 
times  for  five  marker proteins:  beta-amylase (200 kDa),  alcohol  dehydrogenase (1 50 
kDa),  bovine  serum  albumin (66 kDa),  carbonic  anhydrase (29 kDa), cytochrome 
C (12.4 kDa). 
Kinetics 
The  substrate  kinetics  was analysed by Hofstee  plots  (v versus v/s) and Wilkinson 
plots  (slv  versus S). v  is the  initial  velocity and S is  the  substrate  concentration. 
V,,, was calculated using nonlinear regression analysis to obtain the best fit 
between  the  experimental  data and the expression, v = As2 + Bs/(s2 + CS +D), 
where A, B, C, D are constants and S is the  concentration  of  the  varied  substrate. 
For S + m, A  is used as  an estimate  of V,,,. 
K, values  and the Hill coefficient  were  determined  by  Hill  plots  of log(v/(V,,, - v) 
= nlogs - nlogS,.,. n is  the Hill coefficient and So,5 is  the  substrate  concentration 
a t  half-maximal velocity ( =  K,). 
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Results 
Results for quantification of TKI mRNA in healthy lymphocytes  and in 
lymphocytes from patients with CLL. 
TKI  ‘ is a  strictly  cell  cycle  regulated enzyme with a close  correlation  between  the 
TK activity and the  proliferative  state  of  the cell. In  a  variety  of cancer it has been 
shown that the expression of TKI is deregulated. Generally, the TK activity is 
higher in patients  with cancer than in control persons (Ellims et al 1981, Hallek 
1992, O’Neill et al  1992,  Robertson  et al 1990) and in several  cases TKI  activity 
has been observed in non-dividing cells (Ellims et al 1981, Munch-Petersen and 
Tyrsted  1986, Russo et al 1987). Likewise, TK enzymes with enzymatic  properties 
different  from T K I  and TK2  in  normal cells, have  been found  (Munch-Petersen and 
Tyrsted  1986,  Munch-Petersen and Tyrsted  1988).  As  different  regulation 
mechanism may cause the development of malignancy, the expression of   TKI 
mRNA in healthy  cells and in CLL cells  was  investigated. CLL cells were  chosen  for 
my investigation because,  despite that  they are characterized as non-dividing  cells 
TKI activity has been observed (Ellims et al 1981, Ellims et al 1983, Munch- 
Petersen and Tyrsted  1986). 
By comparing  the  level of TKI  mRNA with  the TK activity in normal cells 
and  in CLL  cells it can be  investigated  if  the  regulation  mechanisms(s)  are  different 
in  these cells. 
Determination of TK activity in control persons 
The  expression  of TK activity  in  quiescent and PHA stimulated  lymphocytes  were 
measured  for  six  control  persons.  The  lymphocytes  were  stimulated with PHA for 
48, 72, 9 6  and 168 hours,  respectively.  Crude  extracts  were  prepared from  5x1 O6 
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cells and TK activity and total  protein  was measured. Figure 12 shows  the  amount 
of TK activity expressed in  relation to  the  total  protein  content. 
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Figure 12: PHA induced  variation of TK activity lnmol min- 1 mg- 1 prOteinl for Control  Person 1 - 6. The 
lymphocytes were stimulated  witb PHA for the indicated  periods. TK activity was measured at standard 
conditions as described  in "Methods': 
The TK activity in the  quiescent  lymphocytes  from  the  six  control  donors 
was  between 0.009 to 0.01 6 nmol min" mg-'  protein  with a coefficient of variation 
(CV) of 25%". The TK activity increases as cells are stimulated  with PHA, resulting 
in a  peak  level for  five  of six control  persons  after 96 hours. After PHA stimulation 
"In the  thymidine kinase activity assay the  coefficient of variation (CV) 
of triplicate samples are below  5%. 
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the TK activity in the cells for  the six control  donors  was  between 0.12 and 0.76 
nmol min.’ mg-’  protein,  corresponding to a  9 to  62-fold increase in TK activity. For 
the  phytohemagglutinin  stimulated  lymphocytes  the  CV  was 60%. A  high  individual 
variation  has earlier been reported by Koefoed et al (1  986) and Munch-Petersen  et 
al (1985)  in experiments  where  the  UVR-induced  DNA  synthesis  in 
phytohemagglutinin  lymphocytes  was measured with  incorporation  of  [3Hl- 
thymidine.  The  variations  probably  reflect  individual  variations  in  the response to 
PHA among the  donors  or  the  immune response in some donors  has  been  activated. 
Distinction of TK7 and TK2 
Investigations  by  Munch-Petersen and Tyrsted (1 977) have shown  that in dividing 
lymphocytes l - 2 %  of  the TK activity is due  to TK2, whereas in  quiescent 
lymphocytes  the TK activity  exclusively  is  due to  TK2. Both TKI and TK2 use  ATP 
as phosphate donor. Thus, the standard enzyme assay performed in this work 
reflects  the  total TK activity. However, it is possible to  distinct  between  TKI and 
TK2 by  the  different  substrate  specificity  for  the  two enzymes. TK2  can use CTP 
efficiently as a  phosphate donor,  whereas it is  a  poor  substrate  for TKI  (Adler and 
McAusian  1974, Ellims et al 1981 ). Figure 13  shows  the  ratio  of CTP- and ATP- 
mediated  TK  activity  in  the  six  control persons. The CTP phosphate  donor  capacity 
is most pronounced with crude extract from quiescent cells, showing that  the 
dominating  enzyme is TK2. The ability to use CTP as phosphate  donor  decrease as 
the  cells are stimulated to  enter the cell cycle.  After 96 hours  of PHA stimulation 
the  dominating enzyme is  TKI. 
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Figure 13: The ratio  between phosphate donorcapacityof CTPandATP.  In each  experiment the enzyme 
activity is  normalized to 100% with ATP as phosphate donor. (AI Quiescent lymphocytes; (B] 
lymphocytes  after 96 hours of PHA stimulation. The  numbers  on the x-axis refer to the  individual donors. 
Reprinted from Leukemia  Res. vol. 18, Kristensen, T., Jensen, H.K and Munch-Petersen, B.: 
Overexpression of human thymidine kinase mRNA without corresponding enzymatic  activity  in  patients 
with chronic  lymphatic leukemia, 86 1-886, copyright 119941, with kind permission from Elsevier  Science 
Ltd,  The  Boulevard,  Langford  Lane,  Kidlington OX5 IGB, UK. 
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The  reverse  transcriptase  reaction 
As  described in "Methods"  the  steps in the  competitive PCR (Gilliand et al 1990) 
procedure is purification  of  total RNA from lymphocytes,  reverse  transcription of 
RNA to cDNA  and  quantification  of  TK1-cDNA  exon 1 and 2, simultaneously with 
the  corresponding  genomic DNA serving as a competitive  internal  standard in the 
PCR-reaction. To achieve the best  yield of the reverse transcription  of RNA to cDNA 
(the RT-reaction), optimization with respect to [MgCI,], [RNA] and [dNTPl was 
performed.  The  extent  of  the RT-reaction was  followed  by  applying 'H-TTP instead 
of TTP to the reaction  mixture  and  measuring  the  amount  of  incorporated 
radioactivity by scintillation  counting. 
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Figure 14: Optimization of the reverse  transcription lRTl reaction. 
(AI MgCI,-titration of 0.67 Mg total RNA  and 7.4 Mg total RNA 
(B) RNA-titration, (Cl dNTP-titration. 
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When  the MgCI,-concentration was optimized, the RT-reaction was  performed  with 
two  different RNA concentrations,  0.67 pg  and 7 . 4 ~ 9 ,  respectively, in a  5Opl RT- 
reaction  (figure  14.A). For both RT-reactions the MgCI, concentration  was  varied 
from 1.5 mM  to  16  mM. As seen from  figure  14.A  the  optimal MgCI, concentration 
for  both  reactions  is in the range  of  9-12  mM. However, the  RT-reaction  with 7.4 
pug RNA had a lower 3H-TTP incorporation than the RT-reaction with the lower 
concentration  of RNA. 
Figure 14.B  shows  a  closer  optimization of the RNA concentration with 10.5 
mM MgCI,. On behalf of  this RNA titration it is  not recommended to  use  less than 
0.2 p g  total RNA/50 pol RT-reaction since no incorporation of 3H-TTP could be 
measured for RT-reactions with RNA below  this limit. The last  titration,  shown  in 
figure 14.C was  with  different dNTP concentrations. The reactions  contained 0.67 
p g  total RNA, 10.5  mM MgCI, and 0.5,  1 .O or 2.0 mM dNTP, respectively. The RT- 
reaction with 1 mM dNTP gave the best  result.  Increasing the dNTP concentration 
to  2 mM gave  a  negative  effect. 
When PCR-reactions were performed with cDNA products from the RT- 
reactions  in  figure  14,  there  was  clear relation  between  a  non-optimal  RT-reaction 
and the presence of many unspecific amplification products in the PCR-reaction 
(results  not  shown). 
Based on  these  experiments  the  reverse  transcription  was  performed with 
0.5-1.0 pg  total RNA, 10.5 mM MgCI, and 1 mM dNTP. 
Quantification of TKI mRNA in  control  persons 
The TKI  mRNA  level  was  quantified  in  quiescent  and  in  PHA-stimulated 
lymphocytes isolated from the six control persons. The TKI  mRNA level was 
quantified by competitive PCR. In the competitive PCR reaction TKI-cDNA is 
amplified with a primer pair enclosing  exon  1 and 2, resulting  in a 138  bp fragment. 
With genomic  DNA this primer  pair  amplify  a 248 bp  fragment.  Initially,  the PCR- 
reaction  was  performed  with a broad  range of genomic  DNA  dilutions to  titrate  the 
“competition  region”.  Afterwards, a fine-adjustment  of the internal  standard  was 
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performed (figure 15.A and 15.B). 
Figure 15: TK1 genomic DNA versus TKI cDNA for controlperson 4 stimulated with PHA for 94 hours. 
A: Titration with a  broad range  of dilutions of TK l .genomic DNA (248 bp],  competing with l p1 of TK1- 
cDNA (138 bpl. Lane l is  without genomic DNA.  Lane 2 - 8 contain various amounts of genomic DNA 
( 1 0 ”  g - IO-“ g], decreasing with a  factor 10 for each  lane. Lane 9 is a PCR-reaction without DNA 
(negative  controll. B: Closer titration based on the  competition range (about 10‘’ g1 determined in A. 
Lane 2-9 represent titration  from l o f 4  to 10“g. Lane 1 is  cDNA only and  lane 10 is a  negative  control. 
The amount  (gram) of cDNA in the sample was  estimated as that  amount 
(gram) of genomic DNA giving equal intensity of the  two  amplification  products 
(1 5.B, lane 8). From  this  quantity,  the  number of TKI cDNA  copies  were  calculated 
by division with the average molecular weight of the 138 bp cDNA fragment 
(average molecular weight/base = 308). The number of TKI cDNA copies was 
regarded as representative  for  the number of  TKI mRNA’s. The PCR reactions  were 
always  performed with a  positive  (TKI  cDNA) and  a  negative  control  (no  DNA). 
Figure 16  shows  the increase in  the  TKI mRNA level  expressed in relation 
to  the  protein  content  for  lymphocytes  stimulated  to  growth  with PHA. 
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Figure 16: PHA induced  variation of TK1 mRNA (copies/mg protein) for control person 1-6, The 
lymphocytes were stimulated with PHA for the indicated periods. TKI mRNA was estimated by 
competitive PCR. The ordinate scale for donor 3, 5 and 6, differs from the ordinate  scale for donor 7, 
2 and 4. 
As seen in  figure  16  the  level  of TKI mRNA in  quiescent  cells  is  very low 
and in  four of the  six  control persons below the limit  that  is  detectable with the 
competitive PCR method.  The limit of  detection  in  the PCR reactions with  cDNA 
f rom lX105 cells is 6 copies of TK1 mRNA/1000 cells. Below  this  level an 
amplification  product  of 248 bp appears. The 248  bp  product  is  probably  traces of 
DNA or non-spliced RNA in the RNA preparation. 
After PHA stimulation the level of TK1 mRNA increase about 100-fold, 
reaching  a  peak  level  after 96 hours.  Figure 17.A  (page 65) shows  that  after PHA- 
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stimulation of lymphocytes  the  amount  of  TKI mRNA and TK activity increases 
concomitantly. 
TKI mRNA  and TK activity in  lymphocytes  from  patients with CLL 
Chronic lymphatic leukemia (CLL) cells are non-dividing cells, and therefore it is 
plausible that  the  low TK activity in these  cells  almost  exclusively is due to  TK2. 
Ellims et al (1  981)  showed  that in eight  patients  out o f   12 patients,  the  dominating 
enzyme  was  TK2, as evaluated of  the TK activity  from  the CTP/ATP  ratio. However, 
with  four  of  the  12  patients  the  ability  of  the TK activity  to use CTP  as phosphate 
donor was low,  indicating  that  the  dominating TK was  TKI.  As  the  four  patients 
with TKI suffered  from a more  aggressive form  of CLL, it was  suggested that TKI  
was an indicator of a change to  a  more aggressive form. 
Occurrence of a TKI isoenzyme in quiescent CLL cells may be due to  a 
change in the control of the cell-cycle regulated expression of the TKI gene. 
Therefore, it was investigated if any difference in expression of TKI mRNA in 
normal and malignant  cells  could  be  detected. 
In  the  five CLL patients used in these  experiments, the TK activity  was  low 
and at  the same  level as that  in quiescent  lymphocytes.  Investigation of the enzyme 
activity by the CTPlATP ratio showed that the TK activity from the five CLL 
patients  behaved like TK2  in  quiescent  lymphocytes. Due to  the  quiescent  stage of 
CLL cells  and  the dominance of the  TK2 isoenzyme, a low level  of TKI  mRNA  was 
expected. However, when TKI mRNA in CLL cells was quantified the level was 
about 30 to  300-fold higher  than  the level in quiescent  lymphocytes. In fact,  the 
level  was  in the same range as  PHA stimulated  lymphocytes.  Duplicate 
determination  of  TKI mRNA showed a CV of -20%. Figure 17.A and 17.B  show 
the  amount of TKI mRNA and  TK activity  in one control  donor and in  the  five CLL 
patients. 
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Figure 17: A: The  PHA induced  variation of TK1 mRNA &W and TK activity N for control  donor 1. 8; 
The amounts of  TKI mRNA in CLL cell.. . The  number  on the x-axis refer  to  tbe  individual CLL patient. 
Reprinted  from - Leukemia Res. vol. 18,  Kristensen, T., Jensen, H.K and Munch-Petersen, 8.: 
Overexpression of human thymidine kinase mRNA without corresponding  enzymatic activity in patients 
with  chronic  lymphatic leukemia, 861-886, copyright (19941, with  kindpermission  from Elsevier  Science 
Ltd, The Boulevard, Langford Lane, Kidhgton OX5 IGB, UK. 
Resume of  quantification of TKI mRNA in  healthy  lymphocytes  and  in 
lymphocytes from patients  with CLL 
The relation  between  TK1 mRNA and TK enzyme activity has  been investigated in 
control  persons and in  patients with CLL. Human  lymphocytes,  which are truly G, 
cells, can be stimulated to  growth  by PHA and  these  experiments  have  been  used 
as a model  system  for  expression of TKI  mRNA and  TK activity in normal cells. 
PHA stimulation of lymphocytes  from  control persons results in an about  100-fold 
increase in TKI mRNA copies' mg-' protein and is followed by a concomitant 
increase  in TK activity. 
In CLL cells  which are  quiescent  cells  the TK activity  level  was  low  and in 
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the same range as quiescent  lymphocytes  from  control persons.  The dominating 
enzyme in the CLL cells was TK2. However,  the  level  of TKI  mRNA copies mg.’ 
protein  was 30 to  300-fold higher  that  the level found  in  quiescent  lymphocytes 
from control persons and actually the level was in the same range as in PHA 
stimulated  lymphocytes. 
Results  from  structure-function  relationship  of  human TKI 
Recombination  PCR 
Two deletions mutants were constructed for the investigation of the structure- 
function relationship of human TKI. In one mutant, TKI-193, a stop codon is 
introduced  at  amino  acid  position  194,  deleting 40 amino  acids from  the  C-terminal. 
In  the  other  mutant, T K I - l  76,  a  stop  codon  was  introduced a t  amino  acid position 
177,  deleting  57 amino  acids from  the C-terminal. The mutants  were  constructed 
by  the  recombination PCR method,  where two separate PCR-reactions was 
performed. Each reaction  contained  the pGEX2T-TK1 plasmid  carrying  the  amino 
acid  coding sequence for  human TKI .  By changing  a few nucleotides in the  primer 
sequence  used for  the PCR-amplifications  a new  stop  codon as well as a restriction 
site  was  introduced  into  the  TKI  cDNA. Each PCR-reaction was  performed with a 
mutagenic and  a non-mutagenic primer.  A sense and an antisense version  of  both 
primers were constructed. The PCR-reactions results in a PCR-fragment with 
homologous ends and transforming PCR-fragments from each PCR-reaction into 
E.coli will result in an in vivo recombination. 
pGEX2T-TK1  linearized with Hpal and Aatll,  respectively, was used in the 
PCR-reactions. For construction of the TK I - l   93  clone, the  “right  side”  (figure 9, 
page 47) of pGEX2T-TK1 was amplified with the Lacl-1/TK1-193-1 primer pair, 
resulting  in  a  fragment  of  2563 bp. Amplification  of  the  “left  side”  of  pGEX2T-TK1 
was performed with the Lacl-2/TKl-l93-2 primer pair, resulting in a 3138 bp 
fragment. For construction  of  the TKI  -1  76 mutant, similar reactions are set  up, but 
with  TKI  -1  76 primers  instead  of TK I - l   93  primers. These reactions  result in PCR 
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fragments  of  2612  bp  for  amplification  with  the  Lacl-I/TKl-l76-1 primer  pair and 
of  3089 bp with the  Lacl-2/TKI -1  76-2 primer  pair. Figure 18  shows an agarose gel 
electrophoresis  of  the PCR-reactions. 
Figure 18: PCR-amplification of pGEX2T-TKI. Lane l :  pGEX2T-TKl/Aatll with primers Lac/-2 + TKl-  
193-2. Lane 2: pGEX2T-TKl/Hpal  with primers Lacl-l + TK193-l. Lane 3: pGEX2T-TKl/Aat/l  with 
Lacl-2 + TKI-1  76-2. Lane 4: pGEX2T-TKl/Hpal  with  Lacl-l + TKI - l  76-1. Lane 6: Marker NBstEIl: 
from  bottom; 700, 1264, 1371,  1929, 2323,  3675,4824 bp. 
The PCR-fragments were  cut  out  of  the gel, purified and transformed  into 
MAX Efficiency DH5a  €,coli. Table 2 shows  the number of  transformants. 
No. of colonies No. of clones  Transformation 
efficiency with Sac1 site 
(CFU”/Ng pUC) 
pGEX2T-TKI-193 
17/17 33 pGEX2T-TKI-176 
5/5 10 
pUC-control/l93 
1x108 pUC-control/l76 
4x1 0’ 
Table 2: Number of transformants of pGEX2T-TKI-193 and pGEX2T-TK-l76  after transformation and 
recombination of  the PCR fragments from the PCR reactions in figure  18.  a: CFU, colony forming units. 
pUC-control refers to  the transformation efficiency for that particular experiment, as controlled by 
transformation with pUC  DNA. 
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As it appears from table 2 both  transformation  experiments with pGEX2T- 
T K I - l 9 3  and pGEX2T-TKI-176  plasmid  resulted  in  transformed colonies, 10 and 
33, respectively.  The  frequency  of the site-specific.  mutagenesis in these 
experiments is 100%, as the plasmid DNA from all the tested clones could be 
digested with Sacl.  As  the  only  Sacl site in the pGEX2T plasmid is  part  of  the 
inserted  stop  codon,  a  digest is  obtained  only if the  site-specific  mutagenesis  has 
been  performed. 
Considering  the  amount of purified PCR products (=30 ng  of  each PCR- 
product)  transformed  into  MAX  Efficiency  DH5oE.colithe number of  transformants 
may seem low.  The  control experiments, with  transformation  of pUC plasmid shows 
that  he  transformation  efficiency  in  each  experiment  is acceptable,  as the 
efficiency is  higher  than  1  x1 O6CFU/pg pUC. There are several  reasons for  the  low 
number  of  transformants  with  the PCR fragments.  First,  the  transformation 
frequencies with linear plasmid  molecules  are  several  orders of magnitude ( I O 2  - 
1 03) lower  than  those  obtained  with  equivalently closed  circular  molecules  and of 
the  transformed  fragments  only  a small part ( <  1 O3 per 10” added  molecules) will 
survive the nucleases in €.coli (Conley  et  al  1986a).  Therefore it is  important t o  use 
high competent €.coli strains in the recombination PCR procedure. I tried to 
transform PCR products  into  competent  Library  DH5a €.coli and €.coli cells  made 
competent  by  the CaCI, method  (Sambrook  et al 1989),  respectively,  but  without 
success. This was probably due to a lower transformation efficiency of l x 1 0 7  
transformants/pg of monomer pUCl9 for both strains (Sambrook et al 1989). 
Secondly, the  low number of  transformants  is due to  the  recA-  genotype  of  the 
DH5o  €.co/ihost. The numbers  of  transformants  in  recA-€.colistrains are about 40- 
fold  lower  than  in  recA‘ €.coli strains (Conley and Saunders 1984).  Conley and 
Saunders (1 984) and Conley  et al (1  986b)  have  shown that transformation of  blunt- 
ended  pBR322  into  a  recA’  €.colistrain  result  in a mutation  frequency  (not  to  be 
confused with site-specific  mutagenesis  frequency) of 80%. The types  of  mutation 
are mainly  deletions  of bases and Conley et al (1 986b)  propose  that  exonucleolytic 
processing of the  terminus  of linear  plasmid  DNA  generates  fragments  suitable  for 
recombinational  recyclization and  deletion.  Actually,  transformation of €.coli with 
linearized plasmid DNA molecules is used deliberately as a method of obtaining 
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deletions  of  cloned  DNA  sequences invivo  (Sambrook  et al 1989).  However, Jones 
and Howard  (1991) have shown  that  a  recA-Ecolistrain can  recombine  DNA with 
minimal stretches of homology. The transformation efficiency is decreased, but 
likewise is the  mutation  frequency.  In  a series of  recombination PCR experiments 
Jones  and  Howard (1  991 ) found  that  the  highest  mutation  frequency  was  50% and 
in several experiments the mutation frequency was 0%. The best results (0% 
mutation frequency) were obtained when the region of homology between the 
mutating ends (corresponding to  end 1 and 3 in figure 9, page 47) and the  non- 
mutating ends (corresponding to  end 2 and 4 in figure g), respectively, was 
delimited to  - 30 bases. Increasing the area of homology also increased the 
mutation  frequency.  It is not  known  how  the recombination between very short 
regions of  homology  in  a  recA-  host proceeds  (Jones  and Howard  1991 ). 
Induction of wild  type  and  mutants GST-TKI fusion  proteins 
An €.coli strain defective in TK expression (KY895, Hiraga et al 1967) was 
transformed  with  pGEX2T-TKI,  pGEX2T-TKI-193 and pGEX2T-TKI-176, 
respectively. Due to  observations by Fetzer and Folkers (1992) and Fetzer et al 
(1  994)  the  fusion  proteins  were xpressed a t  25OC They  found  that  expression  of 
Herpes simplex virus l-thymidine kinase (HSV-1 TK) as a GST-fusion protein in 
E.coliKY895  resulted  in GST-TK,,, inclusion  bodies  at 37OC but  not a t  25OC. The 
GST-TK,,, inclusion bodies, which are aggregates of  insoluble  proteins,  could  be 
solubilized  in  6 M guanidin HCL, but  then  the  ability  to  bind  to  glutathione  was  lost, 
making the purification by glutathione affinity chromatography impossible. Why 
eukaryotic  polypeptides are sequestered into  inclusion bodies in €.coli is  not  fully 
understood. It is  not simply a response by  €,colit0  "foreign" proteins,  since normal 
€.coli proteins synthesized to high  levels  using  recombinant  DNA  techniques  can 
also accumulate in insoluble  forms  (Marston  1986). 
Figure 19 shows  the  time  course  of  expression  of  the  GST-TKI  (wild  type) 
fusion protein at 25OC. The expression is measured by the TKI activity. The 
expression of GST-TKI is optimal after four hours, whereafter the level slightly 
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decreases. 
Time (hours) 
Figure 19: Expression of the GST-TK1 fusion protein measured by the TKI activity. Open circles are 
induction of GST-TK1 with IPTG. Filled  circles  are  control: GST-TK1 without IPTG. Units: nmol min-’- 
Table 3 shows  the  induction  of  TKI  activity with IPTG. The  results  shown 
here are for induction in LB medium, but expression in minimal ABTG medium, 
supplemented with an FNI 8 amino  acid  mix (see  appendix  1 ) gives  the same result. 
The purpose of using  minimal  medium is to obtain  isotope  labelling  of  the  expressed 
protein with an  amino  acid.  This may be useful  for  the NMR analyses. 
Table 3: The yield of wild type and mutants GST-TK1 fusion proteins,  measured  by TK assay. U: unit 
(nmol min-”. 
~ ~~ ~~~ 
- IPTG 
Ulml bac.cuiture Ulml bac.culture 
f IPTG 
I 
GST-TKI 100-250 1-10 
GST-TK1-193 
0.1-1.0 0.1-1.0 GST-TKI-1 76 
20-40 0.1-1.0 
c 
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As seen from Table 3  no  increase of  TKI  activity  was  found  for GST-TK1- 
176 after  induction  of pGEX2T-TK 1-1 76. It was  investigated if the GST-part of the 
fusion  protein  was expressed, with the GST substrate CDNB (1-chloro-2,4- 
dinitrobenzene). GST mediates a reaction  between CDNB and  glutathione,  and  the 
product of the enzyme reaction is measured at 340 nm. The increase in the 
absorbance  at 340 nm, as shown in figure 20 shows that the GST-TK1 -1 76 is 
expressed. 
, 6  
Time  (minutes) 
Figure 20:  CDNB assay for GST-TKI-  176 fusion protein. Open  circles: 50 p1 of total protein from €.coli 
KY895/pGEX2T-TKl-176 sonicate harvest 15 hours after IPTG  induction.  Filled  circles: 5 0 p I  of total 
protein from E.coli KY 895/pGEX2T-TK1-176 sonicate haNeSt before IPTG induction. 
Sequence analysis 
The  sequence of  TKI cDNA in pGEX2T-TKI-193 and pGEX2T-TKl-176 was 
determined to ensure that  no  mutation,  except  the  site-directed mutagenesis,  had 
occurred  during  the PCR-amplification  and the  recombination process.  The wildtype 
pGEX2T-TK1 that has not been subjected to  PCR-amplification or recombination 
was  used as a "control." The sequence strategy  was  shown  on page  52. 
Apart  from  the  introduced  mutations,  the  pGEX2T-TK1-193 and pGEX2T-TK1-176 
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cDNA sequences were  identical to  pGEX2T-TK1 and thus  no  mutations  had 
occurred  during  the PCR-reactions or the  recombination processes. However,  when 
comparing the published sequence for human TKI  (pTK11, based on DNA from 
HeLa cells,  Bradshaw  and  Deininger 1984) and the  lymphocyte  TKI  cDNA 
sequence in pGEX2T-TK1 two base changes  was  observed:  base 31 6,  A, in pTK l1  
is  changed to a G in pGEX2T-TKI.  This  results in an amino  acid  change from  Met’“ 
in pTK11  to Val in lymphocytes. The other  change is base 632,  where A in  pTK11 
is  changed to a G in  pGEX2T-TKI. The amino  acid  change  is from Lys”’ in  pTK11 
to  Arg  in  lymphocytes. 
pTKl1 
A (nucleotide 31 6) Met’“ 
A (nucleotide  632) 
pGEX2T-TKI 
G (nucleotide  31  6) 
G (nucleotide  632) 
- GTG 
Arg’” AGG 
Table 4: Differences  between TK1  cDNA  sequence in  pTK1 l and pGEX2T-TKI. The specific bases  are 
numbered according to the  first base in the  start codon. The codon with the changed base and  the 
corresponding amino acid are shown  in column 2 and 3. The altered bases in pGEX2T-TK1 are shown 
in dark and underlined. 
As  the  observed changes are identical in  pGEX2T-TKI-176,  pGEX2T-TKI- 
193 and pGEX2T-TKI, it is very  unlikely that  they arise from PCR-amplification or 
recombination. 
Purification of recombinant TKI protein 
Enzymatic  characterization of  the  recombinantly expressed  enzymes is  performed 
on pure enzymes. Cleavage of the TKI protein from the GST fusion partner is 
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therefore necessary. In these experiments it is performed with thrombin, after 
immobilization  of  the  fusion  protein to a  glutathione agarose column.  The 
glutathione agarose  chromatography  results  in an approximately 80% pure 
preparation. Remains of  the  fusion  protein  (50 kDa for  GST-TKI and .46 kDa  for 
GST-TKI-193),  the GST-part of  the  fusion  protein  (26  kDa) and a 70 kDa protein 
band  was  present  in  the gel (lane 2 and  5 in figure  21).  GST-TKI-l76  was  purified 
as well  to ensure that  a  subunit molecular size of 18.1 kDa was expressed, but as 
the  mutant is without  TKI  activity  the results  from  the  purification are omitted. 
Fractions containing TKI protein  from  glutathione agarose columns were 
applied to a G-25 column and the desalted protein were then applied on a CM- 
sepharose. T K I  has  a positive  netto-charge and will  therefore  bind to  the  negatively 
charged  carboxymethyl-groups  in CM-sepharose. This  procedure  gave a preparation 
of approximately 99% pure (lane 3 and 6 in  figure  21). For recombinant TKI  the 
expected  submolecular size is 24 kDa and for T K I - l  93 the  expected size is 20,l 
kDa. Figure 21 shows  that  the  subunit molecular weights  were as expected. 
Figure 21: Silver-stained SDS-PAGE (15% separation gel)  of pure recombinant TK1 and TK1-193. Lane 
l, 4, 7 and 8 are markers: 97, 66, 45, 31, 2 l and 14 kDa.  Lane l and 4 contains 40 ng of each protein, 
lane 7 and 8 contains 60 ng of each protein. Lane 2: 0.3 pg recombinant TK l from  glutathione agarose 
chromatography, Lane 3: 0.3 pg recombinant TK1 after CM-column, Lane 5: 0.3 Kg TKI-193  from 
glutathione agarose chromatography, Lane 6: 0.3 pg TKl-  193 after CM-column. 
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In table 5 the yield and purification degree of recombinant TKI protein 
corresponding to  crude  extract  from  1  litre  bacteria  culture  is  shown. The yield is 
based on  the  total  enzyme  activity and protein  in  the  crude  extract.  From  1  litre  of 
bacteria  culture  0.8-1 .O mg pure  recombinant TKI protein  can  be  purified. 
Table 5: Purification of recombinant TK1 
Volume Yield YO Total Units/mg Units/ml Protein 
11 Crude extract II 
50 159 I 78350 I 1567 490 
Glutathione  agarose  chromatography loo I 
I1 I 30 I 9.43 I 151 1 I 4812 I 45330 I 58 11 
11 Seohadex G-25  chromatoaraohv II 
II top# I 71.5 I 3.43 I 261 I 5437 I 18661 I 23 11 
11 CM-sepharose  chromatography II 
The  TK activity has been  measured on enzyme stored with 2.5 mM ATP. Units: nmol min-'. 
Kinetic studies 
Munch-Petersen et a1 (1  993) have  shown  that  pure  lymphocyte  TKI has different 
enzymatic  properties  when  stored  with or without ATP. When  stored  without ATP 
the  lymphocyte enzyme is a dimer with low  affinity  for  thymidine (K, = 15 PM). 
Stored with ATP, the enzyme is a  tetramer with high  affinity  for  thymidine (K, = 
0.5 PM) as'described  on page 22. 
As T K I - l 7 6  is without  activity,  only  the  nzymatic  properties  of 
recombinantTK1 and TKI  -1  93 enzymes were examined.  The top-fraction  from  CM- 
sepharose was  divided  into two aliqouts. 2.5  mM ATP was added to one fraction 
and this  fraction  is  referred  to as the  +ATP form,  while  the  other  fraction  without 
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ATP is  referred as the -ATP  form. 
Reaction  mechanisms 
The effect of ATP on  the  thymidine  substrate  kinetics  of  recombinant TKI and TKI - 
193 appears from  the Hofstee  plots  in  figure 22 A  and B. The initial  velocities  were 
measured at various concentrations of thymidine. The effect of ATP on the 
thymidine substrate kinetics of recombinant TKI  and T K I - l 9 3  is similar to  that 
observed with  lymphocyte  TKI (Munch-Petersen et al 1993). 
In  the  Hofstee  plot  for  the  +ATP  forms  of  recombinant  TKI and TK I - l   93  
the  points  have  been  fitted to a  straight line, but a  curved  tendency  may  indicate 
positive cooperativity. Positive cooperativity is obtained when binding of one 
substrate  molecule enhance  binding of  the  next  molecule.  All  the  +ATP samples 
of TKI (n=3) and TK I - l 93  (n=3)  display the same curved  tendency.  This 
phenomenon  is also observed  for  the  native  lymphocyte TKI  (Munch-Petersen et 
al 1993). For the  -ATP  forms  the  curve has a clear biphasic shape that may  indicate 
negative  cooperativity, e.g. binding of one  substrate  molecule decrease binding  of 
the next  to  the neighbour  subunit.  The degree of apparent cooperativity has  been 
analysed from Hill plots of log v/(V,,,-v) versus log [dThdl (FM), where v is the 
initial  velocity. The slope of  the curve, the  Hill  coefficient (n), gives  a measure of 
the  apparent  cooperativity. Values of n below one  indicate  negative  cooperativity 
while n values  above one indicate  positive  cooperativity.  The Hill coefficient  for the 
+ATP  forms  was  1.38 k0 .05  (mean -c s.d, n = 3) for  recombinant TKI  and 1.25 
k0 .15   (n  = 3) for TKI-193. For the -ATP forms the Hill coefficient was 0.46 
k0.08 (n = 3) for recombinant TKI  and 0.5 f O . l  (n = 3) for TKI-193. 
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Figure 22: Hofstee  plots of (AI recombinant  TK1  and (B1 TKI-193. The filled  circle  represent the +ATP 
form of the enzyme and  the unfilled  circles  represent the -ATP form. 
The  -ATP form has  a low  affinity  for  thymidine with a K, value  of 14.08 20.68 
(mean is.d., n = 3) pM for  TKI-ATP and 12.8 20.65 (n = 3) MM for  TK1-193- 
ATP. Incubation  of  the enzymes with ATP gave  a K, value of 0.5 kO.1 (n = 3) pM 
for  recombinant TKI  +ATP and for  TKI- l93+ATP 0.5 kO.15  (n = 3) pM. This 
indicates  that  the  affinity  of  the  +ATP  forms is about  25-fold  higher  for  thymidine 
than  that  of  the  -ATP  forms. 
Determination  of  the  maximal  velocity, V,,,, revealed a difference  between 
recombinant T K I  and TKI-193. For recombinant TKI  the V,,, value was 9700 
unitslmg  but  for  TK1-193 a  2.5-fold decrease was observed (Vmax = 3800 
uni tshg) .  
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kc,, indicates  the  maximum number of substrate  molecules that can  be converted 
to  product per active  site per unit  time, and is therefore also called the  ”turn-over 
number”  of  the enzyme. 
K,, is calculated  from V,, and the  total enzyme concentration (V,, = k, x [ET]), 
presuming  a  molecular  weight  of 4 x 24,000 for  recombinant TKI  and 4 x 20,000 
for TK1 -1 93. 
K,,, with dThd as substrate  is 16 5-l for  recombinant TKI  but 5 5-l for  TKI  -1  93. 
Stability 
Investigations  of  the  effect  on  the  stability  of  the  deletion  of 40 amino acids  from 
the  C-terminal. 
The  investigations  of  stability  were  performed  on  the  +ATP and -ATP  forms 
of  recombinant TKI  and TKI-193. The  -ATP  forms  was  incubated  in 50 m M   i r i s  
and 10 mM DTT  whereas for  the  +ATP  form ATP to a  final  concentration  of 2.5 
mM  was added. The TK activity  was measured after incubation  of  the  enzymes  for 
0, 4, 8, 12, 1 6  and 20 minutes a t  37OC. For each measurement the TK activity 
was  normalised to  the TK enzyme  level at 0 minutes of  incubation. Figure 23 shows 
the  stability  for  recombinant  TKI and T K I - l  93. 
78 
1 
0 
0 5 10 15 20 25 
t 
min o f  incubation at 37'C 
5 
Comparison of  the  +ATP  forms  of  recombinant  TK1  and  TK1  -1  93  indicates 
that  the mutant is less stable. Measurement of the TK activity for TKI + ATP 
(n=4) and T K I - l 9 3  + ATP (n=4)  a t  0 minutes  and 4 minutes revealed that  the 
difference in stability  was  significant  (P<0.005,  t-test). 
The  stabilising  effect  of ATP is clear from  these  experiments,  as for  the - 
ATP forms  only -20% of  the  activity  is preserved after 4 minutes  of  incubation 
whereas  for  the  +ATP  forms  50-70%  activity remains. 
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Molecular weight 
The native molecular weight for  recombinant TKI and T K I - l 9 3  was  estimated  by 
gelfiltration  in absence  and  presence of ATP on a Superose 12 column. In presence 
of ATP the  column  was pre-equilibrated with buffer  containing 2.5 mM ATP. The 
molecular  weight  was  estimated  by  comparing  the  retention  times  for the sample 
with  the  retention  times  for  the  following marker proteins:  beta-amylase 200 kDa, 
alcohol  dehydrogenase 150 kDa, bovine serum  albumin 66 kDa, carbonic anhydrase 
29 kDa, cytochrome C 12.4 kDa. 
Table 6: Native  molecular weight determination.  n = number of experiments 
SDS n  molecular size mean 
2s.d (kDa) 
TKI -ATP 4 55 +3.3 24 
TKI  +ATP 3 116 k4.7 24 
TKI  -1 93-ATP 
4 92 22.5 20 T K I - l 9 3 + A T P  
5 44 k2.8 20 
The effect  of ATP on  the  native molecular weight  of  TKI and TK I - l   93  is 
seen in Table 6. Without ATP the enzymes appeared as a dimer, with sizes of - 55 
kDa and -44 kDa for  recombinant TKI  and T K I - l  93, respectively.  In  the presence 
of  ATP  during  chromatography  the  enzymes  eluted as tetramers, of  116 and 92 
kDa, respectively.  This  indicates  that  ATP  induces  a  tetramerization  of  the 
recombinantely expressed enzymes similarly to what observed with the native 
lymphocyte TK I .  
Determination of the native molecular weight was quite difficult as the 
recovery  of  the nzyme was  very  low. The  experiments  were  repeated  several  times 
with  high  levels of enzyme. Normally 0.003 units  of  lymphocyte  TKI  activity  gives 
a recovery of about 70.80% on Superose 12  column. For the recombinantly 
expressed  enzymes  the applied amounts  were  2-3  units and the  recovery  was  1-5 
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%. The reason for the low recovery may be that the recombinantly expressed 
enzymes are more  hydrophobic  due to amino acid  changes or that  they are more 
unstable and therefore monomerisize. 
Table 7: The kinetic  data 
*The  results for the  native TK1 are from Munch-Petersen et a1 1993. 
Resume  for  investigations of TK l structure-function  relationship 
For the investigation of the structure-function relationship of human TKI, two 
deletion  mutants  were  constructed.  Deletion  of 57 amino acids from  the C-terminal 
(TKI-176) resulted in an inactive protein. Deletion of 40 C-terminal amino acids 
reduced V,,, 2.5 fold  the  level  of  recombinant TKI,  but  did  not  affect  the K,,, value 
or the  Hill  constant. 
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Discussion 
The principal  subject  of  my  work  was to study  various  aspect  of  the  regulation  of 
human TKI  a t  the cellular  and the enzymatic  level. 
In  the  first  part  of  these  investigations I have quantified  the  level  of  TKI 
mRNA in quiescent and PHA stimulated  lymphocytes  from  control  persons and in 
lymphocytes  from  patients  with  chronic  lymphatic leukemia (CLL). Comparing  the 
level of  TKI mRNA and the TK activity  can reveal if these  cells have any differences 
in  the regulation mechanism(s) of TKI .  The TKI mRNA was quantified with the 
competitive PCR method. There are two advantages of the competitive PCR 
method: the method is more sensitive than Northern blot techniques and the 
quantisation are independent  of  the  many  variables  that  affect PCR amplification 
(different templates are amplified with different efficiency, the primers have 
different  efficiency,  intrinsic  variability of PCR reactions). With  competitive PCR it 
is  possible t o  detect  a  very  low  amount of TKI mRNA in  quiescent  lymphocytes 
from  control persons.  The detection  limit  was  6 copies  per 1000 cells. Below  this 
level, a 248 bp amplification  product  interferes  with  the  competitive PCR. This  is 
probably a result of traces of DNA or non-spliced RNA in the RNA preparation. 
However, the competitive PCR method has some limitations, it quantifies the 
amount  of  cDNA  in a given sample and if the  efficiency  of  reverse  transcription  is 
less than  1 OO%, the  method will underestimate  the  actual  amount of mRNA.  As the 
same protocols  have  been used for all donors, I presume that  the  underestimation 
is in  the same range for all donors. 
Lymphocytes  stimulated to  growth  by PHA are used as a model-system  for 
studying S-phase specific  events.  The  system  is  well  characterized with respect to  
TK activity,  DNA  synthesis and cell division  (Loeb e t  al 1970,  Munch-Petersen and 
Tyrsted  1977,  Tyrsted and Munch-Petersen 1977).  In  my  experiments  a  very  low 
level of  TKI mRNA quiescent cells was estimated. After  96 h of PHA stimulation 
the TKI mRNA level reached a maximum, with a 100-fold higher level than in 
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quiescent  lymphocytes. Based on  the  ability  to use CTP  as phosphate  donor it was 
established that  the  dominating enzyme in quiescent  lymphocytes  was TK2, while 
the  dominating  enzyme in dividing  lymphocytes  was TKI .  It was  demonstrated that  
the  amounts  of  TKI mRNA and TK activity increase concomitantly  during 
incubation  of  the  lymphocytes  with PHA. This  pattern  correlates  well  with  serum- 
starved cells stimulated to reenter the cell cycle by serum (Stuart et al 1985, 
Stewart e t  al 1987).  In these  cells  the increase in  TKI mRNA is accompanied by a 
corresponding  increase in TK activity, and both  transcription and post-transcription 
mechanisms  account  for  the  induction  of  TKI mRNA (Coppock and Pardee 1987, 
Stuart et al 1985, Steward et al 1987). PHA-stimulated lymphocytes probably 
display  the same cell  cycle  regulated  patterns as serum-stimulated cells. However, 
there are some  differences.  In the experiments  by  Steward e t  al (1  987) a low level 
of  TKI mRNA, as  measured by Northern  blot analysis, was  detected  in  the  serum- 
stimulated cells.  The TKI  mRNA level  was  not  quantified  but  after 12  h of serum 
stimulation  the  level  of  TKI mRNA  reached  a peak level  (Stuart  et al 1985,  Steward 
et al 1987). For the PHA stimulated  lymphocytes,  my  experiments  show  that T K I  
mRNA  does not reach  a peak level  until  96 h after  stimulation  and with  the  Northern 
blot technique it was not possible to detect any transcription of TKI mRNA in 
quiescent  lymphocytes. The explanation  for  this  difference is probably  that 
peripheral  blood  lymphocytes are truly G, cells and may  have  spent  several  years 
in  a  non-dividing stage.  The length  of  the  first G, period  (after  stimulation)  depends 
on  how  long  time  the cells were  in G,. In  experiments  with W138 cells (a 
nontransformed  mortal  human  diploid  fibroblast) wo distinct stages of quiescence 
have  been  identified. Cells that  were  in G, for 1-1 0 days  were  minimally  affected, 
in  contrast  to  cells  that  were  in G, for  10-20 days. In the  last case a  decrease in 
overall  protein  and RNA content  was observed.  When the  cells  were  stimulated to  
reenter the cell cycle, expression of several late response genes, e.g. TKI  was 
considerably  retarded  (Hofbauer  and  Denhardt  1991). The serum-starved  cells are 
stopped  while  they progress through  the  cell  cycle, so when  they are stimulated to  
reenter the cell  cycle  their  "machinery"  for  replication is still  active and therefore 
provide a quicker  entry  into  the cell  cycle. 
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CLL cells are in a  quiescent stage, so I expected to obtain similar results as 
with the lymphocytes from control persons, e.i. a low TKI mRNA level and a 
corresponding low TK activity. The TK activity  was  low,  in  the same range as in 
quiescent  lymphocytes, and when  investigated  for  phosphate  donor  specificity, it 
was  established that  the enzyme activity  was  TK2. It was  therefore  unexpected to  
find  a  high  level o f  TKI mRNA, about  100-fold  higher  than  the TKI mRNA level in 
quiescent  lymphocytes.  This  shows  that CLL cells  have an abnormal regulation  of 
the S-phase regulated TKI.  TKI mRNA level  is  high and is  prevented  from 
translation  into an active enzyme. It is  generally  accepted that  the R-point 
mechanism in late G, controls normal cell proliferation and this mechanism are 
deregulated in several  cancer cells. The  mechanisms to control  the passage through 
the  R-point are among  others:  cyclins, Cdk, Rb and p53.  An  altered  regulation and 
increased  level of cyclins, particularly  cyclin  D  (Musgrove  et al 1994), E and  A (Dou 
et al 1993, Keyomarsi and Pardee 19931, have been shown  in several transformed 
cell  lines and in breast cancer tumours.  As  mentioned  on page 12, TKI carries  an 
E2F (a cellular transcription factor) binding site in its promoter. An intact E2F 
binding  site is  required  for  transactivation  of TKI expression by polyoma  large  T 
antigen, as well as for  serum  stimulation.  Ogris et al (1 993) have shown  by  mobility 
shift assays that an increase in free E2F coincided  in  time with  the appearance of 
TK1 mRNA. It could be, that the level of free E2F in CLL cells is increased and 
thereby  provides an  over-expression  of TKI.  The level of free E2F can  increase if 
the  Cdk2-cyclin E complex  phosphorylates Rb in the E2F-Rb complex  and  thereby 
release "free" E2F. An over-expression of  cyclin E mRNA and  a deranged 
expression  of  cyclin E protein has actually been measured in proliferating  breast 
tumour  cell  lines  (Keyomarsi and Pardee 1993). These mechanisms could  explain 
the  occurrence of a  high  level o f  TKI mRNA in the CLL cells. However,  they do not 
explain  why an  increase in TK activity is not observed, either do  they  explain  why 
the CLL cells remain  quiescent  and  do  not  initiate  cell  division as a respond to  the 
high  TKI mRNA level. It  is possible, that  the  TKI mRNA is defect, preventing it 
from being  translated  into an active enzyme. For the  quantification  of TKI  mRNA 
only  exon 1 and 2 out  of  total 7 exons  have been PCR amplified, so a  truncation 
could not be excluded. However, in experiments by Laursen et al (1994), TKI 
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mRNA from  normal persons  and CLL patients  were  investigated to  detect  possible 
sequence  differences.  They  used  the SSCP analysis  (Single  Stranded 
Conformational  Polymorphism, Orita et al 19891, which can detect  down  to single 
nucleotide  deletions or substitutions  in PCR fragments of 300-400 bases.  The PCR- 
fragments were denatured and electrophoresed on a polyacrylamid gel. These 
experiments  were  performed  on  five  normal  donors and four CLL patients  but  did 
not reveal  any  sequence  differences  in  the TKI mRNA. 
Another purpose of  my  work was to  investigate  the  relationship  between 
structure and function  of  TKI.  Two  mutant, T K I - l 9 3  and TKI-176 were 
constructed.  In T K I - l  93 40 C-terminal  amino acids were  deleted  whereas in  TKI- 
176 57 amino  acids from  the  C-terminal were  deleted. According to  the 
hypothetical  structure  for  TKI (Folkers et al 1991)  no  functional-essential  site has 
been deleted in TKI-193. In T K I - l 7 6  a site including the residues C Y S ’ ~ ~  and
Arg’”, which  may  contribute  to  binding and transfer of a phosphate  group  from 
ATP to thymidine,  was deleted. The mutants  were  constructed by  the 
recombination PCR method.  With  its  high  site-specific mutagenesis frequency  this 
method  is  a  very  efficient  method  for  site-directed mutagenesis. In  my  experiments, 
where I have  introduced  both a Sacl  restriction  site and a stop  codon in the  primer 
used for PCR-amplification, it was shown  that  the  plasmid  DNA  from  all  the  tested 
clones (17) could be  digested with  Sacl. This  shows tha t  all clones  possess the 
desired  mutation. 
An expression system (pGEX2T-TKI) constructed by the groups of R. 
Hofbauer, lnstitut fur Molekularbiologie, Universitat fur Wienna, and G. Folkers, 
lnstitut  fur Pharmazie, ETH Zurich, Switzerland, was chosen. In this  construct  TKI 
purified  from  lymphocytes  is expressed as a  glutathione-S-transferase  (GST)-fusion 
protein in €.coli. Purification  of  the  recombinant TKI  mutant  proteins  from 
glutathione.agarose  columns  resulted  in  5-1 0 mg - 80% pure TKI  mutant  protein 
pr. litre  bacterial  culture. The SDS  PAGE shows remains of  the  fusion  protein and 
a 70 kDa  protein. The 70 kDa  protein is  probably an Ecoliprotein  produced  by  the 
gene dnaK.  This gene product is involved  in  degradation  of  “abnormal”  proteins  in 
€.co/i(Yu-Sherman  and  Goldberg  1992). Further purification to  99%  purity  by CM- 
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affinity column resulted in 0.8 - 1.0 mg protein per litre of bacteria culture. For 
NMR-analyses 1-2  mg  should be  sufficient, so with this expression  and purification 
system it is  possible to achieve sufficient  TK1  protein  for  structure  elucidation  by 
NMR-analyses. 
By measuring the  glutathione transferase activity and SDS-PAGE it is shown 
that  the  fusion  protein is expressed in  both  mutants,  but T K I - l 7 6  is  devoid  of TK 
activity. Sequence analysis revealed that  no base mutations had  occurred  during  the 
PCR and recombination procedure.  Therefore, it can  be  concluded that deletions  of 
57 amino  acids from  the  C-terminal  completely  destroy  the TK activity.  The  mutants 
were  constructed  by  a  site-directed mutagenesis-based  method.  However, to  state 
that  the  mutants are performed by site-directed  mutagenesis are an incorrect  term, 
in the sense that site-directed mutagenesis refers to change of one (or a few) 
residues. My  mutants  have "severe" alterations as 40 and 57 amino acids have 
been  deleted. For T K I - l 7 6  it is not possible to establish, if the  lack  of  activity is 
due t o  removal of  the  putative  phosphate  binding residues (CyslE6 and ArglE7) or 
more  likely that  deletions  of  the  57  amino acids destroy  the  protein  structure.  In 
TKI  -1  76  both a putative P-strand and part  of  a  putative a-helix  is  removed. Another 
mutant  constructed in the  laboratory  recently (Larsen and Ssnnichsen 1995)  is  TK1 - 
184,  where 50 amino acids  from  the  C-terminal  were deleted.  In this  mutant  the 
residues  for  the  putative  phosphate  binding C ~ S " ~  and ArglE7 are deleted as well 
as the last putative P-strand.  This mutant  has no TK activity either, but as TKI  -1 84 
has not  yet been  sequenced  entirely, the  interpretation  that  the  activity  is abolished 
due to  lost  of  50 amino acids must be regarded with precautions. As TKI  -1  93 
posses TK activity  these results  indicate that  structural elements between residue 
193 and  176 are important  for TK activity. Kaufmann  and Kelly (1  991)  have  shown, 
that  the last 40 amino acids of HeLa TKI  are not necessary for TK activity, but do 
have  a  regulatory role. In experiments with  TKI minigenes  expressed in TK deficient 
mouse cells they have shown  that  there  is  a  mitosis  specific  degradation  of  TK1 
protein.  When  the cells were  transfected  with a TKI-minigene  with  deletion  of 40 
C-terminal amino acids the M-phase specific degradation of TKI protein was  
abolished  and  TK1  protein and activity  were stabilized throughout  the  cell  cycle. 
Likewise,  investigations  of primary  amino acid alignments  through several 
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vertebrates TKI and €.coli TK shows that exon 7, which codes for the 40 C- 
terminal amino acids, has a very high degree of variation and some TK’S, e.g. 
vaccinia  virus TK  do not have the  last 40 amino  acids. 
My  results  establish that  the  last 40 amino acids are not necessary for TK 
activity  but may posses a structural role. Removal of more  than 40 amino acids 
from  the C-terminal it not possible without  destroying  the  protein  structure. 
Investigations of  the  kinetics  for  recombinant  TKI and TKI-1 93 showed 
that  the recombinant enzymes display the same kinetic properties as the  native 
lymphocyte TK I .  Thus, without ATP, recombinant TKI  and T K I - l 9 3  appear as 
dimers with apparent negative co-operativity and low affinity for thymidine (Hill 
coefficient = 0.4, K, = 12 PM). With ATP, TKI  and T K I - l 9 3  appears as 
tetramers  with  positive  co-operativity and high  affinity  for  thymidine  (Hill  coefficient 
= 1.3, K, = 0.4pM). Although,  these  results agree with  those  obtained with TKI  
purified  from  human  lymphocytes  (Munch-Petersen  et  al  1991,  Munch-Petersen  et 
al 1993)  they  conflict  with results  obtained by Jensen (1 994). Here, an  expression 
system  in  €.colifor  direct  expression  of  unmodified HeLa TK1  was established. The 
recombinant HeLa TKI stored  both  without and with ATP  behaved as the  native 
lymphocyte  TKI stored with ATP with respect to size, specific  activity,  substrate 
specificity and K, value for the two substrates, thymidine and ATP. Thus, the 
recombinant HeLa TK1 was a tetramer with high  affinity  for  thymidine also in the 
absence  of ATP. It has been  shown  by Chang e t  al (1 994) that TK1  is  differentially 
phosphorylated  through  the cell cycle (see post-translation  regulation  mechanisms). 
Jensen  (1  994)  suggested  that  a  post-translational  mechanism responsible for  the 
ATP-shift  in  human  cells  was  lacking  in €.coli cells. However as the  ATP-shift  is 
observed  in  my  experiments  where  recombinant  lymphocyte TK1  and T K I - l   9 3  are 
expressed in E.coli as well, the post-translational explanation does not seem 
correct. Regrettably, at  the  moment I cannot give  a satisfactory  explanation. 
For the  recombinant  TKI  the V,,, value  was  determined to  9700 units/mg. 
This  value is in correspondence to V,,, values  for T K I  purified  from  lymphocytes, 
being 9600 units/mg (Munch-Petersen et al 1991, Jensen 1994). However, the 
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mutant T K I - l   9 3  has a 2.5-fold  lower V,,, value (3800 units/mg)  than  recombinant 
TKI .   An unchanged  affinity  for  the  natural substrate,  thymidine,  combined with a 
lower V,,, value suggest  that  the  last 40 amino  acids have a structural role, or that  
the ATP binding is disturbed. The last 40 amino acids can be of importance for 
stablishing  the  active  site  conformation r for  the  flexibility  of  the  protein  during  the 
induced-fit  movement  of  the  phosphate  transfer. It is possible  that, due to  the  lack 
of the 40 residues, the  two phosphate  binding  residues C ~ S ” ~  and Arg18’ are not 
able to  “get close enough” to  the ATP. This  may  inhibit  the  transfer of a  phosphate 
group  from ATP to thymidine.  Another  possibility is that  the  lower V,,, value is  due 
to a disturbed  binding  of ATP. The stability  experiments  showed that TKI-1 93 is 
less  stable (p<O.OOS, n =4) than  recombinant TKI .  This  may  favour  the  hypothesis 
that  there  is  a  disturbed  binding  of ATP. 
The kinetic analyses showed that recombinant TKI  behave similarly as 
lymphocyte TKI, but there are some differences. Determination of the native 
molecular  weight  for  recombinant TK1  and T K I - l  93,  respectively,  did cause some 
problems, as the recovery of enzyme activity was very low ( ~ 5 % ) .  A possible 
explanation is that  the recombinantly expressed enzymes are more hydrophobic 
than  the  native enzyme. The enzyme may  therefore adhere to  the  chromatography 
tubes  before and after  the column.  The  reason for  such a higher  hydrofobicity  is  not 
known,  but  there are amino acid  changes in  recombinant TKI,  which may  confer 
the  higher  hydrofobicity. The  recombinant TKI and T K I - l 9 3  have two additional 
residues in the N-terminal; Gly and Ser, due to reconstruction of the thrombin 
cleavage  sequence LVPRGS (single  letter  code).  Thrombin  cleaves  after  the  arginine 
(Chang 1985) and therefore all the cleavage products  start  with  the amino  acids Gly 
and Ser at their  amino  terminus.  The  sequencing  experiments  revealed a difference 
between  the sequence in  wildtype pGEX2T-TK1 and the  published sequence of   TKI  
cDNA  purified  from HeLa cells. Examinations  of  the two mutations Met’“ + Val  and 
Lys2” - Arg, shows that Met’“ + Val is located in the putative fifth =-helix, 
shortly after the putative Mg2’-binding Asp8’. Comparison with several other 
mammalian TKs shows that they also posses a Val and not a Met. As seen on 
figure 4 (page  25) Met’“ is  located in an area that  is  highly  homologous.  According 
to Dr. Hofbauer  (personal  communication) who has  sequenced  several TKI genes, 
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there  is  in  fact  a  difference  between HeLa and lymphocyte cDNA. Lymphocytes 
posses  a  valine at  position  106  while HeLa cells posses a methionine.  The  other 
mutation, Lys’” + Arg, is  currently under investigation  by Dr.Hofbauers group  in 
Vienna. However,  ifthe Lys Arg  mutation has arisen during  the  cloning 
procedures, it is  according  to Bordo and Argos (1  991) a so-called “safe”  mutation. 
In  this  context  safe means that  the  alteration  provides a very small conformational 
change  of  the  protein.  That  the Lys’” + Arg  alterationlmutation in recombinant TK1 
is  not  of  importance  can lso be  concluded from  the  kinetic data.  Recombinant TKI  
has  the same specific  activity and enzyme kinetics as the  native  lymphocyte  TKI. 
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English summary 
Thymidine kinase  (TK)  catalyses the ATP-dependent phosphorylation  of  thymidine 
to  thymidine  monophosphate,  which is  subsequency  phosphorylated to  thymidine 
triphosphate  and  utilized  for  DNA  synthesis. Human cytosolic TK (TKI)  is cell  cycle 
regulated, e.g. the TK1  activity increases  sharply at  the G,-S phase transition and 
remains  elevated  throughout S-phase. The  r gulation  f TKI  involves 
transcriptional,  post-transcriptional,  translational and post-translational  regulation 
mechanisms. In a variety  of cancers the  regulation  mechanisms(s) are changed  and 
TK isoforms  with  altered  biochemical  properties  have been  observed. An 
investigation  of  TK1 gene expression will  not  only  provide  insight  into  the  regulation 
mechanism  in  normal  cells but also in cancer  cells. Besides, differences  in 
expression, substrate specificity and molecular structure of TKs in healthy and 
malignant  cells  can be  used for  construction  of  selective  nucleoside analogs, only 
used by cancer TK isoenzymes. 
In  this Ph.D thesis  the  cell  cycle  regulated TKI  has been  subject  for two  different 
approaches. 
1: Investigation of the relationship between TK1 mRNA level and TK activity 
in  lymphocytes  from  healthy  donors and in  lymphocytes  from  patients  with 
chronic  lymphatic leukemia (CLL). 
2: Structure-function  relationship  of recombinant TKI .  
In the first part a sensitive method (competitive PCR) for quantification of TKI  
mRNA was established. The TKI  mRNA level was quantified  in quiescent 
lymphocytes  from  control  donors  (n = 6 )  and in  lymphocytes  stimulated to  growth 
by  the  mitogen  phytohemagglutinin. The expression in  normal cells was compared 
with the level of TK1 mRNA level in patients with chronic lymphatic leukemia 
(n = 5). 
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The results  for  the  six  control  donors  show a very  low  level of TK1 mRNA 
(below 0 . 0 0 6 ~ 1  O6 copies  mg-’  protein) and TK activity  (0.009  to  0.01 6 nmol  min-’ 
mg-’ protein) in quiescent lymphocytes. In dividing lymphocytes the TKI  mRNA 
level increases 50  to  5000-fold (3 to 98 x I O 6  copies  mg-’  protein) with a 
concomitant  increase  in TK activity  (0.1 2 to  0.76  nmol min-’ mg-’  protein). In CLL 
cells which are characterized as being  quiescent, the TK activity  was  in  the same 
range  as  in  quiescent  lymphocytes  from  control  donors.  However,  quantification  of 
the  TKI mRNA level  shows that all five CLL patients  had a very  high  level (6 to 22 
x IO6 copies mg-’ protein) of TKI mRNA, corresponding to the level in dividing 
lymphocytes.  As  the  high T K I  mRNA level is  not translated  into an active enzyme, 
these  results  indicate a defect  in  the  regulation  of  TKI  in CLL cells. 
For the studies of  the  structure-function  relationship  of TKI  a recombinant TKI  
protein,  which  is  expressed as a glutathione-S-transferase  (GST) fusion  protein was 
used. TKI  protein  is cleaved from  the GST-part with thrombin. Two  TKI mutants, 
T K I - l  93 and T K I - l  76, with deletions from  the C-terminal were  constructed  by  the 
recombinant PCR method. Deletion of  57 amino acids from  the  C-terminal (TKI- 
176)  results  in an inactive enzyme.  Deletion of 40 amino acid  from  the  C-terminal 
decreases V,,, 2.5-fold (3800 nmol min‘’ mg-’)  than  the  level  of  the  recombinant 
wildtype  (recombinantTK1)  which has a V,,, value of 9700  nmol min-’ mg-’. Except 
for  the  Vmaxvalue  the  recombinant  TKI and T K I - l   9 3  behave  similarly as the  native 
lymphocyte T K I .  When ATP is absent from  the enzyme, the  enzyme appears as a 
dimer with  low  affinity  for  thymidine and when ATP is  present  the  enzyme appears 
as a tetramer  with  high  affinity  for  thymidine. K, for  thymidine  for  recombinant  TKI 
and T K I - l 9 3  incubated with ATP is 0.5 *O. l  (mean +s.d., n = 3) pM,  while 
enzyme  incubated  without ATP has a K, of  14.08  20.68 (n = 3) pM for  TKI and 
12.8 k0 .65  (n = 3) ,uM for  TKI-193. The Hill coefficient for enzyme incubated 
with ATP  is 1.38 k0 .05  (n = 3) for  recombinant TKI and 1.25  20.1 5 (n = 3) for 
TKI-193. For the -ATP forms the Hill coefficient is 0.46 k0.08 (n = 3) for 
recombinant TKI  and 0.5 kO.l (n = 3) for TKI-193. 
An  unchanged  affinity  for  the  natural substrate,  thymidine,  combined with 
a lower V,,, value  suggest that  the  last 40 amino  acids  have a structural  role or 
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that  the ATP binding is disturbed. 
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Danish summary 
Thymidin  kinase  (TK) er et salvage pathway enzym, der  katalyserer  fosforylering af 
thymidin til thymidin monofosfat, som derefter fosforyleres videre til thymidin 
trifosfat  og  indgir i DNA syntesen.  Human cytoplasmatisk TK (TKI)  er celle cyklus 
reguleret  og  fslger  DNA  syntesen, d.v.s hOj aktivitet i delende og maligne  celler  og 
lav eller ingen  aktivitet i hvilende celler. Celle cyklus  regulering  af TKI  involverer e t  
sammenspil mellem  transkriptionel,  post-transkriptionel,  translationel og  post- 
translationel  r guleringsmekanismer. I nogle  cancer  celler er regulerings 
mekanismerne aendret og der er observeret  forskellige  isoformer af  TK. 
Underssgelse  af TKI gen  ekspression vi1 give  informationer om regulerings 
mekanismer ikke kun i normale celler men o g s i  i maligne celler. Desuden kan 
eventuelle  forskelle i ekspression, substrat  specificitet  og  struktur  mellem  TK's i 
raske og  maligne celler udnyttes  til  konstruktion af nukleosid  analoger  som  virker 
selektivt p i  maligne  celler. 
Afhandlingen  omfatter: 
1: Bestemmelse af  TKI  mRNA og TK aktivitet i lymfocytter fra raske donorer 
og i lymfocytter  fra  patienter med kronisk  lymfatisk  leukemi  (CLL). 
2: Struktur-funktions underssgelser af rekombinant TKI .  
I forste del af  afhandlingen er en f~l lsom metode  (competitive PCR) til kvantitering 
af TKI  mRNA blevet etableret. TKI mRNA niveauet er kvantiteret i hvilende 
lymfocytter  fra raske  donorer (n = 6) samt i lymfocytter der er stimuleret til v z k s t  
med  phytohemagglutinin. Expressionen i normale  celler er sammenholdt  med 
niveauet  af TKI  mRNA i patienter  med  kronisk  lymfatisk leukaemi (n= 5). 
Resultaterne fra de  6  normale  donorer viser, at der er et  meget  lavt  niveau 
af T K I  mRNA (under 0 . 0 6 ~ 1 0 ~  kopier mg.' protein)  og TK aktivitet (0.009 til  0.01 6 
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nmol  min-’ mg-’ protein) i hvilende  celler. I delende lymfocytter  stiger  miengden af 
TKI  mRNA 50  til  5000 gange (3  til 98 x 1 O6 kopier  mg-’ protein)  og  bliver  efterfulgt 
af  en stigning i TK aktiviteten  (0.12 til 0.76  nmol  min-’  mg-’). I CLL celler, der er 
karakteriseret  ved a t  viere  hvilende celler, er  TK aktiviten af samme sterrrelsesorden 
som i hvilende lymfocytter fra raske donorer. Kvantitering af  TKI mRNA viser 
overraskende a t  der i alle  5 CLL patienter er et  meget herjt TKI  mRNA (6  til 22 x 1 O6 
kopier  mg-’  protein) niveau, svarende til niveauet i delende Iymfocytter.  TKI mRNA 
niveauet er  herjt men  bliver  ikke  udtrykt  som  aktivt enzym. Dette  indikerer a t  der er 
en defekt i  reguleringen af det S-fase  specifikke TKI  enzym i CLL celler. 
Til  struktur-funktions undersergelserne  af TKI  anvendes et  rekombinant TKI  protein 
der udtrykkes  som  et  glutathion-S-transferase-(GST)  fusions  protein. TKI protein 
klerves fra GST-delen med thrombin. To deletions  mutanter, T K I - l  93 og   TK I - l  76, 
er konstrueret v.h.a.  recombination PCR metoden. Fjernelse af 57 amino  syrer fra 
C-terminalen (TKI- l   76)  resulterer i et  inaktivt enzym.  Deletion  of 40 amino  syrer 
(TKI-1 93) f ra  proteinets C-terminal medferrer a t  V,,, formindskes  2.5-gange (3800 
nmol  min-’  mg”) i forhold til den  rekombinante  vildtype  (rekombinant TKI)  der  har 
en V,,, p2 9700  nmol  min-’  mg-’.  Bortset  fra V,,, vzrdien opferrer rekombinant TKI  
og T K I - l   9 3  sig som den  native  lymfocyt  TKI, d.v.s n2r ATP er fjernet  fra enzymet, 
optraeder det  som en  dimer  med  lav affinitet  for  thymidin  og  nsr ATP er tilstede 
optraeder enzymet  som en tetramer  med herj affinitet  for  thymidin. K, for  thymidin 
for  rekombinant  TKI  og T K I - l 9 3  inkuberet med ATP er 0.5  20.1 (middel ks.d, 
n = 3) p M ,  mens  enzym  inkuberet  uden ATP har K, p: 14.08 20.68  (n  = 3) pM 
for TKI og 12.8 i 0 . 6 5  (n = 3) FM for TKI-193. Hill koefficienten for enzym 
inkuberet med ATP er 1.38 i.0.05 (n = 3) for rekombinant TKI  og 1.25 k 0 . 1 5  
(n = 3) for T K I - l  93. For -ATP  formerne er Hill koefficienten  0.46 k0.08 (n = 3) 
for rekombinant T K I  og 0.5 i O . 1   ( n  = 3)  for  TKI-193. 
En uaendret affinitet  for  thymidin  kombineret  med en lavere V,,, indikerer 
a t  de 40 C-terminal  amino  syrer  har  en  strukturel  rolle  og/eller  at  bindingen  af ATP 
er  aendret. 
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Abbreviations 
a.a 
ADK 
ATP 
AZT 
Cdk 
CDNB 
CDP 
CFU 
CHAPS 
CKI 
CLL 
CML 
C-point 
Comp-PCR 
dATP 
dCDP 
dCK 
dCMP 
dCTP 
dCyd 
dGDP 
dGTP 
dNDP 
dNTP 
dThd 
dTMP 
dTTP 
dUDP 
Amino acids 
Adenylate kinase 
Adenosine  triphosphate 
Azidothymidine, 3’-Azido-2’,3‘-dideoxythymidine 
Cyclin-dependent  protein  kinase 
1 -chloro-2,4-dinitrobenzene 
Cytidine  diphosphate 
Colony  forming  units 
3-[(3-cholamidopropyl)dimethylammoniol-l-propanesulfonate 
Cdk inhibitory  proteins 
Chronic lymphatic leukemia 
Chronic  myelocytic leukemia 
Competence  point, located in G, phase 
Competitive  reverse transcriptase-PCR 
Deoxyadenosine  triphosphate 
Deoxycytidine  diphosphate 
Deoxycytidine kinase 
Deoxycytidine  monophosphate 
Deoxycytidine  triphosphate 
Deoxycytidine 
Deoxyguanosine  diphosphate 
Deoxyguanosine  triphosphate 
Deoxyribonucleoside  diphosphates 
Deoxyribonucleoside  triphosphates 
Thymidine 
Thymidine  monophosphate 
Thymidine  triphosphate 
Deoxyuridine  diphosphate 
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dUMP 
EFTU 
E2F 
FCS 
G, 
G ST 
GST-TKI 
HeLa 
HIV 
HL-60 
HSV 
IPTG 
K, 
KY895 
n 
N F-Y 
NMR 
PCR 
pGEX2T 
Deoxyuridine  monophosphate 
Elongation  factor 
Cellular transcription  factor 
Fetal calf  serum 
G,-phase. The  period  in  the cell cycle  where  the  cells prepares for 
DNA  synthesis 
Glutathione-S-transferase 
Glutathione-S-transferase-thymidine  kinase  fusion  protein 
Human  cervix cancer  derived  cell line 
Human  immumodeficiency  virus 
Human  promyelocytic  cell line 
Herpes simplex virus 
Isopropyl  P-D-thiogalactoside 
Michaelis  constant 
A TK- €.coli strain 
Hill constant 
DNA  binding nuclear factor Y 
Nuclear  magnetic  resonance 
Polymerase  chain  reaction 
Expression vector  for GST fusion  proteins 
pGEX2T-TK1 TKI cloned  into pGEX2T 
pGEX2T-TKI-193  Mutant clone.  Amino  acid 193  is  the last  amino  acid in   TKI  
pGEX2T-TKI-176  Mutant clone.  Amino  acid 176 is the  last amino  acid in  TKI 
PHA Phytohemagglutinin 
PMSF Phenylmethylsulfonyl  flouride 
Rb Retinoblastoma protein 
R-point  Restriction-point, a control mechanism located  in G, 
RT Reverse transcriptase 
S-phase Period in the cell cycle  where DNA is  duplicated 
TK Thymidine kinase 
TKI  The cytosolic  thymdine kinase, it is  cell cycle  r gulated 
TK2 The mitochondrial  thymidine kinase, it is  constitutively expressed 
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TKI -1 93 Mutant  protein 
TKI - l 76  Mutant protein 
v,, The maximal velocity 
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Appendix 1 
ABTG medium: 
A I  0 salt: 100 g (NH,),SO, 300 g Na,HP04 2H,O, 150 g KH,PO, 150 NaCI, H,O 
ad 5 litre.  pH = 7.1, autoclave. 
B salt: 1 ml 1 M MgCI,, 1 ml 0.1 M CaCI, and 0.3 ml 0.01 M FeCI, per litre 
medium. 
T(thiamin): 0.5 ml 4 rng/ml thiamin per litre medium. 
G(glucose) 10 rnl 20% glucose per litre medium. 
LB medium: 
1 0  g bacto-tryptone, 5 g bacto-yeast extract, 10 g NaCI, 950  ml H,O, pH 7.0, 
adjust  with 5 M NaOH. H,O add 1000 ml. Autoclave  the  solution. 
S.0.C medium: 
2 g bacto-tryptone, 0.5 g bacto-yeast  extract, 1 ml 1 M NaCI, 0.25 r n l  1 M KCI, H,O 
to   100  r n l .  Autoclave and after  cooling  add  1  m12 M Mg2+  stock (1 M MgCI,-6 H,O, 
1 M MgS04-7 H,O) and 1 ml 2  M glucose. Sterile filter  the  solution. 
TB medium: 
1 2  g bacto-tryptone, 24 g bacto-yeast extract, 4 ml glycerol, H,O add 900 ml. 
Autoclave and add 100 ml  0.17 M KH,P04, 0.72 M K,HPO,) 
FN18 amino  acid  mix  (met, -led: 
L-alanine 0.71 0 g, L-arginine 0.700 g, L-histidine 0.310 g, L-lysine/HCI 0.580 g, L- 
proline 0.460 g, L-threonine 0.480 g, glycine 0.600 g, L-aspargine 0.530 g, L- 
glutamine 0.270 g, L-isoleucine0.520g,  L-phenylalanine0.240 g, L-tyrosine  0.360 
g, L-valine 0.700 g, L-aspartate 0.530 g, L-glutamate 0.880 g, L-cysteine 0.1 20 g, 
L-serine 10.00 g, L-tryptophan 0.200 g. Dissolve in 200 ml H,O, sterile  filter.  Dilute 
1 :40 when use). 
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Abstract-The  level of cytosolic  thymidine kinase (TK1)  mRNA in lymphocytesfrom  six  healthy 
was determined with competitive polymerase chain reaction (competitive PCR). Using th is  
people  and in lymphocytesfrom  five  patients with untreated  chronic lymphatic leukemia (CLL) 
procedure we have  shown  that in patients with CLL, there is an  overexpression of  TK1 mRNA 
without corresponding enzymatic activity. The TKI mRNA level is approximately 100-fold 
higher in lymphocytes  from CLL patients  than in lymphocytes  from healthy persons. A high 
level of TKI mRNA without corresponding enzyme activity may indicate a defect in the 
processing of the  enzyme.  This may disturb the cells' normal feedback  system  and  thereby 
influence the  development of malignant conditions. 
Key words; Thvmidine kinase, mRNA;chronic lymphatic leukemia, competitive PCR, quanti. 
fication, CLL. 
Introduction 
Thymidine  kinase (ATF': thymidine  5'phospho- 
transferase  E.C. 2.7.1.21) is a  pyrimidine  nucleoside 
salvage  pathway  enzyme  with two isoenzymes:  TK1 
and TK2, also  called  cytosolic and  mitochondrial  TK, 
respectively. Both  enzymes  catalyse  the  phosphoryl- 
ation of thymidine to TMP which is subsequently 
converted to TTP and utilized in DNA synthesis. 
TKI is the  dominating  form in  dividing  lymphocytes 
and TK2 is the only form present in non-dividing 
lymphocytes,  but  in low amounts [l]. The  two iso- 
enzymes  have  characteristic differences  in  their 
enzyme  kinetic  pattern  and  subunit  molecular 
weights [2,3]. TK1 is cell-cycle regulated and the 
enzyme level  is low or  undetectable in quiescent (G,) 
cells, but increases  dramatically  when  the  cells  enter 
S-phase [4-71. It is generally accepted  that  there is 
proliferative  state of the cell [l, 6 ,  %IO]. 
a close correlation between TKI activity and the 
thymidine  kinase; TKI, thymidine kinase characteristic for 
Abbreviariom: CLL, chronic  lymphatic  leukemia; TK, 
dividing cells; TKZ, thymidine kinase characteristic for 
non-dividing  cells; PCR, polymerase  chain  reaction; PHA, 
phytohemagglutinin; FCS, fetal calf serum; ATP, adeno- 
sine triphosphate; CTP, cytidine  triphosphate. 
Jensen, at the above address. 
Correspondence IO: Tina  Kristensen  or  Helle Kock 
paper. 
* The two first  authors made equal contribution  to this 
leukemia  (CLL) are  non-dividing  and  it  is, therefore, 
Lymphocytes from  patients with chxonic lymphatic 
plausible that  the low TK  activity in  these cells  almost 
exclusively is due  to TK2. However,  Munch-Petersen 
and Tyrsted  found  that  the  dominating TK activity 
isolated from  lymphocytes  from  a CLL  patient dis- 
played an enzyme kinetic pattern similar to that 
observed with TKI [Ill. 
be due to a change in the control of the cell-cycle 
The  occurrence of TKI in quiescent CLL cells  may 
regulated  expression of the  TK1  gene.  The c ll-cycle 
regulation of TK1 is  a very complex  system  involving 
transcriptional,  post-transcriptional [4,12,13],  trans- 
lational and post-translational regulation  mech- 
anisms  [14,15]. To  investigate the  expression of TK1 
mRNA in CLL cells at  the  transcriptional level we 
have  measured  the level of TK1  mRNA by the very 
sensitive  competitive  polymerase  chain  reaction 
(competitive  PCR),  and  compared  this  with  the  TK 
enzyme activity. Surprisingly, we have found that 
the level of TKI  mRNA in lymphocytes  from  CLL 
patients was about 100-fold higher  than  in  lympho- 
cytes from  healthy persons. 
Materials  and  Methods 
Materials 
mmol), Megaprime  DNA labeling systems (RPN 1604) and 
3H-thymidine (2 Ci/mmol), [d2P]dCTP (3000 Cij 
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Hybond N+ membrane were from Amersham Denmark 
ApS. Isopaque-Ficoll was from Nycomed. RPMI-1640, 
fetal calf serum (FCS), phytohemagglutinin (PHA) and 
bovineserum albumin  (BSA)  were  from  Gibco.  All  nucleo- 
sides  were from Boehringer  and  Mannbeim,  RNasin, ran- 
H minus were from Promega. Thermus aquaficus DNA 
dom hexamer and M-MLV reverse transcriptase RNase 
The primers  used  were  synthesized at the Department of 
polymerase (AmpliTaq) was from Perkin Elmer/Cetus. 
Microbiology at the Technical University of Denmark. 
SpinBind  DNA  extraction  Unit  was from FMC  Bio- 
products Europe. DEAE and  3MM filters  were  from  What- 
man. All other reagents  were of the highest  quality  gen- 
erally  available. 
Cells 
Peripheral  blood  from six healthy  persons was  collected 
in heparin  vacuum  tubes.  Peripheral  blood,  similarly  col- 
lected  from five patients with untreated CLL  was  kindly 
provided by  Sven Erik Nielsen  (M.D.),  Roskilde  Hospital. 
The lymphocytes  were  isolated by Isopaque-Ficoll  gradient 
centrifugation  [l61 and washed in RPMI-1640 containing 
in a  Coulter counter'and cell  pellets  were  stored  at -8O'C. 
10% beat-inactivated  FCS.  The  cell  number was  estimated 
Phytohemagglutinin  (PHA)  stimulation of lymphocytes 
from healrhy  persons 
The lymphocytes  were  stimulated  by PHA in  RPMI-1640 
medium  supplemented  with  10%  FCS, 20 p g h l  PHA and 
20 pg/ml penicillin/streptomycin, at a concentration of 
lo6 cells  per m1 in 5% COz  at  37°C. For flow  cytometry 
analysis  aliquots of llYcells  were  centrifuged at 5Og for 
10  min  and  fixed  in  250 p1 buffer (6.1 mM glucose, 140  mM 
NaCI, 5mM KCI, 2.7mM Na2HP04, 1.1mM M 2 P 0 4 ,  
0.5 mM EDTA) and 750 pl EtOH. The DNA  was  stained 
with 20 pg/ml EtBr and 10 pg/ml mithramycin  and  moni- 
tored by  flow cytometry. In quiescent  lymphocytes  the S- 
with PHA the  S-fraction was  in the range of 30%. These 
fraction  was  about 8%. In lymphocytes  cultured for 48 h 
data were  in  agreement  with  previous  observations [17]. 
Extraction of lymphocytes for TK acfiuiry  measuremenr 
The  cells  were  suspended in Loebs buffer (20 mM K- 
pbosphate buffer (pH 7.4), 15% glycerol, 1 mM K-EDTA, 
3 x 1-2s) and centrifuged at 20,OoOg for 30min. The 
10mM dithiotreitol (DTT)), lysed by sonication (40 W, 
measurement  and total protein  measurement. 
supernatant ( e w e  extract) was used for TK activity 
TK actiuiry assay 
the  DEAE-cellulose 81 paper  square  method  as  previously 
TK activities  were  determined as initial  velocities  using 
described [2,3]. The standard assay mixture contained: 
50mM Tris-HCI (pH7.5), lOmM D n ,  2.5 mM ATP, 
2.5 mM  MgCI2, 3 mM  NaF,  0.5  mM CHAPS  (3-[(3-Chol- 
3 mg/ml bovine serum albumin (BSA) and 10 pM )H- 
amidopropyl)-dimethylammonio]-l-propanesulphonate), 
thymidine (2 Ci/hyol). In assays  with CTP as  phosphate 
donor ATP was substituted with  equimolar  CTP.  Samples 
of 13 pl were  applied  on DEAE filters  5, 10 and 15 min 
after starting  the  reaction by addition of enzyme  extract to 
the assay  mixture to a  total  volume of 50 pl. The  reaction 
temperature was  37°C. The filters  were  washed,  eluted  and 
the radioactivity determined by scintillation counting as 
described  [3]. 
enzyme  catalysing  the formation of 1 nmol  dTh#P  per  min. 
One  unit of enzyme activity  is defined as  the amount of 
Prorein  determination 
liant  blue as  dexribed 1181. 
RNA  isolation 
method described by Chomuynski and Sacchi (191. To 
Total  RNA  was  isolated  using  the  guanidine  thiocyanate 
improve  purification  an  extra  phenol  extraction  and  alcohol 
precipitation was applied. RNA concentration was esti- 
mated  from the optical  density at 260 nm,  and  the  RNA 
quality was  examined  by  agarose  gel electrophoresis. 
Estimation of RNA  recovery 
5 Ci/mmol) durin PHA-stimulation in two experiments. 
'H-uridine  was  added to the growth  medium  (5  pCi/ml, 
A  total of 5 X 10 f labeled cells  were  harvested  on  3  MM 
filters  and  non-incorporated  )H-uridine  was  washed  away. 
From an equal number of cells, RNA was isolated and 
applied to 3MM filters. The radioactivity on the filters 
was  determined by scintillation  counting. The amount of 
isotope in  RNA  was  compared  with the  amount of isotope 
in the cells. The RNA recovery estimated from these 
comparisons  was  in the  range  of 70-90%. 
Reverse transcriprion 
of PCR buffer (10mM Tris-HC1 (pH&3), 50mM KC1, 
RNA  (2.5 @) was transcribed to cDNA  in  a  50 plvolume 
0.015% gelatine,  0.1%  Tween  20),  7.5 mM  MgCI2, 1 mM 
amers  and  25Ounits of M-MLV reverse  transcriptase 
of each of the dNTPs, 40 U RNasin,  7 p M  random  hex- 
37°C.  The  extent of reverse  transcription  was  controlled 
RNase  H minus. The  reaction was terminated after  2  h at 
added.  Aliquots of the  reaction  mixture  were  applied  on 
by a  parallel  reaction  where  )H-"TP,  instead of TTP was 
3 MM filters.  The  non-incorporated )H-lTP was  removed 
from  the  filter by  washing 3 x 10 min  in 1 M  HCI containing 
0.6mM Na5P3010,  lOmin  in  0.26M NaAc/EtOH and 
finally  in EtOH. The  radioactivity was  measured by scin- 
tillation  counting  (results  not  shown). 
Compefifiue  PCR 
The  principle in the  competitive  PCR  method,  as 
reported by Gilliand er al. [ZO], is a co-amplification of 
target  cDNA  concurrently  with the corresponding  genomic 
DNA. Thus, the two templates compete for the same 
fication.  The  genomic DNA serves as internal standard.  In 
substrates and primers  ensuring  equal  efficiency  of  ampli- 
our experiments we chose  exons 1 and  2  with  intron 1 from 
the TK gene as internal standard and exons 1 and 2 as 
the  target  cDNA  fragment. The fragments  were  amplified 
using a  pair of primers  identical to those reported by  Lipson 
and  Baserga [ZI]. The  sizes  of  the  resultingfragments  were 
138  bp  with  cDNA as template  and  248 bp with  genomic 
DNA as template.  The  internal  standard of  248 bp genomic 
DNA was prepared by PCR with DNA as a template 
and  using the primers  mentioned  above. The product  was 
quantified by agarose gel electrophoresis together with 
different known  amounts of DNA. The unknown  amount 
of cDNA was estimated from a set of PCR reactions 
performed  in  a  dilution  series  with  known  amounts of the 
The  protein  content was measured by Coomassie bril- 
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1 2 3 4 5  
Fig. 1. Northern  blot  analysis of TK1 mRNA. Total RNA 
was isolated from lymphocytes  from donor 5 with 24 pg 
loaded in each  lane. The lymphocytes  were  stimulated to 
grow with PHA. Non-stimulated  (lane 1); 48 h (lane 2); 
72 h (lane 3); 96 h (lane 4); 168 h (lane 5 ) .  (A) Hybrid- 
ization  with a TK probe  detecting a single  mRNA  species 
of 1.5 kilobases. (B) After stripping the filter in (A) for 
TK probe, the filter was rehybridized to a probe  for  the 
constitutively expressedpactin, detecting a mRNA  species 
of 2.1  kb. 
genomic DNA. The PCR products were separated by 
agarose gel electrophoresis. The amount of cDNA (in 
grams) in the sample was estimated as that amount (m 
grams) of genomic  DNA  giving  equal  intensity  of the two 
was calculated from the amount of cDNA, by division 
amplification  products. The number of T K 1  cDNA  copies 
with the  molecular weight of the 138 bp cDNA  fragment 
(average molecular weight/base = 308). The number of 
copies of TK1 cDNA was taken as  being  representative for 
the number of copies of TK1 mRNA. 
vol.  of  PCR buffer, 7 pmol  of  each primer, 200 PM of each 
The competitive  PCR  analyses  were  performed  in a 25 PI 
dNTP, 1.5mM MgCI, and 0.5 unit  of Thermus nquaticus 
DNA polymerase. Heat-denatured cDNA (lOO"C, 2 min) 
and internal standard  were  added to the reaction  mixture 
with a layer of mineral oil to avoid evaporation. The 
amplification was performed in a Perkin-Elmer/Cehls 
Thermal  Cycler  according to the following  program:  de- 
naturation for 1 min at 95T ,  annealing for 1 min at 6O'C 
and  polymerization for 1 min at 72T,  for 35  cycles. 
Northern blot 
Total RNA was prepared as described above. RNA 
preparations were denatured and  electrophoresed  through 
a 1.8% agarose gel containing 2.2M formaldehyde and 
transferred to a Hybond N+ membrane  according to pub- 
cDNA  from  plasmid pTKll[23] and  human pactin cDNA 
lished  procedures [22]. The probes  used  were human TK1 
labeled with 32P-dCTF' using Megaprime DNA labeling 
systems. The TK1  probe was 720 bp and  the  actin  probe 
was 400 bp.  Non-incorporated  nucleotides were  removed 
with a SpinBind  DNA  extraction  unit. In a 20mI  hybrid- 
ization reaction a 100 ng (3.4 pCi/pg) probe was used. 
Hybridization was performed according to the  guidelines 
ing: 0.1 X SSPE-buffer (3.6M NaCI, 0.2M sodium  phos- 
from Amersham  Denmark  ApS  with  high  stringency  wash- 
phate, 0.02M EDTA pH7.7) and 0.1% SDS at 68°C. 
Induction with PHA (hours) 
Fig.  2.  Cell-cycle-specific variation of TK1  mRNA  (copies/ 
mg protein) Vd and TK activity (nnitsimg protein) B are 
illustrated for donor 1. The  lymphocytes  were  stimulated 
with PHA for the indicated time periods. TK1 mRNA 
was estimated by competitive  PCR  and  TK  activity was 
measured  at  standard  conditions as described in 'Methods'. 
Results 
Determination of TKI mRNA by Norrhern  blotting 
PHA stimulated  lymphocytes was analysed for two 
Expression of TK1  mRNA during the cell cycle of 
donors by Northern blot analysis. As seen in Fig. 
1(A) it is clear that TK1 mRNA i$ not expressed 
in quiescent lymphocytes, whereas a 1.5 kb band, 
corresponding  to TKI  mRNA, is  seen  in  lymphocytes 
cultured with PHA.  The level of TK1  mRNA 
increases  reaching a maximum  after 96 h of culture 
with PHA,  whereafter  the level  decreases.  Hybrid- 
ization with a probe for the constitutive  expressed p 
actin shows that  equal  amounts of RNA  were applied 
to each lane. 
TKI mRNA and TK activity in lymphocytes from 
healthy donors 
TK1  mRNA  in quiescent  lymphocytes.  Figure 2 
With competitive PCR it is possible to measure 
shows the level of TK1  mRNA (copies/mg  protein) 
and  the  TK activity (units/mg protein) in lympho- 
cytes from  donor 1. It is clearly demonstrated  that 
the  amounts of TK1  mRNA  and TK activity increase 
concomitantly  during  incubation of the lymphocytes 
with PHA, reaching a peak  level  at 96 h.  The  same 
cell-cycle regulated pattern was observed in lym- 
phocytes from  the five other  donors.  Table 1 shows 
the actual  amounts of TK1  mRNA  and  TK activity 
in the six donors. In quiescent  lymphocytes, the level 
of TKI  mRNA is very low and in four out of six 
donors below the limit of detection which in our 
reactionscorrespond to 0.006 copies of TK1  mRNA/ 
cell. After  PHA stimulation, the level of TK1  mRNA 
transcripts increases to a maximum level, between 
W T. Kristensen er d. 
Table 1. The amount of TK1 mRNA  (copies/mg protein) and TK activity (units/mg protein) in 
non-stimulated  lymphocytes  and  lymphocytes incubated with PHA  for  96 h 
(copies X W / m g  protein) 
TK1 mRNA 
TK activity (units/mg protein) 
Donor 
No. 
Non-stimulated 
lymphocytes 
PHA-stimulated 
lymphocytes 
Non-stimulated 
lymphocytes 
PHA-stimulated 
lymphocytes 
1 N.D  3.2  0.009  0.195 
2 
3 0.215 
N.D 
20.0 
4.9 0.013 
0.013 
0.120 
0.292 
4 0.061  5.4 0.00s 
5  0.009 
6 
N.D  85.7 
0.503 
0.285 
N.D 98.8 0.016  0.760 
N.D =Not detectable. 
Table 2. The amount of TK1  mRNA  (copies/mg  protein) 
and TK activity (units/mg protein) in lymphocytes from 
five patients with CLL 
TK1  mRNA TK activity 
(units/mg 
patient No. protein) protein) 
CLL  (copies X 1oS/mg 
1 10.3 
2  7.4 
0.008 
0.006 
3 
4 
22.7 
15.2 
0.013 
0.005 
5 6.1 0.006 
t"' 
Fig. 3. The amounts of TK1  mRNA  (copies/mg  protein) 
isolated  from  CLL  cells.  The  numbers on the x-axis refer 
E2 and TK activity (units/mg protein) in lymphocytes 
to the five CLL patients. 
50 and 5000-fold higher  than in  quiescent cells. The 
vidual variation  between  the different donors. 
broad  range in TK1  mRNA level may reflect indi- 
TKI mRNA and TK activity in CLL cells 
Our results show that the TK activity in CLL 
cells is low and in the same range as in quiescent 
lymphocytes,  between 0.005-0.013 units/mg  protein 
(Table 2). Surprisingly,  despite the low TK activity, 
lymphocytes from CLL patients express very high 
levels of TK1 mRNA (Fig. 3). .The level of TK1 
mRNA/mg protein was between 30 and 300-fold 
higher  than  the level in quiescent  cells  from  healthy 
donors. 
Characterizatiorr of the TK isoenzyme in C L L  cells 
Owing to  the high TK1 mRNA level  it  was impor- 
tant  to establish to which degree  the  TK activity  was 
due  to  TK1  or TK2. The low amounts of TK activity 
in the crude extracts, however, did-not allow any 
further separation of TK1  and  TK2.  Therefore, we 
have distinguished  between TK1  and  TK2  using  the 
pronounced differences in substrate specificity. 
Both isoenzymes utilize adenosine triphosphate 
also use cytidine triphosphate  (CTP) efficiently, 
(ATP) efficiently as  phosphate  donor,  but  TK2  can 
whereas it is a  poor  phosphate  donor  for  TK1 [24]. 
similar to  TK2 in quiescent cells or  to  TK1 in dividing 
To clarify whether  the  isoenzyme in CLL cells  is 
cells, we have compared the phosphate  donor 
efficiency of ATP  and  CTP  in  quiescent  lymphocytes, 
PHA stimulated lymphocytes and CLL cells. TK 
TK activity with ATP  as  donor. 
activity with CTP  as  donor is given  as a percent of 
As  seen in Fig. 4, CTP  was  a poor  phosphate  donor 
for  the TK enzyme  in PHA  stimulated  lymphocytes, 
but  an efficient phosphate  donor  for  the TK enzyme 
in  quiescent  lymphocytes  and CLL cells. These 
results  indicate that  the  TK in CLL cells is the  same 
as in  quiescent  lymphocytes,  namely TK2. 
Discussion 
lutionized the area of molecular biology. With its 
The  development of the  PCR  reaction  has  revo- 
high  sensitivity,  competitive PCR  makes it possible 
to  measure gene expression of even a  low  copy  gene, 
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Fig. 4. The ratio between phosphate donor capacity of 
CTP and ATP. In each experiment the enzyme activity is 
normalized to 100% with ATP as phosphate  donor. (A) 
Non-stimulated  lymphocytes; (B) lymphocytes 96 h after 
PHA stimulation; (C) CLL cells.  The  numbers on the x- 
axis refer to the individual  donors  and  patients. 
such  as  thymidine  kinase. We wanted to  quantitate 
TK1  gene  expression in  lymphocytes  from  untreated 
CLL patients, but were restricted by the limited 
method  for  determination of gene expression is 
availability of material. The most frequently used 
Northern blot analysis, but the results were very 
weak when carried out on PHA stimulated lym- 
phocytes. To  be  able  to  detect  TK1  mRNA in the 
very limited CLL samples,  a  more  sensitive  method 
was  required.  Using  competitive  PCR  it was possible 
to quantify  the  level of TK1  mRNA,  even in  quies- 
cent  lymphocytes.  We  have  estimated  a  very  low,  but 
detectable  level, in two donors.  The  amount of TK1 
mRNA in  quiescent  lymphocytes  is  very  close to the 
detection  limit, which is  about 0.006 copies of TK1 
mRNA/cell.  Below  this  level,  a 248 bp  amplification 
product  interferes  with  the  competitive  PCR.  This  is 
probably  as  a  result of traces of DNA  or non-spliced 
RNA  in  our  RNA  preparation.  As  there is  a  minor 
loss during the RNA purification and the cDNA 
synthesis (see Methods), the actual level of TK1 
mRNA is slightly underestimated.  However, we pre- 
sume  that  the  underestimation is in the  same  range 
in all samples,  since we have  used  the  same  protocols 
for all  donors. 
As a model system we have used human lym- 
phocytes which are truly Go cells. Culturing the 
quiescent  lymphocytes in the  presence of PHA stimu- 
lates  the cells to  enter  the  cell  cycle, allowing  events 
in the GI and S-phases to  be  investigated.  A  clear 
advantage of using lymphocytes as representatives 
for  normal cells instead of immortal cell lines is the 
ability of cell lines  to  grow  continuously.  This due 
to  the  occurrence of at  least  one  feature  required  to 
turn  normal cells into  cancer  cells. 
lated on multiple levels and the regulation mech- 
The expression of TK has  been  shown  to be  regu- 
anisms differ, depending on the cell system. For 
in TK activity  is  largely  accounted for by an increase 
example, in cycling HeLa  cells,  the  S-phase  increase 
in the  rate of TK protein  translation [7]. In serum- 
starved cells stimulated to  re-enter  the  cell cycle, the 
increase in TK activity is accompanied by a cor- 
responding  increase  in TKI mRNA. In this  system 
both  transcription  and  post-transcriptional  mech- 
anisms account for the induction of TKI mRNA 
known that TK activity  increases  dramatically  when 
[4,25,26]. In PHA stimulated  lymphocytes  it  is well 
the  cells  enter  the  cell cycle [ l ,  27,281. However,  for 
this cell system, we have  not  been  able to find  any 
reports regarding the fluctuations in TK1 mRNA 
level  as  a  characteristic of regulatory  mechanisms. 
Our results  show  that  both TK1 mRNA and TK 
activity  in PHA stimulated  lymphocytes  display  the 
same  cell-cycle  regulated pattern  as timulated 
serum-starved cells. An  increase  in  TK1  mRNA in 
lymphocytes  at  the  entry to S-phase  is  followed by 
an increase  in TK enzymatic  activity. The TK1 
mRNA level  increases  about  100-fold  when  the cells 
are  stimulated.  When cells leave  S-phase,  the  TK1 
mRNA level  and TK  enzyme  activitydecrease. 
tems is that  lymphocytes  are  truly Go cells, they do 
An  important  difference  between  the  two cell sys- 
not  enter  S-phase  before 48 h  after  addition of PHA. 
This is in  contrast  to  stimulated  serum-starved  cells 
which  reach  S-phase  after 12  h [25]. 
In CLL cells we found, surprisingly, that TK1 
mRNA expressed per mg protein is 30-300 fold 
higher than in  quiescent  lymphocytes. The TK 
activity level is very low and  in  the  same  range  as 
in quiescent lymphocytes. Exploiting the different 
substrate specificities of TK1 and TK2 using CTP 
instead of ATP  as  phosphate  donor, it was shown 
that  the  TK  activity in the  CLL  cells is due to TK2. 
This  phenomenon of a high TK1 mRNA level  with 
no TK1 enzyme activity has to our knowledge not 
been  described  elsewhere. 
Our  experiments  indicate  that  CLL  cells  have  an 
TK1 mRNA level is high and is prevented from 
abnormal  regulation of the  S-phase-regulated  TK1. 
translation  into  active  enzyme.  Owing to its associ- 
ation with the  proliferative  state of cells,  TK  activity 
is  regarded  as  a  useful  tumor  marker  with  prognostic 
value for a number of malignant diseases such as 
human breast cancer [29-311, non-Hodgkins lym- 
phoma [32] and acute lymphatic leukemia [33]. In 
CLL  cells  the TK activity is very  low  and  can,  there- 
fore,  not  be  used  as  a  tumor  marker. On the  other 
866 T. Kristensen er al. 
hand,  the  level of TK1 mRNA is very high and may, 
therefore, serve as an alternative  tumor  marker  in 
these cells to predict the diagnosis at an earlier stage. 
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INTRODUCTION 
Thymidine  kinase is an enzyme  in the pyrimidine  salvage  pathway that, with ATP as 
co-substrate.  catalyzes the phosphorylation of deoxythymidine to deoxythymidine 
monophosphate (dTMP)  which is subsequently  converted to d r r P  and utilized for  DNA 
synthesis. 
In mammalian  cells there are two thymidine  kinases (TK), the constitutively 
expressed TK2, and  the S-phase  specific TK1 which  is  only present in  dividing  cells'. 
Lymphocytes  from patients with  chronic  lymphatic leukemia (CLL) are non-dividing 
and it  is therefore plausible that the low TK activity in these cells  almost  exclusively  is 
due to TK2. However, a thymidine kinase with similar enzyme kinetic pattern as that 
observed  with TK1 from  lymphocytes  stimulated to growth by the mitogene 
phytohemagglutinin  has been reported'.  Since TK1 expression is tightly  regulated 
thoughout the cell cycle with transcriptional. translational as well as post-translational 
regulatory  mechanism3, the occurrence of TK1 in  non-dividing CLL cells may be due  to 
a change  in the control of the cell cycle regulated  expression of the TK1 gene. 
To investigate the transcriptional  expression of TK1 mRNA in CLL cells, we have 
measured the level of TK1 mRNA with the competitive polymerase chain reaction 
(competitive PCR), and compared  this  mRNA  level  with the TK enzyme  activity. Surpri- 
singly, we have  found that the ratio of TK1 mRNA/TK  activity  in  lymphocytes from CLL 
patients  was about 60-400 fold  higher than in  lymphocytes from healthy  persons. 
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METHODS 
Lymphocytes  from peripheral blood  from 6 healthy  persons  and  from 5 patients with 
untreated  CLL were  isolated by the Ficoll-Isopaque  technique. 
Lymphocytes from healthy persons were stimulated to growth by PHA in RPM1 1640 
medium supplemented with 10% fetal calf serum, 20 pg/ml PHA and 20 pg/ml 
peniciUin/streptomycin at a concentration of lo6 cells pr ml in 5% CO, at 37°C. The 
lymphocytes were divided  in portions of 5 x 10' cells, and in  each portion, TK activity  was 
determined by the DE-81 paper method as described4 and total protein was determined 
by the Bradford assag.  Total  RNA was isolated with the guanidine  thiocyanate  method6, 
transcribed to cDNA and quantitated by the competitive PCR method'. TK1 cDNA, 
taken as representative for TK1 mRNA, was co-amplified with a dilution series of 
competitor DNA. Exon 1 and 2 with intron from the TK1 gene served as competitor 
DNA and exon 1 and 2 of the TK1 gene as the cDNA fragment to  be quantitated.  The 
fragments were amplified using a pair of primers identical to those reported by Lipson 
and Basergas. The sizes of the resulting fragments was 138 bp with cDNA as template 
and 248 bp with competitor DNA as template. The relative amounts of cDNA  versus 
competitor DNA were  measured by scanning of ethidium-bromide  stained  gels.  Because 
the starting concentration of the competitor  DNA was known, the amount of cDNA (in 
grams) in the sample could  be estimated as that amount of competitor  DNA  where equal 
intensities of the two amplification  products  were obtained. The number of TK1 cDNA 
copies  was calculated from the amount of cDNA, by dividing the amount of cDNA with 
the molecular weight of 1 copy  of the 138 bp  cDNA fragment. 
The amplification was performed in a Perkin-Elmer/Cetus Thermal Cycler  according 
to  the following  program: denaturation for 1 min at 95T, annealing  for 1 min at 60°C 
and polymerization  for 1 min at  72T, for 35 cycles. 
RESULTS  AND DISCUSSION 
Table 1 shows the ratio of TK1 mRNA copies and TK activity in non-dividing 
lymphocytes  from 6 healthy persons and  in  lymphocytes  from 5 patients with  CLL. As 
seen, the  ratio TK1 mRNA  copies/TK  activity  in  CLL cells is 60 to 400 fold  higher than 
in  non-dividing  lymphocytes. The TK activity in CLL  cells  is  of a magnitude as expected 
for  non-dividing  cells,  while the expression of TK1 mRNA is  very high and in the range 
of the TK1 mRNA level in PHA stimulated healthy donor lymphocytes. In these 
experiments the TK1 mRNA level is 3-98 x lo6 copies/mg protein (results are not 
shown). 
The  detection limit  in  the  assay  is around 6 x 104 copies of TK1 mRNA/mg protein 
or 0.006 copies/cell. Below  this  level, a 248 bp  amplification product, interferes with the 
competitive PCR. This is probably a result of traces of DNA  or  non-spliced RNA in the 
RNA  preparation.  The results indicate that there,  as expected, is no TK1 mRNA in  non- 
dividing  lymphocytes  from  healthy  persons. 
Due  to  the high TK1 mRNA  level  in  non-dividing CLL cells it was of importance 
to clarify whether the dominating TK in  CLL  cells  was TK1 or W ,  using the 
characteristic differences in phosphate donor specificity towards ATP and CTP. Both 
enzymes can utilize ATP, but only TK2 is capable of utilizing C T P 9 .  The relative TK 
activity with CTP as phosphate donor was expressed as % of activity with ATP as 
phosphate donor. PHA-stimulated lymphocytes showed a 8590% decrease in relative 
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activity,  while  non-dividing  lymphocytes  from  healthy  persons  and  lymphocytes from CLL 
patients showed a 7-30% decrease. The conclusion  is that  the enzyme  in CLL cells  is the 
same as in  non-dividing  lymphocytes  from  healthy  persons,  namely TK2. 
Table 1. Ratio of TK1 mRNA  copies and TK activity. 
TK1 mRNA copies TK activity TK1 mRNA  copies 
x 1o6/mg  protein Units/mg  protein x 106/TK activity 
Non-dividing 
lymphocytes 
1 < 0.06 0.009 < 6.7 
2 < 0.06 0.013 < 4.6 
3 0.21 0.013  16.2 
4 0.06 0.008 7.5 
5 < 0.06 0.009 < 6.7 
6 < 0.06 0.016 < 3.8 
Lymphocytes from 
CLL patients 
1 10.3 0.008 1287 
2 7.4 0.006 1233 
3 22.7 0.013 1746 
4 -  15.2 0.005 3040 
5 6.1 0.006  101  
The  ratio between TK1 mRNA and TK activity as estimated in non-dividing lymphocytes from 6 donors and 
in lymphocytes from 5 patients with CLL. The numbers refer to the individual donors and patients. 
1 unit is the amount of enzyme that phosphorylate 1 nmol substrate  per minute. 
The occurence of a  high  level  of TK1 mRNA  without  concomittant  expression of 
T K 1  enzyme  activity  may  indicate that CLL  cells  have an abnormal regulation of the cell- 
cyclus regulated TK1. The regulations  mechanism are not fully  understood, but several 
investigations  have  shown that the  changes  in TK1 mRNA during  cell  cycle can not  fully 
account for the rise  in TK activity.  Translational and post-translational  modifications  may 
contribute to the regulation of TK1. Chang and Huang"  have demonstrated that seryl 
residues of the TK1 polypeptide are phosphorylated in cycling  HL-60  cells. An increasing 
phosphorylation of the polypeptide  was  followed  by an increase in  enzyme  activity,  during 
the  cell  cycle. Another post-translational  mechanism has been reported by Kauffman and 
Kelly". They  have  shown that amino acid  residues near  the C-terminal end are 
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responsible for degradation of thymidine  kinase protein in the G, and M phase, and that 
mutations in this part of the gene allow  expression in G, cells. 
It is  possible that a post-translational mechanism  serve as a secondary  back-up  system for 
the regulation of TK. This may  explain why we can measure a high TK1 mRNA level  but 
no T K I  activity. 
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